ID   1433B_HUMAN             Reviewed;         246 AA.
AC   P31946; A8K9K2; E1P616;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   09-JAN-2013, entry version 149.
DE   RecName: Full=14-3-3 protein beta/alpha;
DE   AltName: Full=Protein 1054;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
DE   Contains:
DE     RecName: Full=14-3-3 protein beta/alpha, N-terminally processed;
GN   Name=YWHAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Keratinocyte;
RX   MEDLINE=93294871; PubMed=8515476; DOI=10.1006/jmbi.1993.1346;
RA   Leffers H., Madsen P., Rasmussen H.H., Honore B., Andersen A.H.,
RA   Walbum E., Vandekerckhove J., Celis J.E.;
RT   "Molecular cloning and expression of the transformation sensitive
RT   epithelial marker stratifin. A member of a protein family that has
RT   been involved in the protein kinase C signalling pathway.";
RL   J. Mol. Biol. 231:982-998(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=21638749; PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-11; 14-57; 63-70; 106-117; 130-169 AND 215-246,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [7]
RP   PROTEIN SEQUENCE OF 3-20.
RC   TISSUE=Platelet;
RX   MEDLINE=22608298; PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [9]
RP   INTERACTION WITH CRTC2.
RX   PubMed=15454081; DOI=10.1016/j.cell.2004.09.015;
RA   Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G.,
RA   Jeffries S., Guzman E., Niessen S., Yates J.R. III, Takemori H.,
RA   Okamoto M., Montminy M.;
RT   "The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive
RT   coincidence detector.";
RL   Cell 119:61-74(2004).
RN   [10]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [11]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [12]
RP   INTERACTION WITH YAP1.
RX   PubMed=17974916; DOI=10.1101/gad.1602907;
RA   Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J.,
RA   Ikenoue T., Yu J., Li L., Zheng P., Ye K., Chinnaiyan A., Halder G.,
RA   Lai Z.C., Guan K.L.;
RT   "Inactivation of YAP oncoprotein by the Hippo pathway is involved in
RT   cell contact inhibition and tissue growth control.";
RL   Genes Dev. 21:2747-2761(2007).
RN   [13]
RP   INTERACTION WITH ROR2, FUNCTION, PHOSPHORYLATION, DIMERIZATION, AND
RP   MASS SPECTROMETRY.
RX   PubMed=17717073; DOI=10.1210/me.2007-0323;
RA   Liu Y., Ross J.F., Bodine P.V.N., Billiard J.;
RT   "Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-
RT   3(beta) phosphorylation and promotes osteoblast differentiation and
RT   bone formation.";
RL   Mol. Endocrinol. 21:3050-3061(2007).
RN   [14]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH SRPK2.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-70 AND LYS-117, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-239, MASS SPECTROMETRY,
RP   INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
RN   [20]
RP   VARIANT ILE-99.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner. Negative
CC       regulator of osteogenesis. Blocks the nuclear translocation of the
CC       phosphorylated form (by AKT1) of SRPK2 and antagonizes its
CC       stimulatory effect on cyclin D1 expression resulting in blockage
CC       of neuronal apoptosis elicited by SRPK2.
CC   -!- SUBUNIT: Homodimer. Interacts with SAMSN1 and KRPCE (By
CC       similarity). Interacts with SSH1 and TORC2/CRTC2. Interacts with
CC       ABL1; the interaction results in cytoplasmic location of ABL1 and
CC       inhibition of cABL-mediated apoptosis. Interacts with ROR2
CC       (dimer); the interaction results in phosphorylation of YWHAB on
CC       tyrosine residues. Interacts with GAB2 and YAP1 (phosphorylated
CC       form). Interacts with the phosphorylated (by AKT1) form of SRPK2.
CC       Interacts with PKA-phosphorylated AANAT.
CC   -!- INTERACTION:
CC       Q76353:- (xeno); NbExp=3; IntAct=EBI-359815, EBI-6248077;
CC       Q9P0K1-3:ADAM22; NbExp=2; IntAct=EBI-359815, EBI-1567267;
CC       O00257:CBX4; NbExp=2; IntAct=EBI-359815, EBI-722425;
CC       P30304:CDC25A; NbExp=8; IntAct=EBI-359815, EBI-747671;
CC       O94921:CDK14; NbExp=5; IntAct=EBI-359815, EBI-1043945;
CC       Q9NYF0:DACT1; NbExp=4; IntAct=EBI-359815, EBI-3951744;
CC       Q13627-2:DYRK1A; NbExp=3; IntAct=EBI-359815, EBI-1053621;
CC       Q11184:let-756 (xeno); NbExp=2; IntAct=EBI-359815, EBI-3843983;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-359815, EBI-5323863;
CC       Q99683:MAP3K5; NbExp=3; IntAct=EBI-359815, EBI-476263;
CC       Q7KZI7:MARK2; NbExp=2; IntAct=EBI-359815, EBI-516560;
CC       P27448:MARK3; NbExp=2; IntAct=EBI-359815, EBI-707595;
CC       P04049:RAF1; NbExp=10; IntAct=EBI-359815, EBI-365996;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Melanosome. Note=Identified by
CC       mass spectrometry in melanosome fractions from stage I to stage
CC       IV.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P31946-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P31946-2; Sequence=VSP_018632;
CC         Note=Acetylated on Met-1 (By similarity);
CC   -!- PTM: The alpha, brain-specific form differs from the beta form in
CC       being phosphorylated (By similarity).
CC   -!- PTM: Isoform Short contains a N-acetylmethionine at position 1 (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57346; CAA40621.1; -; mRNA.
DR   EMBL; AK292717; BAF85406.1; -; mRNA.
DR   EMBL; AL008725; CAA15497.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75893.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75894.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75896.1; -; Genomic_DNA.
DR   EMBL; BC001359; AAH01359.1; -; mRNA.
DR   IPI; IPI00216318; -.
DR   IPI; IPI00759832; -.
DR   PIR; S34755; S34755.
DR   RefSeq; NP_003395.1; NM_003404.3.
DR   RefSeq; NP_647539.1; NM_139323.2.
DR   UniGene; Hs.643544; -.
DR   PDB; 2BQ0; X-ray; 2.50 A; A/B=1-239.
DR   PDB; 2C23; X-ray; 2.65 A; A=1-239.
DR   PDB; 4DNK; X-ray; 2.20 A; A/B=1-246.
DR   PDBsum; 2BQ0; -.
DR   PDBsum; 2C23; -.
DR   PDBsum; 4DNK; -.
DR   ProteinModelPortal; P31946; -.
DR   SMR; P31946; 1-234.
DR   DIP; DIP-743N; -.
DR   IntAct; P31946; 53.
DR   MINT; MINT-99570; -.
DR   STRING; P31946; -.
DR   PhosphoSite; P31946; -.
DR   DMDM; 1345590; -.
DR   Cornea-2DPAGE; P31946; -.
DR   OGP; P31946; -.
DR   REPRODUCTION-2DPAGE; IPI00216318; -.
DR   PaxDb; P31946; -.
DR   PRIDE; P31946; -.
DR   DNASU; 7529; -.
DR   Ensembl; ENST00000353703; ENSP00000300161; ENSG00000166913.
DR   Ensembl; ENST00000372839; ENSP00000361930; ENSG00000166913.
DR   GeneID; 7529; -.
DR   KEGG; hsa:7529; -.
DR   UCSC; uc002xmt.3; human.
DR   CTD; 7529; -.
DR   GeneCards; GC20P043515; -.
DR   HGNC; HGNC:12849; YWHAB.
DR   HPA; CAB003759; -.
DR   HPA; HPA007925; -.
DR   HPA; HPA011212; -.
DR   MIM; 601289; gene.
DR   neXtProt; NX_P31946; -.
DR   PharmGKB; PA37438; -.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P31946; -.
DR   KO; K16197; -.
DR   OMA; CNDVLXT; -.
DR   OrthoDB; EOG4N30PR; -.
DR   PhylomeDB; P31946; -.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; foxopathway; FoxO family signaling.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Pathway_Interaction_DB; p38_mk2pathway; p38 signaling mediated by MAPKAP kinases.
DR   Pathway_Interaction_DB; nfat_3pathway; Role of Calcineurin-dependent NFAT signaling in lymphocytes.
DR   Pathway_Interaction_DB; hdac_classii_pathway; Signaling events mediated by HDAC Class II.
DR   Pathway_Interaction_DB; pi3kplctrkpathway; Trk receptor signaling mediated by PI3K and PLC-gamma.
DR   Reactome; REACT_111045; Developmental Biology.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_21257; Metabolism of RNA.
DR   Reactome; REACT_578; Apoptosis.
DR   Reactome; REACT_6900; Immune System.
DR   Reactome; REACT_71; Gene Expression.
DR   EvolutionaryTrace; P31946; -.
DR   GenomeRNAi; 7529; -.
DR   NextBio; 29453; -.
DR   ArrayExpress; P31946; -.
DR   Bgee; P31946; -.
DR   CleanEx; HS_YWHAB; -.
DR   Genevestigator; P31946; -.
DR   GermOnline; ENSG00000166913; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcriptional repressor complex; IEA:Compara.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Compara.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0051220; P:cytoplasmic sequestering of protein; IDA:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0035329; P:hippo signaling cascade; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0016071; P:mRNA metabolic process; TAS:Reactome.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-dependent; IEA:Compara.
DR   GO; GO:0048011; P:nerve growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006605; P:protein targeting; IEA:Compara.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   Gene3D; 1.20.190.20; 14-3-3; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; 14-3-3; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    246       14-3-3 protein beta/alpha.
FT                                /FTId=PRO_0000367900.
FT   INIT_MET      1      1       Removed; alternate.
FT   CHAIN         2    246       14-3-3 protein beta/alpha, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000000003.
FT   SITE         58     58       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   SITE        129    129       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine; in 14-3-3 protein
FT                                beta/alpha; alternate.
FT   MOD_RES       2      2       N-acetylthreonine; in 14-3-3 protein
FT                                beta/alpha, N-terminally processed.
FT   MOD_RES       6      6       Phosphoserine.
FT   MOD_RES      70     70       N6-acetyllysine.
FT   MOD_RES     117    117       N6-acetyllysine.
FT   MOD_RES     186    186       Phosphoserine (By similarity).
FT   VAR_SEQ       1      2       Missing (in isoform Short).
FT                                /FTId=VSP_018632.
FT   VARIANT      99     99       V -> I (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_064762.
FT   HELIX         5     17
FT   HELIX        21     33
FT   HELIX        40     69
FT   HELIX        75    105
FT   HELIX       107    110
FT   HELIX       114    133
FT   HELIX       139    161
FT   HELIX       167    182
FT   HELIX       187    202
FT   HELIX       203    207
FT   TURN        210    212
FT   HELIX       213    232
SQ   SEQUENCE   246 AA;  28082 MW;  6BE1A9BF97468017 CRC64;
     MTMDKSELVQ KAKLAEQAER YDDMAAAMKA VTEQGHELSN EERNLLSVAY KNVVGARRSS
     WRVISSIEQK TERNEKKQQM GKEYREKIEA ELQDICNDVL ELLDKYLIPN ATQPESKVFY
     LKMKGDYFRY LSEVASGDNK QTTVSNSQQA YQEAFEISKK EMQPTHPIRL GLALNFSVFY
     YEILNSPEKA CSLAKTAFDE AIAELDTLNE ESYKDSTLIM QLLRDNLTLW TSENQGDEGD
     AGEGEN
//
ID   1433E_HUMAN             Reviewed;         255 AA.
AC   P62258; B3KY71; D3DTH5; P29360; P42655; Q4VJB6; Q53XZ5; Q63631;
AC   Q7M4R4;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   09-JAN-2013, entry version 107.
DE   RecName: Full=14-3-3 protein epsilon;
DE            Short=14-3-3E;
GN   Name=YWHAE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=95372385; PubMed=7644510; DOI=10.1073/pnas.92.17.7892;
RA   Conklin D.S., Galaktionov K., Beach D.;
RT   "14-3-3 proteins associate with cdc25 phosphatases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7892-7896(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   MEDLINE=97011338; PubMed=8858348;
RA   Chong S.S., Tanigami A., Roschke A.V., Ledbetter D.H.;
RT   "14-3-3 epsilon has no homology to LIS1 and lies telomeric to it on
RT   chromosome 17p13.3 outside the Miller-Dieker syndrome chromosome
RT   region.";
RL   Genome Res. 6:735-741(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=96300316; PubMed=8684458; DOI=10.1038/382308a0;
RA   Jin D.-Y., Lyu M.S., Kozak C.A., Jeang K.-T.;
RT   "Function of 14-3-3 proteins.";
RL   Nature 382:308-308(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SV), AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=20417184; DOI=10.1016/j.bbrc.2010.04.104;
RA   Han D., Ye G., Liu T., Chen C., Yang X., Wan B., Pan Y., Yu L.;
RT   "Functional identification of a novel 14-3-3 epsilon splicing variant
RT   suggests dimerization is not necessary for 14-3-3 epsilon to inhibit
RT   UV-induced apoptosis.";
RL   Biochem. Biophys. Res. Commun. 396:401-406(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RA   Luk S.C.W., Lee C.Y., Waye M.M.Y.;
RT   "Sequence determination of human epsilon 14-3-3 protein.";
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Tanigami A., Chong S.S., Ledbetter D.H.;
RT   "14-3-3 epsilon genomic sequence.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND SV).
RC   TISSUE=Caudate nucleus, Heart, and Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 1-19.
RC   TISSUE=Platelet;
RX   MEDLINE=22608298; PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [12]
RP   PROTEIN SEQUENCE OF 1-19; 30-50 AND 131-170, ACETYLATION AT MET-1, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAY-2005) to UniProtKB.
RN   [13]
RP   PROTEIN SEQUENCE OF 103-108; 120-123; 131-141 AND 143-153.
RC   TISSUE=Histiocytic lymphoma;
RX   MEDLINE=91224664; PubMed=2026444;
RA   Demeter J., Medzihradszky D., Kha H., Goetzl E.J., Turck C.W.;
RT   "Isolation and partial characterization of the structures of
RT   fibroblast activating factor-related proteins from U937 cells.";
RL   Immunology 72:350-354(1991).
RN   [14]
RP   PROTEIN SEQUENCE OF 131-141 AND 154-190, AND MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [15]
RP   INTERACTION WITH HCV CORE PROTEIN.
RX   MEDLINE=20111292; PubMed=10644344;
RX   DOI=10.1128/JVI.74.4.1736-1741.2000;
RA   Aoki H., Hayashi J., Moriyama M., Arakawa Y., Hino O.;
RT   "Hepatitis C virus core protein interacts with 14-3-3 protein and
RT   activates the kinase Raf-1.";
RL   J. Virol. 74:1736-1741(2000).
RN   [16]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [17]
RP   INTERACTION WITH CDKN1B, AND SUBCELLULAR LOCATION.
RX   PubMed=12042314; DOI=10.1074/jbc.M203668200;
RA   Fujita N., Sato S., Katayama K., Tsuruo T.;
RT   "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3
RT   and cytoplasmic localization.";
RL   J. Biol. Chem. 277:28706-28713(2002).
RN   [18]
RP   INTERACTION WITH GRB10.
RX   PubMed=15722337; DOI=10.1074/jbc.M501477200;
RA   Urschel S., Bassermann F., Bai R.Y., Munch S., Peschel C., Duyster J.;
RT   "Phosphorylation of grb10 regulates its interaction with 14-3-3.";
RL   J. Biol. Chem. 280:16987-16993(2005).
RN   [19]
RP   INTERACTION WITH ABL1, AND MASS SPECTROMETRY.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [20]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [21]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [22]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-38 AND SER-210, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   INTERACTION WITH SRPK2.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-50; LYS-69; LYS-118 AND
RP   LYS-123, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-233, MASS SPECTROMETRY,
RP   INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC   -!- SUBUNIT: Homodimer. Heterodimerizes with YWHAZ. Interacts with
CC       NDEL1, ARHGEF28 and TIAM2 (By similarity). Interacts with HCV core
CC       protein. Interacts with ABL1 (phosphorylated form); the
CC       interaction retains it in the cytoplasm. Weakly interacts with
CC       CDKN1B. Interacts with GAB2. Interacts with phosphorylated GRB10.
CC       Interacts with PKA-phosphorylated AANAT. Interacts with the
CC       phosphorylated (by AKT1) form of SRPK2.
CC   -!- INTERACTION:
CC       O00257-3:CBX4; NbExp=2; IntAct=EBI-356498, EBI-4392727;
CC       O94921:CDK14; NbExp=3; IntAct=EBI-356498, EBI-1043945;
CC       Q9UKT5:FBXO4; NbExp=5; IntAct=EBI-356498, EBI-960409;
CC       Q14678-2:KANK1; NbExp=3; IntAct=EBI-356498, EBI-6173812;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-356498, EBI-5323863;
CC       P61981:YWHAG; NbExp=4; IntAct=EBI-356498, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Melanosome.
CC       Note=Identified by mass spectrometry in melanosome fractions from
CC       stage I to stage IV.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P62258-1; Sequence=Displayed;
CC       Name=SV;
CC         IsoId=P62258-2; Sequence=VSP_040621;
CC         Note=Unable to dimerize with YWHAZ;
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U20972; AAC50175.1; -; mRNA.
DR   EMBL; U54778; AAC50710.1; -; mRNA.
DR   EMBL; U43399; AAC50625.1; -; mRNA.
DR   EMBL; U43430; AAD00026.1; -; mRNA.
DR   EMBL; U28936; AAA75301.1; -; mRNA.
DR   EMBL; AB017103; BAA32538.1; -; Genomic_DNA.
DR   EMBL; AY883089; AAX68683.1; -; mRNA.
DR   EMBL; AK128785; BAG54733.1; -; mRNA.
DR   EMBL; AK295260; BAG58249.1; -; mRNA.
DR   EMBL; AK316185; BAH14556.1; -; mRNA.
DR   EMBL; BT007161; AAP35825.1; -; mRNA.
DR   EMBL; CH471108; EAW90628.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90629.1; -; Genomic_DNA.
DR   EMBL; BC000179; AAH00179.1; -; mRNA.
DR   EMBL; BC001440; AAH01440.1; -; mRNA.
DR   IPI; IPI00000816; -.
DR   IPI; IPI00974544; -.
DR   PIR; A61235; A61235.
DR   PIR; I38947; I38947.
DR   RefSeq; NP_006752.1; NM_006761.4.
DR   UniGene; Hs.513851; -.
DR   PDB; 2BR9; X-ray; 1.75 A; A=1-233.
DR   PDB; 3UAL; X-ray; 1.80 A; A=1-232.
DR   PDB; 3UBW; X-ray; 1.90 A; A=1-234.
DR   PDBsum; 2BR9; -.
DR   PDBsum; 3UAL; -.
DR   PDBsum; 3UBW; -.
DR   ProteinModelPortal; P62258; -.
DR   SMR; P62258; 3-232.
DR   DIP; DIP-36676N; -.
DR   IntAct; P62258; 97.
DR   MINT; MINT-4998623; -.
DR   STRING; P62258; -.
DR   PhosphoSite; P62258; -.
DR   DMDM; 51702210; -.
DR   OGP; P42655; -.
DR   UCD-2DPAGE; P62258; -.
DR   PaxDb; P62258; -.
DR   PeptideAtlas; P62258; -.
DR   PRIDE; P62258; -.
DR   DNASU; 7531; -.
DR   Ensembl; ENST00000264335; ENSP00000264335; ENSG00000108953.
DR   Ensembl; ENST00000571732; ENSP00000461762; ENSG00000108953.
DR   GeneID; 7531; -.
DR   KEGG; hsa:7531; -.
DR   UCSC; uc002fsj.3; human.
DR   CTD; 7531; -.
DR   GeneCards; GC17M001247; -.
DR   H-InvDB; HIX0013751; -.
DR   H-InvDB; HIX0030006; -.
DR   HGNC; HGNC:12851; YWHAE.
DR   HPA; CAB016200; -.
DR   HPA; CAB021109; -.
DR   HPA; CAB047350; -.
DR   HPA; HPA008445; -.
DR   MIM; 605066; gene.
DR   neXtProt; NX_P62258; -.
DR   Orphanet; 217385; 17p13.3 microduplication syndrome.
DR   PharmGKB; PA37440; -.
DR   eggNOG; COG5040; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P62258; -.
DR   KO; K06630; -.
DR   OMA; KESALIM; -.
DR   OrthoDB; EOG4HHP34; -.
DR   PhylomeDB; P62258; -.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; foxopathway; FoxO family signaling.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Pathway_Interaction_DB; lis1pathway; Lissencephaly gene (LIS1) in neuronal migration and development.
DR   Pathway_Interaction_DB; p38_mk2pathway; p38 signaling mediated by MAPKAP kinases.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; telomerasepathway; Regulation of Telomerase.
DR   Pathway_Interaction_DB; nfat_3pathway; Role of Calcineurin-dependent NFAT signaling in lymphocytes.
DR   Pathway_Interaction_DB; hdac_classii_pathway; Signaling events mediated by HDAC Class II.
DR   Pathway_Interaction_DB; tgfbrpathway; TGF-beta receptor signaling.
DR   Pathway_Interaction_DB; pi3kplctrkpathway; Trk receptor signaling mediated by PI3K and PLC-gamma.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_115566; Cell Cycle.
DR   EvolutionaryTrace; P62258; -.
DR   GenomeRNAi; 7531; -.
DR   NextBio; 29461; -.
DR   PMAP-CutDB; P62258; -.
DR   ArrayExpress; P62258; -.
DR   Bgee; P62258; -.
DR   CleanEx; HS_YWHAE; -.
DR   Genevestigator; P62258; -.
DR   GermOnline; ENSG00000108953; Homo sapiens.
DR   GO; GO:0033267; C:axon part; IEA:Compara.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005871; C:kinesin complex; IEA:Compara.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Compara.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Compara.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0035329; P:hippo signaling cascade; TAS:Reactome.
DR   GO; GO:0021766; P:hippocampus development; IEA:Compara.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IEA:Compara.
DR   GO; GO:0048011; P:nerve growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001764; P:neuron migration; IEA:Compara.
DR   GO; GO:0006605; P:protein targeting; IEA:Compara.
DR   GO; GO:0019048; P:virus-host interaction; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.190.20; 14-3-3; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; 14-3-3; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Host-virus interaction;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    255       14-3-3 protein epsilon.
FT                                /FTId=PRO_0000058618.
FT   SITE         57     57       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        130    130       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES      38     38       Phosphothreonine.
FT   MOD_RES      50     50       N6-acetyllysine.
FT   MOD_RES      69     69       N6-acetyllysine.
FT   MOD_RES     118    118       N6-acetyllysine.
FT   MOD_RES     123    123       N6-acetyllysine.
FT   MOD_RES     210    210       Phosphoserine.
FT   VAR_SEQ       1     22       Missing (in isoform SV).
FT                                /FTId=VSP_040621.
FT   CONFLICT    106    107       KH -> NY (in Ref. 13; AA sequence).
FT   CONFLICT    143    143       E -> F (in Ref. 13; AA sequence).
FT   CONFLICT    148    148       S -> T (in Ref. 13; AA sequence).
FT   HELIX         4     17
FT   HELIX        20     31
FT   HELIX        39     73
FT   HELIX        76    106
FT   HELIX       108    111
FT   HELIX       115    135
FT   HELIX       138    162
FT   HELIX       168    183
FT   HELIX       188    204
FT   HELIX       205    208
FT   TURN        211    213
FT   HELIX       214    231
SQ   SEQUENCE   255 AA;  29174 MW;  07817CCBD1F75B26 CRC64;
     MDDREDLVYQ AKLAEQAERY DEMVESMKKV AGMDVELTVE ERNLLSVAYK NVIGARRASW
     RIISSIEQKE ENKGGEDKLK MIREYRQMVE TELKLICCDI LDVLDKHLIP AANTGESKVF
     YYKMKGDYHR YLAEFATGND RKEAAENSLV AYKAASDIAM TELPPTHPIR LGLALNFSVF
     YYEILNSPDR ACRLAKAAFD DAIAELDTLS EESYKDSTLI MQLLRDNLTL WTSDMQGDGE
     EQNKEALQDV EDENQ
//
ID   ARSF_HUMAN              Reviewed;         590 AA.
AC   P54793; Q8TCC5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 4.
DT   28-NOV-2012, entry version 101.
DE   RecName: Full=Arylsulfatase F;
DE            Short=ASF;
DE            EC=3.1.6.-;
DE   Flags: Precursor;
GN   Name=ARSF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-527.
RC   TISSUE=Fetal brain;
RX   MEDLINE=97336043; PubMed=9192838; DOI=10.1006/geno.1997.4716;
RA   Puca A.A., Zollo M., Repetto M., Andolfi G., Guffanti A., Simon G.,
RA   Ballabio A., Franco B.;
RT   "Identification by shotgun sequencing, genomic organization, and
RT   functional analysis of a fourth arylsulfatase gene (ARSF) from the
RT   Xp22.3 region.";
RL   Genomics 42:192-199(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT TYR-527.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-422.
RC   TISSUE=Kidney;
RX   MEDLINE=95236447; PubMed=7720070; DOI=10.1016/0092-8674(95)90367-4;
RA   Franco B., Meroni G., Parenti G., Levilliers J., Bernard L.,
RA   Gebbia M., Cox L., Maroteaux P., Sheffield L., Rappold G.A.,
RA   Andria G., Petit C., Ballabio A.;
RT   "A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia
RT   punctata (CDPX) and implications for warfarin embryopathy.";
RL   Cell 81:15-25(1995).
CC   -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).
CC   -!- ENZYME REGULATION: Not inhibited by DHEAS or warfarin.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 8;
CC   -!- SUBCELLULAR LOCATION: Secreted (Potential).
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity (By similarity).
CC   -!- SIMILARITY: Belongs to the sulfatase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X97868; CAA66462.1; -; mRNA.
DR   EMBL; AC112653; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022389; AAH22389.1; -; mRNA.
DR   IPI; IPI00008405; -.
DR   PIR; A56217; A56217.
DR   RefSeq; NP_001188467.1; NM_001201538.1.
DR   RefSeq; NP_001188468.1; NM_001201539.1.
DR   RefSeq; NP_004033.2; NM_004042.4.
DR   UniGene; Hs.101674; -.
DR   ProteinModelPortal; P54793; -.
DR   SMR; P54793; 26-577.
DR   IntAct; P54793; 1.
DR   STRING; P54793; -.
DR   PhosphoSite; P54793; -.
DR   DMDM; 259016386; -.
DR   PaxDb; P54793; -.
DR   PRIDE; P54793; -.
DR   Ensembl; ENST00000359361; ENSP00000352319; ENSG00000062096.
DR   Ensembl; ENST00000381127; ENSP00000370519; ENSG00000062096.
DR   Ensembl; ENST00000537104; ENSP00000445594; ENSG00000062096.
DR   GeneID; 416; -.
DR   KEGG; hsa:416; -.
DR   UCSC; uc004cre.2; human.
DR   CTD; 416; -.
DR   GeneCards; GC0XP002978; -.
DR   H-InvDB; HIX0016636; -.
DR   HGNC; HGNC:721; ARSF.
DR   HPA; HPA000549; -.
DR   MIM; 300003; gene.
DR   neXtProt; NX_P54793; -.
DR   PharmGKB; PA25012; -.
DR   eggNOG; COG3119; -.
DR   HOGENOM; HOG000135352; -.
DR   HOVERGEN; HBG004283; -.
DR   InParanoid; P54793; -.
DR   KO; K12374; -.
DR   OMA; IMVKEAI; -.
DR   OrthoDB; EOG4V4379; -.
DR   PhylomeDB; P54793; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_17015; Metabolism of proteins.
DR   GenomeRNAi; 416; -.
DR   NextBio; 1759; -.
DR   ArrayExpress; P54793; -.
DR   Bgee; P54793; -.
DR   CleanEx; HS_ARSF; -.
DR   Genevestigator; P54793; -.
DR   GermOnline; ENSG00000062096; Homo sapiens.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0004065; F:arylsulfatase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0006644; P:phospholipid metabolic process; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.720.10; Alk_phosphtse; 2.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR000917; Sulfatase.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; Alkaline_phosphatase_core; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   Calcium; Complete proteome; Glycoprotein; Hydrolase; Metal-binding;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     22       Potential.
FT   CHAIN        23    590       Arylsulfatase F.
FT                                /FTId=PRO_0000033427.
FT   ACT_SITE    139    139       By similarity.
FT   METAL        38     38       Calcium (By similarity).
FT   METAL        39     39       Calcium (By similarity).
FT   METAL        78     78       Calcium; via 3-oxoalanine (By
FT                                similarity).
FT   METAL       345    345       Calcium (By similarity).
FT   METAL       346    346       Calcium (By similarity).
FT   BINDING     137    137       Substrate (By similarity).
FT   BINDING     293    293       Substrate (By similarity).
FT   BINDING     370    370       Substrate (By similarity).
FT   MOD_RES      78     78       3-oxoalanine (Cys) (By similarity).
FT   CARBOHYD     50     50       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    117    117       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    336    336       N-linked (GlcNAc...) (Potential).
FT   VARIANT     527    527       H -> Y (in dbSNP:rs1052638).
FT                                /FTId=VAR_058846.
FT   CONFLICT     20     29       CQAHRVHDDK -> WPGHTGCMTTR (in Ref. 1;
FT                                CAA66462).
SQ   SEQUENCE   590 AA;  65940 MW;  EA9B7289040AE79A CRC64;
     MRPRRPLVFM SLVCALLNTC QAHRVHDDKP NIVLIMVDDL GIGDLGCYGN DTMRTPHIDR
     LAREGVRLTQ HISAASLCSP SRSAFLTGRY PIRSGMVSSG NRRVIQNLAV PAGLPLNETT
     LAALLKKQGY STGLIGKWHQ GLNCDSRSDQ CHHPYNYGFD YYYGMPFTLV DSCWPDPSRN
     TELAFESQLW LCVQLVAIAI LTLTFGKLSG WVSVPWLLIF SMILFIFLLG YAWFSSHTSP
     LYWDCLLMRG HEITEQPMKA ERAGSIMVKE AISFLERHSK ETFLLFFSFL HVHTPLPTTD
     DFTGTSKHGL YGDNVEEMDS MVGKILDAID DFGLRNNTLV YFTSDHGGHL EARRGHAQLG
     GWNGIYKGGK GMGGWEGGIR VPGIVRWPGK VPAGRLIKEP TSLMDILPTV ASVSGGSLPQ
     DRVIDGRDLM PLLQGNVRHS EHEFLFHYCG SYLHAVRWIP KDDSGSVWKA HYVTPVFQPP
     ASGGCYVTSL CRCFGEQVTY HNPPLLFDLS RDPSESTPLT PATEPLHDFV IKKVANALKE
     HQETIVPVTY QLSELNQGRT WLKPCCGVFP FCLCDKEEEV SQPRGPNEKR
//
ID   ARSG_HUMAN              Reviewed;         525 AA.
AC   Q96EG1; Q6UXF2; Q9Y2K4;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   28-NOV-2012, entry version 88.
DE   RecName: Full=Arylsulfatase G;
DE            Short=ASG;
DE            EC=3.1.6.-;
DE   Flags: Precursor;
GN   Name=ARSG; Synonyms=KIAA1001; ORFNames=UNQ839/PRO1777;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=99246063; PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION.
RX   PubMed=12461688; DOI=10.1038/sj.ejhg.5200887;
RA   Ferrante P., Messali S., Meroni G., Ballabio A.;
RT   "Molecular and biochemical characterisation of a novel sulphatase
RT   gene: arylsulfatase G (ARSG).";
RL   Eur. J. Hum. Genet. 10:813-818(2002).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, OXOALANINE AT
RP   CYS-84, GLYCOSYLATION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS
RP   OF CYS-84 AND ALA-501.
RX   PubMed=18283100; DOI=10.1074/jbc.M709917200;
RA   Frese M.A., Schulz S., Dierks T.;
RT   "Arylsulfatase G, a novel lysosomal sulfatase.";
RL   J. Biol. Chem. 283:11388-11395(2008).
CC   -!- FUNCTION: Displays arylsulfatase activity at acidic pH with
CC       pseudosubstrates, such as p-nitrocatechol sulfate and also, but
CC       with lower activity, p-nitrophenyl sulfate and 4-
CC       methylumbelliferyl sulfate.
CC   -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).
CC   -!- ENZYME REGULATION: Inhibited by phosphate. The phosphate forms a
CC       covalent bond with the active site 3-oxoalanine.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=4.2 mM for p-nitrocatechol sulfate;
CC         Vmax=63.5 umol/min/mg enzyme toward p-nitrocatechol sulfate;
CC       pH dependence:
CC         Optimum pH is 5.4;
CC       Temperature dependence:
CC         Most efficient at 45-50 degrees Celsius;
CC   -!- SUBCELLULAR LOCATION: Lysosome. Note=Previously observed
CC       endoplasmic reticulum localization is most likely due to
CC       folding/maturation problems for overexpressed proteins.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with very low expression in
CC       brain, lung, heart and skeletal muscle.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity (By similarity).
CC   -!- PTM: Glycosylated.
CC   -!- SIMILARITY: Belongs to the sulfatase family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76845.2; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB023218; BAA76845.2; ALT_INIT; mRNA.
DR   EMBL; AY358380; AAQ88746.1; -; mRNA.
DR   EMBL; BC012375; AAH12375.1; -; mRNA.
DR   IPI; IPI00402293; -.
DR   RefSeq; NP_001254656.1; NM_001267727.1.
DR   RefSeq; NP_055775.2; NM_014960.4.
DR   UniGene; Hs.437249; -.
DR   ProteinModelPortal; Q96EG1; -.
DR   SMR; Q96EG1; 34-523.
DR   STRING; Q96EG1; -.
DR   DMDM; 74731559; -.
DR   PaxDb; Q96EG1; -.
DR   PeptideAtlas; Q96EG1; -.
DR   PRIDE; Q96EG1; -.
DR   Ensembl; ENST00000448504; ENSP00000407193; ENSG00000141337.
DR   Ensembl; ENST00000570630; ENSP00000459720; ENSG00000263074.
DR   GeneID; 22901; -.
DR   KEGG; hsa:22901; -.
DR   UCSC; uc002jhc.2; human.
DR   CTD; 22901; -.
DR   GeneCards; GC17P066255; -.
DR   HGNC; HGNC:24102; ARSG.
DR   HPA; HPA023245; -.
DR   HPA; HPA023285; -.
DR   MIM; 610008; gene.
DR   neXtProt; NX_Q96EG1; -.
DR   PharmGKB; PA143485307; -.
DR   eggNOG; COG3119; -.
DR   HOGENOM; HOG000135352; -.
DR   HOVERGEN; HBG004283; -.
DR   InParanoid; Q96EG1; -.
DR   KO; K12381; -.
DR   OMA; VTPCCNP; -.
DR   OrthoDB; EOG4J9MZJ; -.
DR   PhylomeDB; Q96EG1; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_17015; Metabolism of proteins.
DR   GenomeRNAi; 22901; -.
DR   NextBio; 43535; -.
DR   ArrayExpress; Q96EG1; -.
DR   CleanEx; HS_ARSG; -.
DR   Genevestigator; Q96EG1; -.
DR   GermOnline; ENSG00000141337; Homo sapiens.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0004065; F:arylsulfatase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0006644; P:phospholipid metabolic process; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006790; P:sulfur compound metabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.720.10; Alk_phosphtse; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR000917; Sulfatase.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; Alkaline_phosphatase_core; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   Calcium; Complete proteome; Glycoprotein; Hydrolase; Lysosome;
KW   Metal-binding; Polymorphism; Reference proteome; Signal.
FT   SIGNAL        1     16       Potential.
FT   CHAIN        17    525       Arylsulfatase G.
FT                                /FTId=PRO_0000042215.
FT   ACT_SITE    139    139       By similarity.
FT   METAL        44     44       Calcium (By similarity).
FT   METAL        45     45       Calcium (By similarity).
FT   METAL        84     84       Calcium; via 3-oxoalanine (By
FT                                similarity).
FT   METAL       302    302       Calcium (By similarity).
FT   METAL       303    303       Calcium (By similarity).
FT   BINDING     137    137       Substrate (By similarity).
FT   BINDING     162    162       Substrate (By similarity).
FT   BINDING     251    251       Substrate (By similarity).
FT   MOD_RES      84     84       3-oxoalanine (Cys).
FT   CARBOHYD    117    117       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    215    215       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    356    356       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    497    497       N-linked (GlcNAc...) (Potential).
FT   VARIANT      11     11       A -> V (in dbSNP:rs8074806).
FT                                /FTId=VAR_052511.
FT   VARIANT     236    236       T -> S (in dbSNP:rs1558876).
FT                                /FTId=VAR_052512.
FT   VARIANT     274    274       W -> R (in dbSNP:rs1558878).
FT                                /FTId=VAR_052513.
FT   VARIANT     385    385       R -> H (in dbSNP:rs9972951).
FT                                /FTId=VAR_052514.
FT   MUTAGEN      84     84       C->A: No sulfatase activity.
FT   MUTAGEN     501    501       A->P: Decrease of sulfatase activity.
FT   CONFLICT    444    445       TG -> MV (in Ref. 2; AAQ88746).
FT   CONFLICT    501    501       A -> P (in Ref. 1; BAA76845).
SQ   SEQUENCE   525 AA;  57061 MW;  ADAB673A02B25754 CRC64;
     MGWLFLKVLL AGVSFSGFLY PLVDFCISGK TRGQKPNFVI ILADDMGWGD LGANWAETKD
     TANLDKMASE GMRFVDFHAA ASTCSPSRAS LLTGRLGLRN GVTRNFAVTS VGGLPLNETT
     LAEVLQQAGY VTGIIGKWHL GHHGSYHPNF RGFDYYFGIP YSHDMGCTDT PGYNHPPCPA
     CPQGDGPSRN LQRDCYTDVA LPLYENLNIV EQPVNLSSLA QKYAEKATQF IQRASTSGRP
     FLLYVALAHM HVPLPVTQLP AAPRGRSLYG AGLWEMDSLV GQIKDKVDHT VKENTFLWFT
     GDNGPWAQKC ELAGSVGPFT GFWQTRQGGS PAKQTTWEGG HRVPALAYWP GRVPVNVTST
     ALLSVLDIFP TVVALAQASL PQGRRFDGVD VSEVLFGRSQ PGHRVLFHPN SGAAGEFGAL
     QTVRLERYKA FYITGGARAC DGSTGPELQH KFPLIFNLED DTAEAVPLER GGAEYQAVLP
     EVRKVLADVL QDIANDNISS ADYTQDPSVT PCCNPYQIAC RCQAA
//
ID   ATN1_HUMAN              Reviewed;        1190 AA.
AC   P54259; Q99495; Q99621; Q9UEK7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   28-NOV-2012, entry version 120.
DE   RecName: Full=Atrophin-1;
DE   AltName: Full=Dentatorubral-pallidoluysian atrophy protein;
GN   Name=ATN1; Synonyms=D12S755E, DRPLA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT
RP   484-GLN--GLN-488 DEL.
RC   TISSUE=Brain;
RX   MEDLINE=95144175; PubMed=7842016; DOI=10.1038/ng1094-177;
RA   Nagafuchi S., Yanagisawa H., Ohsaki E., Shirayama T., Tadokoro K.,
RA   Inoue T., Yamada M.;
RT   "Structure and expression of the gene responsible for the triplet
RT   repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA).";
RL   Nat. Genet. 8:177-182(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT
RP   484-GLN--GLN-488 DEL.
RC   TISSUE=Brain;
RX   MEDLINE=96026098; PubMed=7485154;
RA   Onodera O., Oyake M., Takano H., Ikeuchi T., Igarashi S., Tsuji S.;
RT   "Molecular cloning of a full-length cDNA for dentatorubral-
RT   pallidoluysian atrophy and regional expressions of the expanded
RT   alleles in the CNS.";
RL   Am. J. Hum. Genet. 57:1050-1060(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANTS ILE-339
RP   AND 484-GLN--GLN-488 DEL.
RX   MEDLINE=96262314; PubMed=8965642; DOI=10.1016/0169-328X(95)00241-J;
RA   Margolis R.L., Li S.-H., Young W.S., Wagster M.V., Stine O.C.,
RA   Kidwai A.S., Ashworth R.G., Ross C.A.;
RT   "DRPLA gene (atrophin-1) sequence and mRNA expression in human
RT   brain.";
RL   Brain Res. Mol. Brain Res. 36:219-226(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND POLYMORPHISM OF POLY-GLN
RP   REGION.
RC   TISSUE=Brain;
RX   MEDLINE=97228904; PubMed=9074930;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-76.
RX   MEDLINE=97005364; PubMed=8852663; DOI=10.1093/hmg/5.3.373;
RA   Yanagisawa H., Fujii K., Nagafuchi S., Nakahori Y., Nakagome Y.,
RA   Akane A., Nakamura M., Sano A., Komure O., Kondo I., Jin D.K.,
RA   Soerensen S.A., Potter N.T., Young S.R., Nakamura K., Nukina N.,
RA   Nagao Y., Tadokoro K., Okuyama T., Miyashita T., Inoue T.,
RA   Kanazawa I., Yamada M.;
RT   "A unique origin and multistep process for the generation of expanded
RT   DRPLA triplet repeats.";
RL   Hum. Mol. Genet. 5:373-379(1996).
RN   [6]
RP   INVOLVEMENT IN HRS.
RX   PubMed=7951323; DOI=10.1038/ng0894-521;
RA   Burke J.R., Wingfield M.S., Lewis K.E., Roses A.D., Lee J.E.,
RA   Hulette C., Pericak-Vance M.A., Vance J.M.;
RT   "The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in
RT   an African-American family.";
RL   Nat. Genet. 7:521-524(1994).
RN   [7]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=9361003; DOI=10.1074/jbc.272.46.29238;
RA   Miyashita T., Okamura-Oho Y., Mito Y., Nagafuchi S., Yamada M.;
RT   "Dentatorubral pallidoluysian atrophy (DRPLA) protein is cleaved by
RT   caspase-3 during apoptosis.";
RL   J. Biol. Chem. 272:29238-29242(1997).
RN   [8]
RP   INTERACTION WITH WWP1; WWP2 AND WWP3.
RX   MEDLINE=98313405; PubMed=9647693; DOI=10.1006/mcne.1998.0677;
RA   Wood J.D., Yuan J., Margolis R.L., Colomer V., Duan K., Kushi J.,
RA   Kaminsky Z., Kleiderlein J.J. Jr., Sharp A.H., Ross C.A.;
RT   "Atrophin-1, the DRPLA gene product, interacts with two families of WW
RT   domain-containing proteins.";
RL   Mol. Cell. Neurosci. 11:149-160(1998).
RN   [9]
RP   INTERACTION WITH BAIAP2, AND SUBCELLULAR LOCATION.
RX   MEDLINE=99265910; PubMed=10332026; DOI=10.1093/hmg/8.6.947;
RA   Okamura-Oho Y., Miyashita T., Ohmi K., Yamada M.;
RT   "Dentatorubral-pallidoluysian atrophy protein interacts through a
RT   proline-rich region near polyglutamine with the SH3 domain of an
RT   insulin receptor tyrosine kinase substrate.";
RL   Hum. Mol. Genet. 8:947-957(1999).
RN   [10]
RP   CLEAVAGE AT ASP-109, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF ASP-109.
RX   PubMed=10085113; DOI=10.1074/jbc.274.13.8730;
RA   Ellerby L.M., Andrusiak R.L., Wellington C.L., Hackam A.S.,
RA   Propp S.S., Wood J.D., Sharp A.H., Margolis R.L., Ross C.A.,
RA   Salvesen G.S., Hayden M.R., Bredesen D.E.;
RT   "Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates
RT   cytotoxicity.";
RL   J. Biol. Chem. 274:8730-8736(1999).
RN   [11]
RP   INTERACTION WITH RERE.
RX   MEDLINE=20275632; PubMed=10814707; DOI=10.1093/hmg/9.9.1433;
RA   Yanagisawa H., Bundo M., Miyashita T., Okamura-Oho Y., Tadokoro K.,
RA   Tokunaga K., Yamada M.;
RT   "Protein binding of a DRPLA family through arginine-glutamic acid
RT   dipeptide repeats is enhanced by extended polyglutamine.";
RL   Hum. Mol. Genet. 9:1433-1442(2000).
RN   [12]
RP   INTERACTION WITH MTG8, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=10973986; DOI=10.1083/jcb.150.5.939;
RA   Wood J.D., Nucifora F.C. Jr., Duan K., Zhang C., Wang J., Kim Y.,
RA   Schilling G., Sacchi N., Liu J.M., Ross C.A.;
RT   "Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene
RT   product, interacts with ETO/MTG8 in the nuclear matrix and represses
RT   transcription.";
RL   J. Cell Biol. 150:939-948(2000).
RN   [13]
RP   PHOSPHORYLATION AT SER-739.
RX   PubMed=12812981; DOI=10.1093/hmg/ddg168;
RA   Okamura-Oho Y., Miyashita T., Nagao K., Shima S., Ogata Y., Katada T.,
RA   Nishina H., Yamada M.;
RT   "Dentatorubral-pallidoluysian atrophy protein is phosphorylated by c-
RT   Jun NH2-terminal kinase.";
RL   Hum. Mol. Genet. 12:1535-1542(2003).
RN   [14]
RP   PROTEOLYTIC PROCESSING, NUCLEAR LOCALIZATION SIGNAL, NUCLEAR EXPORT
RP   SIGNAL, AND SUBCELLULAR LOCATION.
RX   PubMed=12464607; DOI=10.1074/jbc.M211224200;
RA   Nucifora F.C. Jr., Ellerby L.M., Wellington C.L., Wood J.D.,
RA   Herring W.J., Sawa A., Hayden M.R., Dawson V.L., Dawson T.M.,
RA   Ross C.A.;
RT   "Nuclear localization of a non-caspase truncation product of atrophin-
RT   1, with an expanded polyglutamine repeat, increases cellular
RT   toxicity.";
RL   J. Biol. Chem. 278:13047-13055(2003).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34; SER-77; SER-101;
RP   SER-107; SER-112; SER-119; SER-632; SER-645; THR-653; SER-661;
RP   THR-669; SER-746 AND SER-748, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; SER-79; SER-101;
RP   SER-103; SER-107; SER-739; SER-746 AND SER-748, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; SER-79; SER-101;
RP   SER-103; SER-107; THR-651; THR-653; SER-661; TYR-734; SER-746 AND
RP   SER-748, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   INTERACTION WITH FAT1.
RX   PubMed=19131340; DOI=10.1074/jbc.M809333200;
RA   Hou R., Sibinga N.E.;
RT   "Atrophin proteins interact with the Fat1 cadherin and regulate
RT   migration and orientation in vascular smooth muscle cells.";
RL   J. Biol. Chem. 284:6955-6965(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-641, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=20977674; DOI=10.1111/j.1742-4658.2010.07893.x;
RA   Suzuki Y., Nakayama K., Hashimoto N., Yazawa I.;
RT   "Proteolytic processing regulates pathological accumulation in
RT   dentatorubral-pallidoluysian atrophy.";
RL   FEBS J. 277:4873-4887(2010).
CC   -!- FUNCTION: Transcriptional corepressor. Recruits NR2E1 to repress
CC       transcription. Promotes vascular smooth cell (VSMC) migration and
CC       orientation (By similarity). Corepressor of MTG8 transcriptional
CC       repression. Has some intrinsic repression activity which is
CC       independent of the number of poly-Asn (polyQ) repeats.
CC   -!- SUBUNIT: Interacts with NR2E1; the interaction represses the
CC       transcriptional activity of NR2E1. Interacts (via its N-terminus)
CC       with FAT1 (via a C-terminus domain) (By similarity). Interacts
CC       with BAIAP2, WWP1, WWP2, WWP3 and RERE. Interacts (via its N-
CC       terminus) with MTG8; the interaction enhances transcriptional
CC       repression of MTG8.
CC   -!- INTERACTION:
CC       Q12805:EFEMP1; NbExp=3; IntAct=EBI-945980, EBI-536772;
CC       O95967:EFEMP2; NbExp=3; IntAct=EBI-945980, EBI-743414;
CC       Q9HAU0:PLEKHA5; NbExp=2; IntAct=EBI-945980, EBI-945934;
CC       P61289:PSME3; NbExp=3; IntAct=EBI-945980, EBI-355546;
CC       Q9NWB1:RBFOX1; NbExp=2; IntAct=EBI-945980, EBI-945906;
CC       Q9P2R6:RERE; NbExp=3; IntAct=EBI-945980, EBI-948076;
CC       Q15654:TRIP6; NbExp=2; IntAct=EBI-945980, EBI-742327;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, perinuclear region. Cell
CC       junction (By similarity). Note=Shuttles between nucleus and
CC       cytoplasm. Colocalizes with FAT1 in the perinuclear area, at cell-
CC       cell junctions and leading edges of cells (By similarity).
CC       Colocalizes with MTG8 in discrete nuclear dots. Proteolytic
CC       fragment F1 appears to remain in nucleus. Fragment F2 is exported
CC       into the cytoplasm. Fragment F2 from mutant sequences with longer
CC       poly-Asn (polyQ) tracts are additionally located to the
CC       cytoplasmic membrane and to certain organelles.
CC   -!- TISSUE SPECIFICITY: Widely expressed in various tissues including
CC       heart, lung, kidney, ovary, testis, prostate, placenta, skeletal
CC       Low levels in the liver, thymus and leukocytes. In the adult
CC       brain, broadly expressed in amygdala, caudate nucleus, corpus
CC       callosum, hippocampus, hypothalamus, substantia nigra, subthalamic
CC       nucleus, and thalamus. High levels in fetal tissues, especially
CC       brain.
CC   -!- PTM: Phosphorylated in vitro by MAPK8/JNK1 on Ser-739. Mutant ATN1
CC       sequences with expanded poly-Asn (polyQ) traits are more slowly
CC       phosphorylated.
CC   -!- PTM: Proteolytically cleaved, probably in the nucleus, to produce
CC       two C-terminal fragments of 140 kDa (F1) and 125 kDa (F2) each
CC       containing poly-Asn (polyQ) tracts. F2 is produced by cleavage by
CC       caspases and is exported into the cytoplasm. In vitro, cleavage
CC       increases with an increase in the number of polyQ tracts. C-
CC       terminal proteolytic products appear to be the cause of cell
CC       toxicity. In vitro cleavage at Asp-109.
CC   -!- POLYMORPHISM: The poly-Gln region of ATN1 is highly polymorphic (7
CC       to 23 repeats) in the normal population and is expanded to about
CC       49-75 repeats in DRPLA and HRS patients. Longer expansions result
CC       in earlier onset and more severe clinical manifestations of the
CC       disease.
CC   -!- DISEASE: Defects in ATN1 are the cause of dentatorubral-
CC       pallidoluysian atrophy (DRPLA) [MIM:125370]. DRPLA is an autosomal
CC       dominant neurodegenerative disorder characterized by a loss of
CC       neurons in the dentate nucleus, rubrum, glogus pallidus and
CC       Luys'body. Clinical features are myoclonus epilepsy, dementia, and
CC       cerebellar ataxia. Onset of the disease occurs usually in the
CC       second decade of life and death in the fourth.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA07534.1; Type=Frameshift; Positions=961, 970, 977, 980, 983, 1005;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ATN1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D31840; BAA06626.1; -; mRNA.
DR   EMBL; D38529; BAA07534.1; ALT_FRAME; mRNA.
DR   EMBL; U23851; AAB50276.1; -; mRNA.
DR   EMBL; U47924; AAB51321.1; -; Genomic_DNA.
DR   EMBL; D63808; BAA23631.1; -; Genomic_DNA.
DR   IPI; IPI00005502; -.
DR   PIR; G01763; G01763.
DR   PIR; S50832; S50832.
DR   RefSeq; NP_001007027.1; NM_001007026.1.
DR   RefSeq; NP_001931.2; NM_001940.3.
DR   UniGene; Hs.143766; -.
DR   ProteinModelPortal; P54259; -.
DR   IntAct; P54259; 85.
DR   MINT; MINT-92928; -.
DR   STRING; P54259; -.
DR   PhosphoSite; P54259; -.
DR   DMDM; 29429203; -.
DR   PRIDE; P54259; -.
DR   DNASU; 1822; -.
DR   Ensembl; ENST00000356654; ENSP00000349076; ENSG00000111676.
DR   Ensembl; ENST00000396684; ENSP00000379915; ENSG00000111676.
DR   Ensembl; ENST00000544325; ENSP00000441744; ENSG00000111676.
DR   GeneID; 1822; -.
DR   KEGG; hsa:1822; -.
DR   UCSC; uc001qrw.1; human.
DR   CTD; 1822; -.
DR   GeneCards; GC12P007033; -.
DR   H-InvDB; HIX0079489; -.
DR   HGNC; HGNC:3033; ATN1.
DR   HPA; HPA031619; -.
DR   MIM; 125370; phenotype.
DR   MIM; 607462; gene.
DR   neXtProt; NX_P54259; -.
DR   Orphanet; 101; Dentatorubral-pallidoluysian atrophy.
DR   PharmGKB; PA27487; -.
DR   eggNOG; NOG331121; -.
DR   HOVERGEN; HBG075369; -.
DR   InParanoid; P54259; -.
DR   KO; K05626; -.
DR   OMA; PHVTPNL; -.
DR   OrthoDB; EOG4RFKT4; -.
DR   PhylomeDB; P54259; -.
DR   GenomeRNAi; 1822; -.
DR   NextBio; 7425; -.
DR   ArrayExpress; P54259; -.
DR   Bgee; P54259; -.
DR   CleanEx; HS_ATN1; -.
DR   Genevestigator; P54259; -.
DR   GermOnline; ENSG00000111676; Homo sapiens.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0031252; C:cell leading edge; IEA:Compara.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IEA:Compara.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0030011; P:maintenance of cell polarity; IEA:Compara.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IEA:Compara.
DR   GO; GO:0009404; P:toxin metabolic process; IEA:Compara.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   InterPro; IPR017993; Atrophin-1.
DR   InterPro; IPR002951; Atrophin-like.
DR   Pfam; PF03154; Atrophin-1; 2.
DR   PRINTS; PR01222; ATROPHIN.
PE   1: Evidence at protein level;
KW   Acetylation; Cell junction; Complete proteome; Cytoplasm; Epilepsy;
KW   Neurodegeneration; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Triplet repeat expansion.
FT   CHAIN         1   1190       Atrophin-1.
FT                                /FTId=PRO_0000064730.
FT   REGION      517    567       Involved in binding BAIAP2.
FT   REGION      879    894       Required for interaction with FAT1.
FT   MOTIF        16     32       Nuclear localization signal.
FT   MOTIF      1033   1041       Nuclear export signal.
FT   COMPBIAS     73     82       Glu/Ser-rich.
FT   COMPBIAS    302    305       Poly-Pro.
FT   COMPBIAS    376    382       Poly-Ser.
FT   COMPBIAS    386    397       Poly-Ser.
FT   COMPBIAS    442    447       Poly-Pro.
FT   COMPBIAS    479    483       Poly-His.
FT   COMPBIAS    484    502       Poly-Gln.
FT   COMPBIAS    509    512       Poly-Pro.
FT   COMPBIAS    569    579       Poly-Ser.
FT   COMPBIAS    709    712       Poly-Pro.
FT   COMPBIAS    807    820       Ala/Arg-rich.
FT   COMPBIAS    821    832       Arg/Glu-rich (mixed charge).
FT   COMPBIAS    930    939       Arg/Glu-rich (mixed charge).
FT   SITE        109    110       Cleavage.
FT   MOD_RES      34     34       Phosphoserine.
FT   MOD_RES      77     77       Phosphoserine.
FT   MOD_RES      79     79       Phosphoserine.
FT   MOD_RES     101    101       Phosphoserine.
FT   MOD_RES     103    103       Phosphoserine.
FT   MOD_RES     107    107       Phosphoserine.
FT   MOD_RES     112    112       Phosphoserine.
FT   MOD_RES     119    119       Phosphoserine.
FT   MOD_RES     632    632       Phosphoserine.
FT   MOD_RES     641    641       N6-acetyllysine.
FT   MOD_RES     645    645       Phosphoserine.
FT   MOD_RES     651    651       Phosphothreonine.
FT   MOD_RES     653    653       Phosphothreonine.
FT   MOD_RES     661    661       Phosphoserine.
FT   MOD_RES     669    669       Phosphothreonine.
FT   MOD_RES     734    734       Phosphotyrosine.
FT   MOD_RES     739    739       Phosphoserine; by MAPK8.
FT   MOD_RES     746    746       Phosphoserine.
FT   MOD_RES     748    748       Phosphoserine.
FT   VARIANT     339    339       M -> I (in dbSNP:rs1058045).
FT                                /FTId=VAR_030937.
FT   VARIANT     484    488       Missing.
FT                                /FTId=VAR_064038.
FT   MUTAGEN     109    109       D->N: Prevents cleavage and suppresses
FT                                apoptosis.
FT   MUTAGEN     739    739       S->A: Abolishes phosphorylation.
FT   CONFLICT     94     94       Missing (in Ref. 3; AAB50276).
FT   CONFLICT    333    333       H -> Y (in Ref. 1; BAA06626).
FT   CONFLICT   1033   1033       A -> G (in Ref. 1; BAA06626).
SQ   SEQUENCE   1190 AA;  125414 MW;  B47603486C672637 CRC64;
     MKTRQNKDSM SMRSGRKKEA PGPREELRSR GRASPGGVST SSSDGKAEKS RQTAKKARVE
     EASTPKVNKQ GRSEEISESE SEETNAPKKT KTEQELPRPQ SPSDLDSLDG RSLNDDGSSD
     PRDIDQDNRS TSPSIYSPGS VENDSDSSSG LSQGPARPYH PPPLFPPSPQ PPDSTPRQPE
     ASFEPHPSVT PTGYHAPMEP PTSRMFQAPP GAPPPHPQLY PGGTGGVLSG PPMGPKGGGA
     ASSVGGPNGG KQHPPPTTPI SVSSSGASGA PPTKPPTTPV GGGNLPSAPP PANFPHVTPN
     LPPPPALRPL NNASASPPGL GAQPLPGHLP SPHAMGQGMG GLPPGPEKGP TLAPSPHSLP
     PASSSAPAPP MRFPYSSSSS SSAAASSSSS SSSSSASPFP ASQALPSYPH SFPPPTSLSV
     SNQPPKYTQP SLPSQAVWSQ GPPPPPPYGR LLANSNAHPG PFPPSTGAQS TAHPPVSTHH
     HHHQQQQQQQ QQQQQQQQQQ QQHHGNSGPP PPGAFPHPLE GGSSHHAHPY AMSPSLGSLR
     PYPPGPAHLP PPHSQVSYSQ AGPNGPPVSS SSNSSSSTSQ GSYPCSHPSP SQGPQGAPYP
     FPPVPTVTTS SATLSTVIAT VASSPAGYKT ASPPGPPPYG KRAPSPGAYK TATPPGYKPG
     SPPSFRTGTP PGYRGTSPPA GPGTFKPGSP TVGPGPLPPA GPSGLPSLPP PPAAPASGPP
     LSATQIKQEP AEEYETPESP VPPARSPSPP PKVVDVPSHA SQSARFNKHL DRGFNSCARS
     DLYFVPLEGS KLAKKRADLV EKVRREAEQR AREEKERERE REREKERERE KERELERSVK
     LAQEGRAPVE CPSLGPVPHR PPFEPGSAVA TVPPYLGPDT PALRTLSEYA RPHVMSPGNR
     NHPFYVPLGA VDPGLLGYNV PALYSSDPAA REREREARER DLRDRLKPGF EVKPSELEPL
     HGVPGPGLDP FPRHGGLALQ PGPPGLHPFP FHPSLGPLER ERLALAAGPA LRPDMSYAER
     LAAERQHAER VAALGNDPLA RLQMLNVTPH HHQHSHIHSH LHLHQQDAIH AASASVHPLI
     DPLASGSHLT RIPYPAGTLP NPLLPHPLHE NEVLRHQLFA APYRDLPASL SAPMSAAHQL
     QAMHAQSAEL QRLALEQQQW LHAHHPLHSV PLPAQEDYYS HLKKESDKPL
//
ID   HPBP1_HUMAN             Reviewed;         362 AA.
AC   Q9NZL4; B3KQP0; O95351; Q6ZNU5;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   28-NOV-2012, entry version 92.
DE   RecName: Full=Hsp70-binding protein 1;
DE            Short=HspBP1;
DE   AltName: Full=Heat shock protein-binding protein 1;
DE   AltName: Full=Hsp70-binding protein 2;
DE            Short=HspBP2;
DE   AltName: Full=Hsp70-interacting protein 1;
DE   AltName: Full=Hsp70-interacting protein 2;
GN   Name=HSPBP1; Synonyms=HSPBP; ORFNames=PP1845;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT 25-GLY--GLY-27 DEL,
RP   FUNCTION, INTERACTION WITH HSPA1A, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   MEDLINE=99047674; PubMed=9830037; DOI=10.1074/jbc.273.49.32883;
RA   Raynes D.A., Guerriero V. Jr.;
RT   "Inhibition of Hsp70 ATPase activity and protein renaturation by a
RT   novel Hsp70-binding protein.";
RL   J. Biol. Chem. 273:32883-32888(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND POLYMORPHISM OF
RP   POLY-GLY REGION.
RC   TISSUE=Heart;
RX   MEDLINE=20246310; PubMed=10786638; DOI=10.1016/S0167-4781(99)00238-9;
RA   Guerriero V. Jr., Raynes D.A.;
RT   "Isolation and characterization of isoforms of HspBP1, inhibitors of
RT   Hsp70.";
RL   Biochim. Biophys. Acta 1490:203-207(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 25-GLY--GLY-27
RP   DEL.
RA   Tanimura S., Tsujimoto M., Kohno M.;
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   25-GLY--GLY-27 DEL.
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=16303743; DOI=10.1093/dnares/12.2.117;
RA   Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J.,
RA   Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S.,
RA   Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y.,
RA   Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S.,
RA   Isogai T.;
RT   "Signal sequence and keyword trap in silico for selection of full-
RT   length human cDNAs encoding secretion or membrane proteins from oligo-
RT   capped cDNA libraries.";
RL   DNA Res. 12:117-126(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   25-GLY--GLY-27 DEL.
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH HSPA1A.
RX   PubMed=12651857; DOI=10.1074/jbc.M301109200;
RA   McLellan C.A., Raynes D.A., Guerriero V. Jr.;
RT   "HspBP1, an Hsp70 cochaperone, has two structural domains and is
RT   capable of altering the conformation of the Hsp70 ATPase domain.";
RL   J. Biol. Chem. 278:19017-19022(2003).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH HSPA1A AND STUB1.
RX   PubMed=15215316; DOI=10.1091/mbc.E04-04-0293;
RA   Alberti S., Boehse K., Arndt V., Schmitz A., Hoehfeld J.;
RT   "The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and
RT   stimulates the maturation of the cystic fibrosis transmembrane
RT   conductance regulator.";
RL   Mol. Biol. Cell 15:4003-4010(2004).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-354 AND SER-359, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 87-362 IN COMPLEX WITH
RP   HSPA1A.
RX   PubMed=15694338; DOI=10.1016/j.molcel.2004.12.023;
RA   Shomura Y., Dragovic Z., Chang H.-C., Tzvetkov N., Young J.C.,
RA   Brodsky J.L., Guerriero V. Jr., Hartl F.U., Bracher A.;
RT   "Regulation of Hsp70 function by HspBP1: structural analysis reveals
RT   an alternate mechanism for Hsp70 nucleotide exchange.";
RL   Mol. Cell 17:367-379(2005).
CC   -!- FUNCTION: Inhibits HSPA1A chaperone activity by changing the
CC       conformation of the ATP-binding domain of HSPA1A and interfering
CC       with ATP binding. Interferes with ubiquitination mediated by STUB1
CC       and inhibits chaperone-assisted degradation of immature CFTR.
CC   -!- SUBUNIT: Interacts with the ATP-binding domain of HSPA1A. Detected
CC       in a ternary complex containing STUB1, HSPA1A and HSPBP1.
CC   -!- INTERACTION:
CC       P54652:HSPA2; NbExp=3; IntAct=EBI-356763, EBI-356991;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NZL4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NZL4-2; Sequence=VSP_015945;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- SIMILARITY: Contains 4 ARM repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF093420; AAC79703.1; -; mRNA.
DR   EMBL; AF187859; AAF35833.1; -; mRNA.
DR   EMBL; AB020592; BAB18742.1; -; mRNA.
DR   EMBL; AF217996; AAG17238.1; -; mRNA.
DR   EMBL; AK130636; BAC85399.1; -; mRNA.
DR   EMBL; CR457118; CAG33399.1; -; mRNA.
DR   EMBL; AK075293; BAG52102.1; -; mRNA.
DR   EMBL; BC001236; AAH01236.1; -; mRNA.
DR   EMBL; BC002373; AAH02373.1; -; mRNA.
DR   IPI; IPI00100748; -.
DR   IPI; IPI00442503; -.
DR   RefSeq; NP_001123578.1; NM_001130106.1.
DR   RefSeq; NP_036399.3; NM_012267.4.
DR   UniGene; Hs.53066; -.
DR   PDB; 1XQR; X-ray; 2.10 A; A/B=87-362.
DR   PDB; 1XQS; X-ray; 2.90 A; A/B=87-362.
DR   PDBsum; 1XQR; -.
DR   PDBsum; 1XQS; -.
DR   ProteinModelPortal; Q9NZL4; -.
DR   SMR; Q9NZL4; 87-353.
DR   IntAct; Q9NZL4; 8.
DR   MINT; MINT-1158196; -.
DR   STRING; Q9NZL4; -.
DR   PhosphoSite; Q9NZL4; -.
DR   DMDM; 74734730; -.
DR   PaxDb; Q9NZL4; -.
DR   PRIDE; Q9NZL4; -.
DR   DNASU; 23640; -.
DR   Ensembl; ENST00000255631; ENSP00000255631; ENSG00000133265.
DR   Ensembl; ENST00000433386; ENSP00000398244; ENSG00000133265.
DR   GeneID; 23640; -.
DR   KEGG; hsa:23640; -.
DR   UCSC; uc002qkc.3; human.
DR   CTD; 23640; -.
DR   GeneCards; GC19M055773; -.
DR   H-InvDB; HIX0015460; -.
DR   HGNC; HGNC:24989; HSPBP1.
DR   HPA; CAB005865; -.
DR   MIM; 612939; gene.
DR   neXtProt; NX_Q9NZL4; -.
DR   PharmGKB; PA164720725; -.
DR   eggNOG; NOG235694; -.
DR   HOVERGEN; HBG053282; -.
DR   InParanoid; Q9NZL4; -.
DR   KO; K09562; -.
DR   OrthoDB; EOG4ZKJN2; -.
DR   EvolutionaryTrace; Q9NZL4; -.
DR   GenomeRNAi; 23640; -.
DR   NextBio; 46437; -.
DR   ArrayExpress; Q9NZL4; -.
DR   Bgee; Q9NZL4; -.
DR   Genevestigator; Q9NZL4; -.
DR   GermOnline; ENSG00000133265; Homo sapiens.
DR   GO; GO:0004857; F:enzyme inhibitor activity; TAS:ProtInc.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0006457; P:protein folding; TAS:ProtInc.
DR   Gene3D; 1.25.10.10; ARM-like; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   SUPFAM; SSF48371; ARM-type_fold; 1.
DR   PROSITE; PS50176; ARM_REPEAT; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat.
FT   CHAIN         1    362       Hsp70-binding protein 1.
FT                                /FTId=PRO_0000084035.
FT   REPEAT      135    177       ARM 1.
FT   REPEAT      180    220       ARM 2.
FT   REPEAT      223    262       ARM 3.
FT   REPEAT      265    304       ARM 4.
FT   COMPBIAS     21     40       Gly-rich.
FT   MOD_RES     354    354       Phosphoserine.
FT   MOD_RES     359    359       Phosphoserine.
FT   VAR_SEQ     207    309       Missing (in isoform 2).
FT                                /FTId=VSP_015945.
FT   VARIANT      25     27       Missing.
FT                                /FTId=VAR_023645.
FT   HELIX        90    104
FT   HELIX       113    134
FT   HELIX       137    145
FT   HELIX       148    154
FT   TURN        155    158
FT   HELIX       162    176
FT   HELIX       180    188
FT   HELIX       191    201
FT   HELIX       205    219
FT   HELIX       223    231
FT   HELIX       234    243
FT   HELIX       247    263
FT   HELIX       265    267
FT   HELIX       268    273
FT   HELIX       276    284
FT   HELIX       291    303
FT   HELIX       307    314
FT   HELIX       316    318
FT   HELIX       320    331
FT   HELIX       335    337
FT   HELIX       338    351
SQ   SEQUENCE   362 AA;  39474 MW;  2B6AAB4161D5A326 CRC64;
     MSDEGSRGSR LPLALPPASQ GCSSGGGGGG GGGSSAGGSG NSRPPRNLQG LLQMAITAGS
     EEPDPPPEPM SEERRQWLQE AMSAAFRGQR EEVEQMKSCL RVLSQPMPPT AGEAEQAADQ
     QEREGALELL ADLCENMDNA ADFCQLSGMH LLVGRYLEAG AAGLRWRAAQ LIGTCSQNVA
     AIQEQVLGLG ALRKLLRLLD RDACDTVRVK ALFAISCLVR EQEAGLLQFL RLDGFSVLMR
     AMQQQVQKLK VKSAFLLQNL LVGHPEHKGT LCSMGMVQQL VALVRTEHSP FHEHVLGALC
     SLVTDFPQGV RECREPELGL EELLRHRCQL LQQHEEYQEE LEFCEKLLQT CFSSPADDSM
     DR
//
ID   1433B_MOUSE             Reviewed;         246 AA.
AC   Q9CQV8; O70455; Q3TY33; Q3UAN6;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   09-JAN-2013, entry version 113.
DE   RecName: Full=14-3-3 protein beta/alpha;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
DE   Contains:
DE     RecName: Full=14-3-3 protein beta/alpha, N-terminally processed;
GN   Name=Ywhab;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J;
RA   Karpitskiy V.V., Shaw A.S.;
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J;
RC   TISSUE=Bone marrow, Embryo, Kidney, Liver, Thymus, and Visual cortex;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   PROTEIN SEQUENCE OF 1-12; 14-57; 61-70; 84-117; 128-169; 196-246 AND
RP   215-224, AND MASS SPECTROMETRY.
RC   STRAIN=C57BL/6, and OF1; TISSUE=Brain, and Hippocampus;
RA   Lubec G., Kang S.U., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [4]
RP   NITRATION [LARGE SCALE ANALYSIS] AT TYR-84 AND TYR-106, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=16800626; DOI=10.1021/bi060474w;
RA   Sacksteder C.A., Qian W.-J., Knyushko T.V., Wang H., Chin M.H.,
RA   Lacan G., Melega W.P., Camp D.G. II, Smith R.D., Smith D.J.,
RA   Squier T.C., Bigelow D.J.;
RT   "Endogenously nitrated proteins in mouse brain: links to
RT   neurodegenerative disease.";
RL   Biochemistry 45:8009-8022(2006).
RN   [5]
RP   INTERACTION WITH PRKCE.
RX   PubMed=18604201; DOI=10.1038/ncb1749;
RA   Saurin A.T., Durgan J., Cameron A.J., Faisal A., Marber M.S.,
RA   Parker P.J.;
RT   "The regulated assembly of a PKCepsilon complex controls the
RT   completion of cytokinesis.";
RL   Nat. Cell Biol. 10:891-901(2008).
RN   [6]
RP   INTERACTION WITH SAMSN1.
RX   PubMed=20478393; DOI=10.1016/j.biocel.2010.05.004;
RA   Brandt S., Ellwanger K., Beuter-Gunia C., Schuster M., Hausser A.,
RA   Schmitz I., Beer-Hammer S.;
RT   "SLy2 targets the nuclear SAP30/HDAC1 complex.";
RL   Int. J. Biochem. Cell Biol. 42:1472-1481(2010).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner. Negative
CC       regulator of osteogenesis. Blocks the nuclear translocation of the
CC       phosphorylated form (by AKT1) of SRPK2 and antagonizes its
CC       stimulatory effect on cyclin D1 expression resulting in blockage
CC       of neuronal apoptosis elicited by SRPK2 (By similarity).
CC   -!- SUBUNIT: Homodimer, and heterodimer with YWHAG, YWHAE and YWHAQ.
CC       Interacts with SSH1 and TORC2/CRTC2. Interacts with GAB2 and YAP1
CC       (phosphorylated form) (By similarity). Interacts with SAMSN1.
CC       Interacts with PKA-phosphorylated AANAT (By similarity). Interacts
CC       with the phosphorylated (by AKT1) form of SRPK2 (By similarity).
CC       Interacts with PRKCE (phosphorylated form).
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Melanosome (By
CC       similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=Long;
CC         IsoId=Q9CQV8-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=Q9CQV8-2; Sequence=VSP_018634;
CC         Note=No experimental confirmation available. Contains a
CC         N-acetylmethionine at position 1 (By similarity);
CC   -!- PTM: Isoform alpha differs from isoform beta in being
CC       phosphorylated (By similarity).
CC   -!- PTM: Isoform Short contains a N-acetylmethionine at position 1 (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF058797; AAC14343.1; -; mRNA.
DR   EMBL; AK002632; BAB22246.1; -; mRNA.
DR   EMBL; AK004872; BAB23631.1; -; mRNA.
DR   EMBL; AK011389; BAB27587.1; -; mRNA.
DR   EMBL; AK083367; BAC38886.1; -; mRNA.
DR   EMBL; AK144061; BAE25678.1; -; mRNA.
DR   EMBL; AK150414; BAE29538.1; -; mRNA.
DR   EMBL; AK151294; BAE30278.1; -; mRNA.
DR   EMBL; AK158932; BAE34730.1; -; mRNA.
DR   IPI; IPI00230682; -.
DR   IPI; IPI00760000; -.
DR   RefSeq; NP_061223.2; NM_018753.6.
DR   UniGene; Mm.34319; -.
DR   PDB; 4GNT; X-ray; 2.41 A; A=1-239.
DR   PDBsum; 4GNT; -.
DR   ProteinModelPortal; Q9CQV8; -.
DR   SMR; Q9CQV8; 1-234.
DR   IntAct; Q9CQV8; 611.
DR   STRING; Q9CQV8; -.
DR   PhosphoSite; Q9CQV8; -.
DR   UCD-2DPAGE; Q9CQV8; -.
DR   PaxDb; Q9CQV8; -.
DR   PRIDE; Q9CQV8; -.
DR   Ensembl; ENSMUST00000018470; ENSMUSP00000018470; ENSMUSG00000018326.
DR   GeneID; 54401; -.
DR   KEGG; mmu:54401; -.
DR   CTD; 7529; -.
DR   MGI; MGI:1891917; Ywhab.
DR   eggNOG; COG5040; -.
DR   GeneTree; ENSGT00690000101832; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; Q9CQV8; -.
DR   KO; K16197; -.
DR   OMA; CNDVLXT; -.
DR   OrthoDB; EOG4N30PR; -.
DR   Reactome; REACT_147847; Translocation of Glut4 to the Plasma Membrane.
DR   NextBio; 311260; -.
DR   ArrayExpress; Q9CQV8; -.
DR   Bgee; Q9CQV8; -.
DR   Genevestigator; Q9CQV8; -.
DR   GermOnline; ENSMUSG00000018326; Mus musculus.
DR   GO; GO:0005813; C:centrosome; IEA:Compara.
DR   GO; GO:0005829; C:cytosol; IEA:Compara.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Compara.
DR   GO; GO:0017053; C:transcriptional repressor complex; IEA:Compara.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:MGI.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Compara.
DR   GO; GO:0051220; P:cytoplasmic sequestering of protein; IEA:Compara.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IEA:Compara.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-dependent; IEA:Compara.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IEA:Compara.
DR   GO; GO:0006605; P:protein targeting; IDA:MGI.
DR   Gene3D; 1.20.190.20; 14-3-3; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; 14-3-3; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Nitration; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN         1    246       14-3-3 protein beta/alpha.
FT                                /FTId=PRO_0000367902.
FT   INIT_MET      1      1       Removed; alternate (By similarity).
FT   CHAIN         2    246       14-3-3 protein beta/alpha, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000000005.
FT   SITE         58     58       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   SITE        129    129       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine; in 14-3-3 protein
FT                                beta/alpha; alternate (By similarity).
FT   MOD_RES       2      2       N-acetylthreonine; in 14-3-3 protein
FT                                beta/alpha, N-terminally processed (By
FT                                similarity).
FT   MOD_RES       6      6       Phosphoserine (By similarity).
FT   MOD_RES      70     70       N6-acetyllysine (By similarity).
FT   MOD_RES      84     84       Nitrated tyrosine.
FT   MOD_RES     106    106       Nitrated tyrosine.
FT   MOD_RES     117    117       N6-acetyllysine (By similarity).
FT   MOD_RES     186    186       Phosphoserine (By similarity).
FT   VAR_SEQ       1      2       Missing (in isoform Short).
FT                                /FTId=VSP_018634.
FT   CONFLICT     10     10       Q -> H (in Ref. 1; AAC14343).
FT   CONFLICT     74     74       N -> D (in Ref. 1; AAC14343).
FT   CONFLICT    126    126       D -> Y (in Ref. 2; BAE29538/BAE30278).
SQ   SEQUENCE   246 AA;  28086 MW;  51C366ED85B38EED CRC64;
     MTMDKSELVQ KAKLAEQAER YDDMAAAMKA VTEQGHELSN EERNLLSVAY KNVVGARRSS
     WRVISSIEQK TERNEKKQQM GKEYREKIEA ELQDICNDVL ELLDKYLILN ATQAESKVFY
     LKMKGDYFRY LSEVASGENK QTTVSNSQQA YQEAFEISKK EMQPTHPIRL GLALNFSVFY
     YEILNSPEKA CSLAKTAFDE AIAELDTLNE ESYKDSTLIM QLLRDNLTLW TSENQGDEGD
     AGEGEN
//
ID   1433B_RAT               Reviewed;         246 AA.
AC   P35213;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   09-JAN-2013, entry version 119.
DE   RecName: Full=14-3-3 protein beta/alpha;
DE   AltName: Full=Prepronerve growth factor RNH-1;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
DE   Contains:
DE     RecName: Full=14-3-3 protein beta/alpha, N-terminally processed;
GN   Name=Ywhab;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Brain;
RX   MEDLINE=93164855; PubMed=8381897; DOI=10.1016/0169-328X(93)90082-Z;
RA   Watanabe M., Isobe T., Ichimura T., Kuwano R., Takahashi Y., Kondo H.;
RT   "Molecular cloning of rat cDNAs for beta and gamma subtypes of 14-3-3
RT   protein and developmental changes in expression of their mRNAs in the
RT   nervous system.";
RL   Brain Res. Mol. Brain Res. 17:135-146(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=96318520; PubMed=8749325;
RA   Takai R., Tanaka E., Miyazaki T., Suda M., Tashiro F.;
RT   "Function of RNH-1/14-3-3 beta gene in cellular differentiation and
RT   proliferation.";
RL   J. Biochem. 118:1045-1053(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 14-57; 63-70; 86-117; 130-159; 161-189 AND
RP   196-224, AND MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain, and Hippocampus;
RA   Lubec G., Kang S.U., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [5]
RP   PROTEIN SEQUENCE OF 30-43, INTERACTION WITH AANAT, AND MASS
RP   SPECTROMETRY.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner. Negative
CC       regulator of osteogenesis. Blocks the nuclear translocation of the
CC       phosphorylated form (by AKT1) of SRPK2 and antagonizes its
CC       stimulatory effect on cyclin D1 expression resulting in blockage
CC       of neuronal apoptosis elicited by SRPK2 (By similarity).
CC   -!- SUBUNIT: Homodimer. Interacts with SSH1 and TORC2/CRTC2. Interacts
CC       with ABL1 (phosphorylated form); the interaction results in
CC       cytoplasmic location of ABL1 and inhibition of cABL-mediated
CC       apoptosis. Interacts with ROR2 (dimer); the interaction results in
CC       phosphorylation of YWHAB on tyrosine residues. Interacts with
CC       GAB2, YAP1 and PRKCE (phosphorylated form). Interacts with SAMSN1
CC       (By similarity). Interacts with PKA-phosphorylated AANAT.
CC       Interacts with the phosphorylated (by AKT1) form of SRPK2 (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Melanosome (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P35213-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P35213-2; Sequence=VSP_018635;
CC         Note=No experimental confirmation available. Contains a
CC         N-acetylmethionine at position 1 (By similarity);
CC   -!- PTM: The alpha, brain-specific form differs from the beta form in
CC       being phosphorylated (By similarity).
CC   -!- PTM: Isoform Short contains a N-acetylmethionine at position 1 (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D17446; BAA04260.1; -; mRNA.
DR   EMBL; S55223; AAA13843.1; -; mRNA.
DR   EMBL; S83440; AAB50874.1; -; mRNA.
DR   EMBL; BC076502; AAH76502.1; -; mRNA.
DR   IPI; IPI00230837; -.
DR   IPI; IPI00760126; -.
DR   PIR; A49023; A49023.
DR   RefSeq; NP_062250.1; NM_019377.1.
DR   UniGene; Rn.8653; -.
DR   ProteinModelPortal; P35213; -.
DR   SMR; P35213; 3-233.
DR   IntAct; P35213; 1.
DR   MINT; MINT-270245; -.
DR   STRING; P35213; -.
DR   PhosphoSite; P35213; -.
DR   PRIDE; P35213; -.
DR   Ensembl; ENSRNOT00000016981; ENSRNOP00000016981; ENSRNOG00000010945.
DR   GeneID; 56011; -.
DR   KEGG; rno:56011; -.
DR   UCSC; RGD:61998; rat.
DR   CTD; 7529; -.
DR   RGD; 61998; Ywhab.
DR   eggNOG; COG5040; -.
DR   GeneTree; ENSGT00690000101832; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P35213; -.
DR   KO; K16197; -.
DR   OMA; CNDVLXT; -.
DR   OrthoDB; EOG4N30PR; -.
DR   Reactome; REACT_111984; Signal Transduction.
DR   NextBio; 611079; -.
DR   ArrayExpress; P35213; -.
DR   Genevestigator; P35213; -.
DR   GermOnline; ENSRNOG00000010945; Rattus norvegicus.
DR   GO; GO:0005813; C:centrosome; IEA:Compara.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Compara.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:RGD.
DR   GO; GO:0003714; F:transcription corepressor activity; IMP:RGD.
DR   GO; GO:0051220; P:cytoplasmic sequestering of protein; IEA:Compara.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IEA:Compara.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-dependent; IMP:RGD.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IEA:Compara.
DR   GO; GO:0051291; P:protein heterooligomerization; IPI:RGD.
DR   GO; GO:0006605; P:protein targeting; IEA:Compara.
DR   Gene3D; 1.20.190.20; 14-3-3; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; 14-3-3; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative initiation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Phosphoprotein; Reference proteome.
FT   CHAIN         1    246       14-3-3 protein beta/alpha.
FT                                /FTId=PRO_0000367904.
FT   INIT_MET      1      1       Removed; alternate (By similarity).
FT   CHAIN         2    246       14-3-3 protein beta/alpha, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000000007.
FT   SITE         58     58       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   SITE        129    129       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine; in 14-3-3 protein
FT                                beta/alpha; alternate (By similarity).
FT   MOD_RES       2      2       N-acetylthreonine; in 14-3-3 protein
FT                                beta/alpha, N-terminally processed (By
FT                                similarity).
FT   MOD_RES       6      6       Phosphoserine (By similarity).
FT   MOD_RES      70     70       N6-acetyllysine (By similarity).
FT   MOD_RES     117    117       N6-acetyllysine (By similarity).
FT   MOD_RES     186    186       Phosphoserine (By similarity).
FT   VAR_SEQ       1      2       Missing (in isoform Short).
FT                                /FTId=VSP_018635.
SQ   SEQUENCE   246 AA;  28054 MW;  B663D1F2182F9C43 CRC64;
     MTMDKSELVQ KAKLAEQAER YDDMAAAMKA VTEQGHELSN EERNLLSVAY KNVVGARRSS
     WRVISSIEQK TERNEKKQQM GKEYREKIEA ELQDICSDVL ELLDKYLILN ATHAESKVFY
     LKMKGDYFRY LSEVASGDNK QTTVSNSQQA YQEAFEISKK EMQPTHPIRL GLALNFSVFY
     YEILNSPEKA CSLAKTAFDE AIAELDTLNE ESYKDSTLIM QLLRDNLTLW TSENQGDEGD
     AGEGEN
//
ID   1433E_MOUSE             Reviewed;         255 AA.
AC   P62259; P29360; P42655; Q63631;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   09-JAN-2013, entry version 89.
DE   RecName: Full=14-3-3 protein epsilon;
DE            Short=14-3-3E;
GN   Name=Ywhae;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND DEVELOPMENTAL STAGE.
RC   STRAIN=Swiss; TISSUE=Kidney;
RX   MEDLINE=95269876; PubMed=7750640; DOI=10.1006/dbio.1995.1139;
RA   McConnell J.E., Armstrong J.F., Bard J.B.;
RT   "The mouse 14-3-3 epsilon isoform, a kinase regulator whose expression
RT   pattern is modulated in mesenchyme and neuronal differentiation.";
RL   Dev. Biol. 169:218-228(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=129/Sv;
RA   Takihara Y., Irie K., Nomura M., Motaleb M., Matsumoto K., Shimada K.;
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=ILS, and ISS;
RX   MEDLINE=21363810; PubMed=11471062; DOI=10.1007/s00335-001-1001-x;
RA   Ehringer M.A., Thompson J., Conroy O., Xu Y., Yang F., Canniff J.,
RA   Beeson M., Gordon L., Bennett B., Johnson T.E., Sikela J.M.;
RT   "High-throughput sequence identification of gene coding variants
RT   within alcohol-related QTLs.";
RL   Mamm. Genome 12:657-663(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 131-141; 154-170 AND 197-215, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, and Hippocampus;
RA   Lubec G., Klug S., Friebe K., Yang J.W., Zigmond M.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [6]
RP   INTERACTION WITH ARHGEF28.
RX   PubMed=11533041; DOI=10.1074/jbc.M107709200;
RA   Zhai J., Lin H., Shamim M., Schlaepfer W.W., Canete-Soler R.;
RT   "Identification of a novel interaction of 14-3-3 with p190RhoGEF.";
RL   J. Biol. Chem. 276:41318-41324(2001).
RN   [7]
RP   INTERACTION WITH NDEL1.
RX   PubMed=12796778; DOI=10.1038/ng1169;
RA   Toyo-oka K., Shionoya A., Gambello M.J., Cardoso C., Leventer R.,
RA   Ward H.L., Ayala R., Tsai L.-H., Dobyns W., Ledbetter D.,
RA   Hirotsune S., Wynshaw-Boris A.;
RT   "14-3-3epsilon is important for neuronal migration by binding to
RT   NUDEL: a molecular explanation for Miller-Dieker syndrome.";
RL   Nat. Genet. 34:274-285(2003).
RN   [8]
RP   INTERACTION WITH GRB10.
RX   PubMed=15722337; DOI=10.1074/jbc.M501477200;
RA   Urschel S., Bassermann F., Bai R.Y., Munch S., Peschel C., Duyster J.;
RT   "Phosphorylation of grb10 regulates its interaction with 14-3-3.";
RL   J. Biol. Chem. 280:16987-16993(2005).
RN   [9]
RP   INTERACTION WITH TIAM2.
RX   PubMed=17320046; DOI=10.1016/j.bbrc.2007.02.028;
RA   Takefuji M., Mori K., Morita Y., Arimura N., Nishimura T.,
RA   Nakayama M., Hoshino M., Iwamatsu A., Murohara T., Kaibuchi K.,
RA   Amano M.;
RT   "Rho-kinase modulates the function of STEF, a Rac GEF, through its
RT   phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 355:788-794(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17203969; DOI=10.1021/pr0604155;
RA   Dai J., Jin W.-H., Sheng Q.-H., Shieh C.-H., Wu J.-R., Zeng R.;
RT   "Protein phosphorylation and expression profiling by Yin-yang
RT   multidimensional liquid chromatography (Yin-yang MDLC) mass
RT   spectrometry.";
RL   J. Proteome Res. 6:250-262(2007).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC   -!- SUBUNIT: Homodimer. Heterodimerizes with YWHAZ (By similarity).
CC       Interacts with NDEL1, ARHGEF28 and TIAM2. Interacts with ABL1
CC       (phosphorylated form); the interaction retains it in the
CC       cytoplasm. Weakly interacts with CDKN1B. Interacts with GAB2 (By
CC       similarity). Interacts with PKA-phosphorylated AANAT (By
CC       similarity). Interacts with phosphorylated GRB10. Interacts with
CC       the phosphorylated (by AKT1) form of SRPK2 (By similarity).
CC   -!- INTERACTION:
CC       Q8CHQ0:Fbxo4; NbExp=2; IntAct=EBI-356480, EBI-3895153;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Melanosome (By
CC       similarity).
CC   -!- DEVELOPMENTAL STAGE: In the E8.5 embryo, expressed throughout the
CC       embryo. Within a day, expression was more marked in mesenchyme
CC       than elsewhere (e.g. epithelial tissue, where it was generally
CC       low), although levels in neural tissue rose again by about E12.5.
CC       This difference was maintained until E15.5 when expression levels
CC       started to drop in most tissues, with those of the nervous system,
CC       tooth, and kidney being exceptions. Strongly expressed in early
CC       mesenchyme. The expression decreased as the mesenchyme
CC       differentiated.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z19599; CAA79659.1; -; mRNA.
DR   EMBL; D87663; BAA13424.1; -; mRNA.
DR   EMBL; AF483478; AAL90752.1; -; mRNA.
DR   EMBL; AF483479; AAL90753.1; -; mRNA.
DR   EMBL; BC058686; AAH58686.1; -; mRNA.
DR   IPI; IPI00118384; -.
DR   PIR; I48337; S31975.
DR   RefSeq; NP_033562.3; NM_009536.4.
DR   UniGene; Mm.234700; -.
DR   ProteinModelPortal; P62259; -.
DR   SMR; P62259; 3-232.
DR   IntAct; P62259; 13.
DR   MINT; MINT-209058; -.
DR   STRING; P62259; -.
DR   PhosphoSite; P62259; -.
DR   REPRODUCTION-2DPAGE; P62259; -.
DR   PaxDb; P62259; -.
DR   PRIDE; P62259; -.
DR   Ensembl; ENSMUST00000067664; ENSMUSP00000070993; ENSMUSG00000020849.
DR   GeneID; 22627; -.
DR   KEGG; mmu:22627; -.
DR   CTD; 7531; -.
DR   MGI; MGI:894689; Ywhae.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P62259; -.
DR   KO; K06630; -.
DR   OMA; KESALIM; -.
DR   OrthoDB; EOG4HHP34; -.
DR   Reactome; REACT_147847; Translocation of Glut4 to the Plasma Membrane.
DR   NextBio; 302987; -.
DR   ArrayExpress; P62259; -.
DR   Bgee; P62259; -.
DR   Genevestigator; P62259; -.
DR   GermOnline; ENSMUSG00000020849; Mus musculus.
DR   GO; GO:0033267; C:axon part; IEA:Compara.
DR   GO; GO:0005871; C:kinesin complex; IEA:Compara.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:MGI.
DR   GO; GO:0021987; P:cerebral cortex development; IMP:MGI.
DR   GO; GO:0021766; P:hippocampus development; IMP:MGI.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IDA:MGI.
DR   GO; GO:0001764; P:neuron migration; IMP:MGI.
DR   GO; GO:0006605; P:protein targeting; IDA:MGI.
DR   Gene3D; 1.20.190.20; 14-3-3; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; 14-3-3; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    255       14-3-3 protein epsilon.
FT                                /FTId=PRO_0000058619.
FT   SITE         57     57       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   SITE        130    130       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine (By similarity).
FT   MOD_RES      38     38       Phosphothreonine (By similarity).
FT   MOD_RES      50     50       N6-acetyllysine (By similarity).
FT   MOD_RES      69     69       N6-acetyllysine (By similarity).
FT   MOD_RES     118    118       N6-acetyllysine (By similarity).
FT   MOD_RES     123    123       N6-acetyllysine (By similarity).
FT   MOD_RES     210    210       Phosphoserine.
SQ   SEQUENCE   255 AA;  29174 MW;  07817CCBD1F75B26 CRC64;
     MDDREDLVYQ AKLAEQAERY DEMVESMKKV AGMDVELTVE ERNLLSVAYK NVIGARRASW
     RIISSIEQKE ENKGGEDKLK MIREYRQMVE TELKLICCDI LDVLDKHLIP AANTGESKVF
     YYKMKGDYHR YLAEFATGND RKEAAENSLV AYKAASDIAM TELPPTHPIR LGLALNFSVF
     YYEILNSPDR ACRLAKAAFD DAIAELDTLS EESYKDSTLI MQLLRDNLTL WTSDMQGDGE
     EQNKEALQDV EDENQ
//
ID   MFS2A_HUMAN             Reviewed;         543 AA.
AC   Q8NA29; A8K675; Q6UWU5; Q96F59; Q9BRC8;
DT   23-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   09-JAN-2013, entry version 77.
DE   RecName: Full=Major facilitator superfamily domain-containing protein 2A;
GN   Name=MFSD2A; Synonyms=MFSD2; ORFNames=HMFN0656, PP9177, UNQ300/PRO341;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hepatoblastoma;
RX   PubMed=15221005; DOI=10.1038/sj.onc.1207782;
RA   Yamada S., Ohira M., Horie H., Ando K., Takayasu H., Suzuki Y.,
RA   Sugano S., Hirata T., Goto T., Matsunaga T., Hiyama E., Hayashi Y.,
RA   Ando H., Suita S., Kaneko M., Sasaki F., Hashizume K., Ohnuma N.,
RA   Nakagawara A.;
RT   "Expression profiling and differential screening between
RT   hepatoblastomas and the corresponding normal livers: identification of
RT   high expression of the PLK1 oncogene as a poor-prognostic indicator of
RT   hepatoblastomas.";
RL   Oncogene 23:5901-5911(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=16303743; DOI=10.1093/dnares/12.2.117;
RA   Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J.,
RA   Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S.,
RA   Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y.,
RA   Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S.,
RA   Isogai T.;
RT   "Signal sequence and keyword trap in silico for selection of full-
RT   length human cDNAs encoding secretion or membrane proteins from oligo-
RT   capped cDNA libraries.";
RL   DNA Res. 12:117-126(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye, Muscle, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   IDENTIFICATION.
RX   PubMed=18694395; DOI=10.1042/BJ20080165;
RA   Angers M., Uldry M., Kong D., Gimble J.M., Jetten A.M.;
RT   "Mfsd2a encodes a novel major facilitator superfamily domain-
RT   containing protein highly induced in brown adipose tissue during
RT   fasting and adaptive thermogenesis.";
RL   Biochem. J. 416:347-355(2008).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION, AND MUTAGENESIS OF
RP   ARG-103; ASP-106; ASP-110; ASN-230; ASN-240 AND LYS-449.
RX   PubMed=21677192; DOI=10.1073/pnas.1018098108;
RA   Reiling J.H., Clish C.B., Carette J.E., Varadarajan M.,
RA   Brummelkamp T.R., Sabatini D.M.;
RT   "A haploid genetic screen identifies the major facilitator domain
RT   containing 2A (MFSD2A) transporter as a key mediator in the response
RT   to tunicamycin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11756-11765(2011).
CC   -!- FUNCTION: Plays a role in thermogenesis via beta-adrenergic
CC       signaling pathway. May be the main plasma membrane tunicamycin
CC       transporter.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (Potential). Endoplasmic reticulum membrane (By similarity);
CC       Multi-pass membrane protein (Potential). Note=Cytoplasmic punctae
CC       that may represent vesicles shuttling between the endoplasmic
CC       reticulum and the plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8NA29-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NA29-2; Sequence=VSP_022539;
CC       Name=3;
CC         IsoId=Q8NA29-3; Sequence=VSP_022540;
CC         Note=No experimental confirmation available;
CC   -!- PTM: N-glycosylated.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY358636; AAQ88999.1; -; mRNA.
DR   EMBL; AK093223; BAC04100.1; -; mRNA.
DR   EMBL; AB073383; BAD38634.1; -; mRNA.
DR   EMBL; AF289609; AAL55793.1; -; mRNA.
DR   EMBL; AK075183; BAC11456.1; -; mRNA.
DR   EMBL; AK291540; BAF84229.1; -; mRNA.
DR   EMBL; AL663070; CAI20268.1; -; Genomic_DNA.
DR   EMBL; AL663070; CAI20269.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07248.1; -; Genomic_DNA.
DR   EMBL; BC006353; AAH06353.2; -; mRNA.
DR   EMBL; BC011587; AAH11587.1; -; mRNA.
DR   EMBL; BC092414; AAH92414.1; -; mRNA.
DR   IPI; IPI00410391; -.
DR   IPI; IPI00647701; -.
DR   IPI; IPI00827704; -.
DR   RefSeq; NP_001129965.1; NM_001136493.1.
DR   RefSeq; NP_116182.2; NM_032793.3.
DR   UniGene; Hs.655177; -.
DR   ProteinModelPortal; Q8NA29; -.
DR   DIP; DIP-47306N; -.
DR   STRING; Q8NA29; -.
DR   TCDB; 2.A.2.3.8; glycoside-pentoside-hexuronide (GPH):cation symporter family.
DR   PhosphoSite; Q8NA29; -.
DR   DMDM; 74751132; -.
DR   PRIDE; Q8NA29; -.
DR   DNASU; 84879; -.
DR   Ensembl; ENST00000372809; ENSP00000361895; ENSG00000168389.
DR   Ensembl; ENST00000372811; ENSP00000361898; ENSG00000168389.
DR   GeneID; 84879; -.
DR   KEGG; hsa:84879; -.
DR   UCSC; uc001ceu.3; human.
DR   UCSC; uc001cev.3; human.
DR   CTD; 84879; -.
DR   GeneCards; GC01P040421; -.
DR   HGNC; HGNC:25897; MFSD2A.
DR   HPA; HPA043107; -.
DR   MIM; 614397; gene.
DR   neXtProt; NX_Q8NA29; -.
DR   PharmGKB; PA165751549; -.
DR   eggNOG; COG2211; -.
DR   HOGENOM; HOG000294186; -.
DR   HOVERGEN; HBG080097; -.
DR   InParanoid; Q8NA29; -.
DR   OMA; SIYVICA; -.
DR   OrthoDB; EOG49S66D; -.
DR   PhylomeDB; Q8NA29; -.
DR   GenomeRNAi; 84879; -.
DR   NextBio; 75189; -.
DR   ArrayExpress; Q8NA29; -.
DR   Bgee; Q8NA29; -.
DR   CleanEx; HS_MFSD2; -.
DR   Genevestigator; Q8NA29; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   InterPro; IPR016196; MFS_dom_general_subst_transpt.
DR   SUPFAM; SSF103473; MFS_gen_substrate_transporter; 1.
DR   PROSITE; PS50850; MFS; FALSE_NEG.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Endoplasmic reticulum; Glycoprotein; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    543       Major facilitator superfamily domain-
FT                                containing protein 2A.
FT                                /FTId=PRO_0000273387.
FT   TRANSMEM     47     67       Helical; (Potential).
FT   TRANSMEM     81    101       Helical; (Potential).
FT   TRANSMEM    129    149       Helical; (Potential).
FT   TRANSMEM    161    181       Helical; (Potential).
FT   TRANSMEM    257    277       Helical; (Potential).
FT   TRANSMEM    311    331       Helical; (Potential).
FT   TRANSMEM    345    365       Helical; (Potential).
FT   TRANSMEM    371    391       Helical; (Potential).
FT   TRANSMEM    394    414       Helical; (Potential).
FT   TRANSMEM    438    458       Helical; (Potential).
FT   TRANSMEM    481    501       Helical; (Potential).
FT   COMPBIAS     35     38       Poly-Lys.
FT   CARBOHYD    230    230       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    240    240       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ       1    186       MAKGEGAESGSAAGLLPTSILQSTERPAQVKKEPKKKKQQL
FT                                SVCNKLCYALGGAPYQVTGCALGFFLQIYLLDVAQKDEEVV
FT                                FCFSSFQVGPFSASIILFVGRAWDAITDPLVGLCISKSPWT
FT                                CLGRLMPWIIFSTPLAVIAYFLIWFVPDFPHGQTYWYLLFY
FT                                CLFETMVTCFHVPYSALTMFIS -> MWLRWALSLPPSSCL
FT                                WAEPGMPSQTPWWASASANPPGPAWVALCPGSSSPRPWPSL
FT                                PTSSSGSCPTSHTARPIGTCFSIASLKQWSRVSMFPTRLSP
FT                                CSSA (in isoform 3).
FT                                /FTId=VSP_022540.
FT   VAR_SEQ      77     89       Missing (in isoform 2).
FT                                /FTId=VSP_022539.
FT   MUTAGEN     103    103       R->A: No effect on cell sensitivity
FT                                toward tunicamycin.
FT   MUTAGEN     106    106       D->A: No effect on cell sensitivity
FT                                toward tunicamycin.
FT   MUTAGEN     110    110       D->A: Drastic loss of cell sensitivity
FT                                toward tunicamycin.
FT   MUTAGEN     230    230       N->Q: Loss of glycosylation; when
FT                                associated with Q-240.
FT   MUTAGEN     240    240       N->Q: Loss of glycosylation; when
FT                                associated with Q-230.
FT   MUTAGEN     449    449       K->A: Loss of plasma membrane
FT                                localization. Loss of cell sensitivity
FT                                toward tunicamycin.
FT   CONFLICT    229    229       L -> F (in Ref. 1; AAQ88999).
SQ   SEQUENCE   543 AA;  60170 MW;  C9933B79335BFBDE CRC64;
     MAKGEGAESG SAAGLLPTSI LQSTERPAQV KKEPKKKKQQ LSVCNKLCYA LGGAPYQVTG
     CALGFFLQIY LLDVAQKDEE VVFCFSSFQV GPFSASIILF VGRAWDAITD PLVGLCISKS
     PWTCLGRLMP WIIFSTPLAV IAYFLIWFVP DFPHGQTYWY LLFYCLFETM VTCFHVPYSA
     LTMFISTEQT ERDSATAYRM TVEVLGTVLG TAIQGQIVGQ ADTPCFQDLN SSTVASQSAN
     HTHGTTSHRE TQKAYLLAAG VIVCIYIICA VILILGVREQ REPYEAQQSE PIAYFRGLRL
     VMSHGPYIKL ITGFLFTSLA FMLVEGNFVL FCTYTLGFRN EFQNLLLAIM LSATLTIPIW
     QWFLTRFGKK TAVYVGISSA VPFLILVALM ESNLIITYAV AVAAGISVAA AFLLPWSMLP
     DVIDDFHLKQ PHFHGTEPIF FSFYVFFTKF ASGVSLGIST LSLDFAGYQT RGCSQPERVK
     FTLNMLVTMA PIVLILLGLL LFKMYPIDEE RRRQNKKALQ ALRDEASSSG CSETDSTELA
     SIL
//
ID   FBW1A_HUMAN             Reviewed;         605 AA.
AC   Q9Y297; B5MD49; Q5W141; Q5W142; Q9Y213;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   28-NOV-2012, entry version 133.
DE   RecName: Full=F-box/WD repeat-containing protein 1A;
DE   AltName: Full=E3RSIkappaB;
DE   AltName: Full=Epididymis tissue protein Li 2a;
DE   AltName: Full=F-box and WD repeats protein beta-TrCP;
DE   AltName: Full=pIkappaBalpha-E3 receptor subunit;
GN   Name=BTRC; Synonyms=BTRCP, FBW1A, FBXW1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   MEDLINE=99075339; PubMed=9859996; DOI=10.1038/25159;
RA   Yaron A., Hatzubai A., Davis M., Lavon I., Amit S., Manning A.M.,
RA   Andersen J.S., Mann M., Mercurio F., Ben-Neriah Y.;
RT   "Identification of the receptor component of the IkappaBalpha-
RT   ubiquitin ligase.";
RL   Nature 396:590-594(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND INTERACTION WITH HIV-1
RP   VPU.
RC   TISSUE=Lymphoid tissue;
RX   MEDLINE=98325370; PubMed=9660940; DOI=10.1016/S1097-2765(00)80056-8;
RA   Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V.,
RA   Thomas D., Strebel K., Benarous R.;
RT   "A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu
RT   connects CD4 to the ER degradation pathway through an F-box motif.";
RL   Mol. Cell 1:565-574(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   MEDLINE=20003060; PubMed=10531035; DOI=10.1016/S0960-9822(00)80020-2;
RA   Cenciarelli C., Chiaur D.S., Guardavaccaro D., Parks W., Vidal M.,
RA   Pagano M.;
RT   "Identification of a family of human F-box proteins.";
RL   Curr. Biol. 9:1177-1179(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Epididymis;
RX   PubMed=20736409; DOI=10.1074/mcp.M110.001719;
RA   Li J., Liu F., Wang H., Liu X., Liu J., Li N., Wan F., Wang W.,
RA   Zhang C., Jin S., Liu J., Zhu P., Liu Y.;
RT   "Systematic mapping and functional analysis of a family of human
RT   epididymal secretory sperm-located proteins.";
RL   Mol. Cell. Proteomics 9:2517-2528(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   IDENTIFICATION IN THE SCF(BTRC) COMPLEX, AND FUNCTION IN
RP   UBIQUITINATION OF NFKBIA.
RX   PubMed=10066435; DOI=10.1006/bbrc.1999.0289;
RA   Suzuki H., Chiba T., Kobayashi M., Takeuchi M., Suzuki T.,
RA   Ichiyama A., Ikenoue T., Omata M., Furuichi K., Tanaka K.;
RT   "IkappaBalpha ubiquitination is catalyzed by an SCF-like complex
RT   containing Skp1, cullin-1, and two F-box/WD40-repeat proteins,
RT   betaTrCP1 and betaTrCP2.";
RL   Biochem. Biophys. Res. Commun. 256:127-132(1999).
RN   [10]
RP   INTERACTION WITH NFKBIB AND NFKBIE, AND FUNCTION IN UBIQUITINATION OF
RP   NFKBIB AND NFKBIE.
RX   PubMed=10497169; DOI=10.1074/jbc.274.40.28169;
RA   Shirane M., Hatakeyama S., Hattori K., Nakayama K., Nakayama K.;
RT   "Common pathway for the ubiquitination of IkappaBalpha, IkappaBbeta,
RT   and IkappaBepsilon mediated by the F-box protein FWD1.";
RL   J. Biol. Chem. 274:28169-28174(1999).
RN   [11]
RP   CHARACTERIZATION.
RX   MEDLINE=99145464; PubMed=9990852;
RA   Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J.,
RA   Harper J.W.;
RT   "The SCF(beta-TRCP)-ubiquitin ligase complex associates specifically
RT   with phosphorylated destruction motifs in I-kappa-B-alpha and beta-
RT   catenin and stimulates I-kappa-B-alpha ubiquitination in vitro.";
RL   Genes Dev. 13:270-283(1999).
RN   [12]
RP   INTERACTION WITH NFKB1, AND FUNCTION IN UBIQUITINATION OF NFKB1.
RX   PubMed=10835356; DOI=10.1093/emboj/19.11.2580;
RA   Orian A., Gonen H., Bercovich B., Fajerman I., Eytan E., Israel A.,
RA   Mercurio F., Iwai K., Schwartz A.L., Ciechanover A.;
RT   "SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB
RT   p105 requires phosphorylation of its C-terminus by IkappaB kinase.";
RL   EMBO J. 19:2580-2591(2000).
RN   [13]
RP   SELF-ASSOCIATION, INTERACTION WITH FBXW11 AND NFKBIA, AND FUNCTION IN
RP   UBIQUITINATION OF NFKBIA.
RX   PubMed=10644755; DOI=10.1074/jbc.275.4.2877;
RA   Suzuki H., Chiba T., Suzuki T., Fujita T., Ikenoue T., Omata M.,
RA   Furuichi K., Shikama H., Tanaka K.;
RT   "Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to
RT   IkappaBalpha for signal-dependent ubiquitination.";
RL   J. Biol. Chem. 275:2877-2884(2000).
RN   [14]
RP   INTERACTION WITH UBQLN1.
RC   TISSUE=B-cell;
RX   MEDLINE=20437281; PubMed=10983987; DOI=10.1016/S1097-2765(00)00040-X;
RA   Kleijnen M.F., Shih A.H., Zhou P., Kumar S., Soccio R.E.,
RA   Kedersha N.L., Gill G., Howley P.M.;
RT   "The hPLIC proteins may provide a link between the ubiquitination
RT   machinery and the proteasome.";
RL   Mol. Cell 6:409-419(2000).
RN   [15]
RP   INTERACTION WITH PHOSPHORYLATED SMAD3, AND FUNCTION IN SMAD3
RP   UBIQUITINATION.
RX   PubMed=11359933;
RA   Fukuchi M., Imamura T., Chiba T., Ebisawa T., Kawabata M., Tanaka K.,
RA   Miyazono K.;
RT   "Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex
RT   of ROC1 and associated proteins.";
RL   Mol. Biol. Cell 12:1431-1443(2001).
RN   [16]
RP   INTERACTION WITH PHOSPHORYLATED ATF4, AND FUNCTION IN ATF4
RP   UBIQUITINATION.
RX   PubMed=11238952; DOI=10.1128/MCB.21.6.2192-2202.2001;
RA   Lassot I., Segeral E., Berlioz-Torrent C., Durand H., Groussin L.,
RA   Hai T., Benarous R., Margottin-Goguet F.;
RT   "ATF4 degradation relies on a phosphorylation-dependent interaction
RT   with the SCF(betaTrCP) ubiquitin ligase.";
RL   Mol. Cell. Biol. 21:2192-2202(2001).
RN   [17]
RP   FUNCTION IN NFKB2 UBIQUITINATION.
RX   PubMed=11994270; DOI=10.1074/jbc.C200151200;
RA   Fong A., Sun S.C.;
RT   "Genetic evidence for the essential role of beta-transducin repeat-
RT   containing protein in the inducible processing of NF-kappa B2/p100.";
RL   J. Biol. Chem. 277:22111-22114(2002).
RN   [18]
RP   INTERACTION WITH PHOSPHORYLATED CTNNB1.
RX   MEDLINE=22072105; PubMed=12077367;
RA   Sadot E., Conacci-Sorrell M., Zhurinsky J., Shnizer D., Lando Z.,
RA   Zharhary D., Kam Z., Ben-Ze'ev A., Geiger B.;
RT   "Regulation of S33/S37 phosphorylated beta-catenin in normal and
RT   transformed cells.";
RL   J. Cell Sci. 115:2771-2780(2002).
RN   [19]
RP   INTERACTION WITH CDC34 AND UBE2R2.
RX   PubMed=12037680; DOI=10.1038/sj.onc.1205574;
RA   Semplici F., Meggio F., Pinna L.A., Oliviero S.;
RT   "CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme
RT   UBC3B induces its interaction with beta-TrCP and enhances beta-catenin
RT   degradation.";
RL   Oncogene 21:3978-3987(2002).
RN   [20]
RP   INTERACTION WITH PHOSPHORYLATED FBXO5, AND FUNCTION IN FBXO5
RP   UBIQUITINATION.
RX   PubMed=12791267; DOI=10.1016/S1534-5807(03)00153-9;
RA   Margottin-Goguet F., Hsu J.Y., Loktev A., Hsieh H.-M., Reimann J.D.R.,
RA   Jackson P.K.;
RT   "Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin
RT   ligase activates the anaphase promoting complex to allow progression
RT   beyond prometaphase.";
RL   Dev. Cell 4:813-826(2003).
RN   [21]
RP   INTERACTION WITH PHOSPHORYLATED CDC25A, AND FUNCTION IN CDC25A
RP   UBIQUITINATION.
RX   PubMed=14681206; DOI=10.1101/gad.1157503;
RA   Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J.,
RA   Harper J.W.;
RT   "SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A
RT   protein phosphatase.";
RL   Genes Dev. 17:3062-3074(2003).
RN   [22]
RP   INTERACTION WITH PHOSPHORYLATED DLG1, AND FUNCTION IN DLG1
RP   UBIQUITINATION.
RX   PubMed=12902344; DOI=10.1074/jbc.M302799200;
RA   Mantovani F., Banks L.;
RT   "Regulation of the discs large tumor suppressor by a phosphorylation-
RT   dependent interaction with the beta-TrCP ubiquitin ligase receptor.";
RL   J. Biol. Chem. 278:42477-42486(2003).
RN   [23]
RP   INTERACTION WITH PHOSPHORYLATED CDC25A, AND FUNCTION IN CDC25A
RP   UBIQUITINATION.
RX   PubMed=14603323; DOI=10.1038/nature02082;
RA   Busino L., Donzelli M., Chiesa M., Guardavaccaro D., Ganoth D.,
RA   Dorrello N.V., Hershko A., Pagano M., Draetta G.F.;
RT   "Degradation of Cdc25A by beta-TrCP during S phase and in response to
RT   DNA damage.";
RL   Nature 426:87-91(2003).
RN   [24]
RP   INTERACTION WITH PHOSPHORYLATED SMAD4, AND FUNCTION IN SMAD4
RP   UBIQUITINATION.
RX   PubMed=14988407; DOI=10.1074/jbc.C400005200;
RA   Wan M., Tang Y., Tytler E.M., Lu C., Jin B., Vickers S.M., Yang L.,
RA   Shi X., Cao X.;
RT   "Smad4 protein stability is regulated by ubiquitin ligase SCF beta-
RT   TrCP1.";
RL   J. Biol. Chem. 279:14484-14487(2004).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=15448698; DOI=10.1038/ncb1173;
RA   Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., Hung M.C.;
RT   "Dual regulation of Snail by GSK-3beta-mediated phosphorylation in
RT   control of epithelial-mesenchymal transition.";
RL   Nat. Cell Biol. 6:931-940(2004).
RN   [26]
RP   INTERACTION WITH CUL4A AND DDB1.
RX   PubMed=17079684; DOI=10.1101/gad.1483206;
RA   He Y.J., McCall C.M., Hu J., Zeng Y., Xiong Y.;
RT   "DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-
RT   ROC1 ubiquitin ligases.";
RL   Genes Dev. 20:2949-2954(2006).
RN   [27]
RP   INTERACTION WITH GLI3.
RX   PubMed=16705181; DOI=10.1128/MCB.02183-05;
RA   Tempe D., Casas M., Karaz S., Blanchet-Tournier M.F., Concordet J.P.;
RT   "Multisite protein kinase A and glycogen synthase kinase 3beta
RT   phosphorylation leads to Gli3 ubiquitination by SCFbetaTrCP.";
RL   Mol. Cell. Biol. 26:4316-4326(2006).
RN   [28]
RP   FUNCTION.
RX   PubMed=16371461; DOI=10.1073/pnas.0509927103;
RA   Wang B., Li Y.;
RT   "Evidence for the direct involvement of {beta}TrCP in Gli3 protein
RT   processing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:33-38(2006).
RN   [29]
RP   INTERACTION WITH CLU.
RX   PubMed=20068069; DOI=10.1158/1541-7786.MCR-09-0277;
RA   Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A.,
RA   Klomp L.W., Nelson C.C., Rennie P.S., Gleave M.E.;
RT   "Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-
RT   kappaB activity in prostate cancer cells.";
RL   Mol. Cancer Res. 8:119-130(2010).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 175-605 IN COMPLEX WITH SKP1
RP   AND CTNNB1.
RX   MEDLINE=22706071; PubMed=12820959; DOI=10.1016/S1097-2765(03)00234-X;
RA   Wu G., Xu G., Schulman B.A., Jeffrey P.D., Harper J.W.,
RA   Pavletich N.P.;
RT   "Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction
RT   motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin
RT   ligase.";
RL   Mol. Cell 11:1445-1456(2003).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 128-177, DOMAIN, AND SUBUNIT.
RX   PubMed=17574027; DOI=10.1016/j.cell.2007.04.042;
RA   Tang X., Orlicky S., Lin Z., Willems A., Neculai D., Ceccarelli D.,
RA   Mercurio F., Shilton B.H., Sicheri F., Tyers M.;
RT   "Suprafacial orientation of the SCFCdc4 dimer accommodates multiple
RT   geometries for substrate ubiquitination.";
RL   Cell 129:1165-1176(2007).
CC   -!- FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-
CC       box protein) E3 ubiquitin-protein ligase complex which mediates
CC       the ubiquitination and subsequent proteasomal degradation of
CC       target proteins. Recognizes and binds to phosphorylated target
CC       proteins. SCF(BTRC) mediates the ubiquitination of CTNNB1 and
CC       participates in Wnt signaling. SCF(BTRC) mediates the
CC       ubiquitination of NFKBIA, NFKBIB and NFKBIE; the degradation frees
CC       the associated NFKB1 to translocate into the nucleus and to
CC       activate transcription. Ubiquitination of NFKBIA occurs at 'Lys-
CC       21' and 'Lys-22'. SCF(BTRC) mediates the ubiquitination of
CC       phosphorylated NFKB1/nuclear factor NF-kappa-B p105 subunit, ATF4,
CC       SMAD3, SMAD4, CDC25A, DLG1, FBXO5 and probably NFKB2. SCF(BTRC)
CC       mediates the ubiquitination of phosphorylated SNAI1. May be
CC       involved in ubiquitination and subsequent proteasomal degradation
CC       through a DBB1-CUL4 E3 ubiquitin-protein ligase. Required for
CC       activation of NFKB-mediated transcription by IL1B, MAP3K14,
CC       MAP3K1, IKBKB and TNF. Required for proteolytic processing of
CC       GLI3.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer. Self-associates. Component of the SCF(BTRC)
CC       complex formed of CUL1, SKP1, RBX1 and a BTRC dimer. Direct
CC       interaction with SKP1 occurs via the F-box domain. Interacts with
CC       phosphorylated ubiquitination substrates SMAD3 and SMAD4.
CC       Interacts with phosphorylated ubiquitination substrates CTNNB1,
CC       NFKBIA, NFKBIB, NFKBIE, NFKB1/nuclear factor NF-kappa-B p105
CC       subunit, ATF4, CDC25A, DLG1, FBXO5 and SNAI1; the interaction
CC       requires the phosphorylation of the 2 serine residues in the
CC       substrate destruction motif D-S-G-X(2,3,4)-S. Binds UBQLN1.
CC       Interacts with CDC34 and UBE2R2. Interacts with FBXW11. Interacts
CC       with CUL4A and DDB1. Part of a SCF(BTRC)-like complex lacking
CC       CUL1, which is associated with phosphorylated NKBIA and RELA; RELA
CC       interacts directly with NFKBIA. Interacts with HIV-1 Vpu.
CC       Interacts with the phosphorylated form of GLI3. Interacts with
CC       CLU.
CC   -!- INTERACTION:
CC       Q00987:MDM2; NbExp=9; IntAct=EBI-307461, EBI-389668;
CC       P63208:SKP1; NbExp=4; IntAct=EBI-307461, EBI-307486;
CC       P30291:WEE1; NbExp=2; IntAct=EBI-307461, EBI-914695;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y297-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y297-2; Sequence=VSP_006764;
CC   -!- TISSUE SPECIFICITY: Expressed in epididymis (at protein level).
CC   -!- DOMAIN: The N-terminal D domain mediates homodimerization.
CC   -!- SIMILARITY: Contains 1 F-box domain.
CC   -!- SIMILARITY: Contains 7 WD repeats.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org//Genes/BTRCID451ch10q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF101784; AAD08702.1; -; mRNA.
DR   EMBL; Y14153; CAA74572.1; -; mRNA.
DR   EMBL; AF129530; AAF04464.1; -; mRNA.
DR   EMBL; GU727631; ADU87633.1; -; mRNA.
DR   EMBL; AK313353; BAG36155.1; -; mRNA.
DR   EMBL; AL133387; CAH70019.1; -; Genomic_DNA.
DR   EMBL; AL445463; CAH70019.1; JOINED; Genomic_DNA.
DR   EMBL; AL627424; CAH70019.1; JOINED; Genomic_DNA.
DR   EMBL; AL133387; CAH70020.1; -; Genomic_DNA.
DR   EMBL; AL445463; CAH70020.1; JOINED; Genomic_DNA.
DR   EMBL; AL627424; CAH70020.1; JOINED; Genomic_DNA.
DR   EMBL; AL445463; CAI12963.1; -; Genomic_DNA.
DR   EMBL; AL133387; CAI12963.1; JOINED; Genomic_DNA.
DR   EMBL; AL627424; CAI12963.1; JOINED; Genomic_DNA.
DR   EMBL; AL445463; CAI12964.1; -; Genomic_DNA.
DR   EMBL; AL133387; CAI12964.1; JOINED; Genomic_DNA.
DR   EMBL; AL627424; CAI12964.1; JOINED; Genomic_DNA.
DR   EMBL; AL627424; CAI41042.1; -; Genomic_DNA.
DR   EMBL; AL133387; CAI41042.1; JOINED; Genomic_DNA.
DR   EMBL; AL445463; CAI41042.1; JOINED; Genomic_DNA.
DR   EMBL; AL627424; CAI41043.1; -; Genomic_DNA.
DR   EMBL; AL133387; CAI41043.1; JOINED; Genomic_DNA.
DR   EMBL; AL445463; CAI41043.1; JOINED; Genomic_DNA.
DR   EMBL; CH471066; EAW49772.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49774.1; -; Genomic_DNA.
DR   EMBL; BC027994; AAH27994.1; -; mRNA.
DR   IPI; IPI00307418; -.
DR   IPI; IPI00413142; -.
DR   RefSeq; NP_003930.1; NM_003939.4.
DR   RefSeq; NP_378663.1; NM_033637.3.
DR   UniGene; Hs.643802; -.
DR   UniGene; Hs.713753; -.
DR   PDB; 1P22; X-ray; 2.95 A; A=175-605.
DR   PDB; 2P64; X-ray; 2.50 A; A/B=128-177.
DR   PDBsum; 1P22; -.
DR   PDBsum; 2P64; -.
DR   ProteinModelPortal; Q9Y297; -.
DR   SMR; Q9Y297; 127-581.
DR   DIP; DIP-31607N; -.
DR   IntAct; Q9Y297; 40.
DR   MINT; MINT-108636; -.
DR   STRING; Q9Y297; -.
DR   PhosphoSite; Q9Y297; -.
DR   DMDM; 13124271; -.
DR   PRIDE; Q9Y297; -.
DR   DNASU; 8945; -.
DR   Ensembl; ENST00000370187; ENSP00000359206; ENSG00000166167.
DR   Ensembl; ENST00000408038; ENSP00000385339; ENSG00000166167.
DR   GeneID; 8945; -.
DR   KEGG; hsa:8945; -.
DR   UCSC; uc001kta.3; human.
DR   UCSC; uc001ktb.3; human.
DR   CTD; 8945; -.
DR   GeneCards; GC10P103103; -.
DR   HGNC; HGNC:1144; BTRC.
DR   HPA; CAB032986; -.
DR   MIM; 603482; gene.
DR   neXtProt; NX_Q9Y297; -.
DR   PharmGKB; PA25465; -.
DR   eggNOG; COG2319; -.
DR   HOGENOM; HOG000006638; -.
DR   HOVERGEN; HBG002521; -.
DR   InParanoid; Q9Y297; -.
DR   KO; K03362; -.
DR   OMA; QRDFITL; -.
DR   OrthoDB; EOG4F1X2M; -.
DR   PhylomeDB; Q9Y297; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_24941; Circadian Clock.
DR   Reactome; REACT_6900; Immune System.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q9Y297; -.
DR   GenomeRNAi; 8945; -.
DR   NextBio; 33645; -.
DR   ArrayExpress; Q5W142; -.
DR   Bgee; Q9Y297; -.
DR   CleanEx; HS_BTRC; -.
DR   Genevestigator; Q9Y297; -.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019005; C:SCF ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0016874; F:ligase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Compara.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Compara.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; IEA:Compara.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; TAS:BHF-UCL.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-dependent; IMP:UniProtKB.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; IEA:Compara.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-dependent; IEA:Compara.
DR   GO; GO:0051437; P:positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0006470; P:protein dephosphorylation; IEA:Compara.
DR   GO; GO:0031648; P:protein destabilization; IMP:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Compara.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:Compara.
DR   GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB cascade; IEA:Compara.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IEA:Compara.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016032; P:viral reproduction; TAS:Reactome.
DR   GO; GO:0019048; P:virus-host interaction; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt receptor signaling pathway; IEA:UniProtKB-KW.
DR   Gene3D; 2.130.10.10; WD40/YVTN_repeat-like; 2.
DR   InterPro; IPR021977; Beta-TrCP_D.
DR   InterPro; IPR001810; F-box_dom_cyclin-like.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   Pfam; PF12125; Beta-TrCP_D; 1.
DR   Pfam; PF00400; WD40; 7.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM01028; Beta-TrCP_D; 1.
DR   SMART; SM00256; FBOX; 1.
DR   SMART; SM00320; WD40; 7.
DR   SUPFAM; SSF81383; F-box_dom_Skp2-like; 1.
DR   SUPFAM; SSF50978; WD40_like; 1.
DR   PROSITE; PS50181; FBOX; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 6.
DR   PROSITE; PS50082; WD_REPEATS_2; 7.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Host-virus interaction; Ligase; Nucleus; Polymorphism;
KW   Reference proteome; Repeat; Ubl conjugation pathway; WD repeat;
KW   Wnt signaling pathway.
FT   CHAIN         1    605       F-box/WD repeat-containing protein 1A.
FT                                /FTId=PRO_0000050980.
FT   DOMAIN      190    228       F-box.
FT   REPEAT      301    338       WD 1.
FT   REPEAT      341    378       WD 2.
FT   REPEAT      381    418       WD 3.
FT   REPEAT      424    461       WD 4.
FT   REPEAT      464    503       WD 5.
FT   REPEAT      505    541       WD 6.
FT   REPEAT      553    590       WD 7.
FT   REGION      128    177       Homodimerization domain D.
FT   REGION      190    228       Required for down-regulation of SNAI1.
FT   VAR_SEQ      17     52       Missing (in isoform 2).
FT                                /FTId=VSP_006764.
FT   VARIANT     543    543       A -> S (in dbSNP:rs4151060).
FT                                /FTId=VAR_022027.
FT   VARIANT     592    592       P -> H (in dbSNP:rs2270439).
FT                                /FTId=VAR_020119.
FT   HELIX       129    141
FT   HELIX       146    158
FT   HELIX       162    172
FT   HELIX       173    175
FT   HELIX       180    183
FT   HELIX       185    187
FT   HELIX       190    197
FT   HELIX       202    211
FT   HELIX       213    221
FT   HELIX       224    233
FT   HELIX       237    244
FT   STRAND      245    247
FT   HELIX       248    251
FT   HELIX       266    285
FT   TURN        286    288
FT   STRAND      306    310
FT   STRAND      313    323
FT   STRAND      325    332
FT   STRAND      335    339
FT   STRAND      346    350
FT   STRAND      353    360
FT   STRAND      365    372
FT   STRAND      375    379
FT   STRAND      386    390
FT   STRAND      395    400
FT   STRAND      405    409
FT   STRAND      411    414
FT   STRAND      417    422
FT   STRAND      429    435
FT   STRAND      438    443
FT   STRAND      446    452
FT   TURN        453    455
FT   STRAND      458    463
FT   STRAND      469    475
FT   STRAND      478    483
FT   STRAND      488    492
FT   TURN        493    495
FT   STRAND      498    502
FT   STRAND      509    513
FT   STRAND      516    523
FT   STRAND      528    532
FT   HELIX       533    536
FT   TURN        543    546
FT   STRAND      547    551
FT   STRAND      561    563
FT   STRAND      568    570
FT   STRAND      573    580
SQ   SEQUENCE   605 AA;  68867 MW;  4C67F3B7E400FD37 CRC64;
     MDPAEAVLQE KALKFMCSMP RSLWLGCSSL ADSMPSLRCL YNPGTGALTA FQNSSEREDC
     NNGEPPRKII PEKNSLRQTY NSCARLCLNQ ETVCLASTAM KTENCVAKTK LANGTSSMIV
     PKQRKLSASY EKEKELCVKY FEQWSESDQV EFVEHLISQM CHYQHGHINS YLKPMLQRDF
     ITALPARGLD HIAENILSYL DAKSLCAAEL VCKEWYRVTS DGMLWKKLIE RMVRTDSLWR
     GLAERRGWGQ YLFKNKPPDG NAPPNSFYRA LYPKIIQDIE TIESNWRCGR HSLQRIHCRS
     ETSKGVYCLQ YDDQKIVSGL RDNTIKIWDK NTLECKRILT GHTGSVLCLQ YDERVIITGS
     SDSTVRVWDV NTGEMLNTLI HHCEAVLHLR FNNGMMVTCS KDRSIAVWDM ASPTDITLRR
     VLVGHRAAVN VVDFDDKYIV SASGDRTIKV WNTSTCEFVR TLNGHKRGIA CLQYRDRLVV
     SGSSDNTIRL WDIECGACLR VLEGHEELVR CIRFDNKRIV SGAYDGKIKV WDLVAALDPR
     APAGTLCLRT LVEHSGRVFR LQFDEFQIVS SSHDDTILIW DFLNDPAAQA EPPRSPSRTY
     TYISR
//
ID   CTNB1_HUMAN             Reviewed;         781 AA.
AC   P35222; A8K1L7; Q8NEW9; Q8NI94; Q9H391;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   09-JAN-2013, entry version 164.
DE   RecName: Full=Catenin beta-1;
DE   AltName: Full=Beta-catenin;
GN   Name=CTNNB1; Synonyms=CTNNB; ORFNames=OK/SW-cl.35, PRO2286;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=95105247; PubMed=7806582; DOI=10.1083/jcb.127.6.2061;
RA   Huelsken J., Birchmeier W., Behrens J.;
RT   "E-cadherin and APC compete for the interaction with beta-catenin and
RT   the cytoskeleton.";
RL   J. Cell Biol. 127:2061-2069(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Wei H., Bi J., Zhou G., Dong C., Zai Y.,
RA   Xu W., Gao F., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 75 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-688.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-312 (ISOFORM 1).
RX   MEDLINE=22013744; PubMed=12019147;
RA   Kim J.-S., Crooks H., Dracheva T., Nishanian T.G., Singh B., Jen J.,
RA   Waldman T.;
RT   "Oncogenic beta-catenin is required for bone morphogenetic protein 4
RT   expression in human cancer cells.";
RL   Cancer Res. 62:2744-2748(2002).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 258-781 (ISOFORM 1).
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-
RT   reactive CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9;
RA   Butz S., Kemler R.;
RT   "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell
RT   adhesion.";
RL   FEBS Lett. 355:195-200(1994).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH PLAG1.
RX   MEDLINE=97172974; PubMed=9020842; DOI=10.1038/ng0297-170;
RA   Kas K., Voz M.L., Roeijer E., Astroem A.-K., Meyen E., Stenman G.,
RA   Van de Ven W.J.M.;
RT   "Promoter swapping between the genes for a novel zinc finger protein
RT   and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12)
RT   translocations.";
RL   Nat. Genet. 15:170-174(1997).
RN   [12]
RP   CHROMOSOMAL TRANSLOCATION WITH PLAG1.
RX   PubMed=10029085;
RA   Astroem A.-K., Voz M.L., Kas K., Roeijer E., Wedell B., Mandahl N.,
RA   Van de Ven W., Mark J., Stenman G.;
RT   "Conserved mechanism of PLAG1 activation in salivary gland tumors with
RT   and without chromosome 8q12 abnormalities: identification of SII as a
RT   new fusion partner gene.";
RL   Cancer Res. 59:918-923(1999).
RN   [13]
RP   STIMULATION OF TYROSINE PHOSPHORYLATION BY EGF, AND DEPHOSPHORYLATION
RP   BY PTPRF.
RX   MEDLINE=99214576; PubMed=10187801; DOI=10.1074/jbc.274.15.10173;
RA   Mueller T., Choidas A., Reichmann E., Ullrich A.;
RT   "Phosphorylation and free pool of beta-catenin are regulated by
RT   tyrosine kinases and tyrosine phosphatases during epithelial cell
RT   migration.";
RL   J. Biol. Chem. 274:10173-10183(1999).
RN   [14]
RP   INTERACTION WITH LEF1; APC; AXIN1; AXIN2 AND TCF7L2, PHOSPHORYLATION
RP   BY GSK3B, AND MUTAGENESIS OF PHE-253; HIS-260; LYS-292; LYS-345;
RP   TRP-383; ARG-386; ASN-426; LYS-435; ARG-469; HIS-470 AND LYS-508.
RX   MEDLINE=20423090; PubMed=10966653; DOI=10.1038/79039;
RA   von Kries J.P., Winbeck G., Asbrand C., Schwarz-Romond T.,
RA   Sochnikova N., Dell'Oro A., Behrens J., Birchmeier W.;
RT   "Hot spots in beta-catenin for interactions with LEF-1, conductin and
RT   APC.";
RL   Nat. Struct. Biol. 7:800-807(2000).
RN   [15]
RP   TISSUE SPECIFICITY, AND VARIANT PTR TYR-32.
RX   PubMed=11703283; DOI=10.1046/j.1365-2133.2001.04455.x;
RA   Moreno-Bueno G., Gamallo C., Perez-Gallego L., Contreras F.,
RA   Palacios J.;
RT   "Beta-catenin expression in pilomatrixomas. Relationship with beta-
RT   catenin gene mutations and comparison with beta-catenin expression in
RT   normal hair follicles.";
RL   Br. J. Dermatol. 145:576-581(2001).
RN   [16]
RP   INTERACTION WITH LEF1, AND INHIBITION BY CTNNBIP1 BINDING.
RX   MEDLINE=21623063; PubMed=11751639; DOI=10.1101/gad.946501;
RA   Tutter A.V., Fryer C.J., Jones K.A.;
RT   "Chromatin-specific regulation of LEF-1-beta-catenin transcription
RT   activation and inhibition in vitro.";
RL   Genes Dev. 15:3342-3354(2001).
RN   [17]
RP   PHOSPHORYLATION AT TYR-86 AND TYR-654, INTERACTION WITH TBP, AND
RP   MUTAGENESIS OF TYR-654.
RX   MEDLINE=21282973; PubMed=11279024; DOI=10.1074/jbc.M100194200;
RA   Piedra J., Martinez D., Castano J., Miravet S., Dunach M.,
RA   de Herreros A.G.;
RT   "Regulation of beta-catenin structure and activity by tyrosine
RT   phosphorylation.";
RL   J. Biol. Chem. 276:20436-20443(2001).
RN   [18]
RP   INTERACTION WITH CTNNA3.
RX   MEDLINE=21474377; PubMed=11590244;
RA   Janssens B., Goossens S., Staes K., Gilbert B., van Hengel J.,
RA   Colpaert C., Bruyneel E., Mareel M., van Roy F.;
RT   "AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein
RT   mediating strong cell-cell adhesion.";
RL   J. Cell Sci. 114:3177-3188(2001).
RN   [19]
RP   INTERACTION WITH SIAH1, AND DEGRADATION.
RX   MEDLINE=21286882; PubMed=11389839; DOI=10.1016/S1097-2765(01)00242-8;
RA   Matsuzawa S., Reed J.C.;
RT   "Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin
RT   degradation linked to p53 responses.";
RL   Mol. Cell 7:915-926(2001).
RN   [20]
RP   INTERACTION WITH SIAH1, AND DEGRADATION.
RX   PubMed=11389840; DOI=10.1016/S1097-2765(01)00241-6;
RA   Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L.,
RA   White R.L., Matsunami N.;
RT   "Siah-1 mediates a novel beta-catenin degradation pathway linking p53
RT   to the adenomatous polyposis coli protein.";
RL   Mol. Cell 7:927-936(2001).
RN   [21]
RP   INVOLVEMENT IN MESOM.
RX   PubMed=11464291; DOI=10.1038/sj.onc.1204557;
RA   Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y.,
RA   Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T.,
RA   Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.;
RT   "Genetic alteration of the beta-catenin gene (CTNNB1) in human lung
RT   cancer and malignant mesothelioma and identification of a new 3p21.3
RT   homozygous deletion.";
RL   Oncogene 20:4249-4257(2001).
RN   [22]
RP   INTERACTION WITH PTPRU.
RX   PubMed=12501215; DOI=10.1021/bi026095u;
RA   Yan H.-X., He Y.-Q., Dong H., Zhang P., Zeng J.-Z., Cao H.-F.,
RA   Wu M.-C., Wang H.-Y.;
RT   "Physical and functional interaction between receptor-like protein
RT   tyrosine phosphatase PCP-2 and beta-catenin.";
RL   Biochemistry 41:15854-15860(2002).
RN   [23]
RP   PHOSPHORYLATION AT SER-45, CHARACTERIZATION OF VARIANT HEPATOCELLULAR
RP   CARCINOMA ALA-41, CHARACTERIZATION OF VARIANT DESMOID TUMOR ALA-41,
RP   AND CHARACTERIZATION OF VARIANT HEPATOBLASTOMA ALA-41.
RX   MEDLINE=22047236; PubMed=12051714; DOI=10.1016/S0006-291X(02)00485-0;
RA   Hagen T., Vidal-Puig A.;
RT   "Characterisation of the phosphorylation of beta-catenin at the GSK-3
RT   priming site Ser45.";
RL   Biochem. Biophys. Res. Commun. 294:324-328(2002).
RN   [24]
RP   INTERACTION WITH CXADR.
RX   MEDLINE=22233435; PubMed=12297051; DOI=10.1016/S0092-8674(02)00912-1;
RA   Walters R.W., Freimuth P., Moninger T.O., Ganske I., Zabner J.,
RA   Welsh M.J.;
RT   "Adenovirus fiber disrupts CAR-mediated intercellular adhesion
RT   allowing virus escape.";
RL   Cell 110:789-799(2002).
RN   [25]
RP   PHOSPHORYLATION BY GSK3B, MUTAGENESIS OF SER-29, CHARACTERIZATION OF
RP   VARIANTS HEPATOCELLULAR CARCINOMA ARG-23; ALA-37 AND ALA-41,
RP   CHARACTERIZATION OF VARIANT PTR TYR-33, CHARACTERIZATION OF VARIANT
RP   MDB ALA-37, CHARACTERIZATION OF VARIANT DESMOID TUMOR ALA-41, AND
RP   CHARACTERIZATION OF VARIANT HEPATOBLASTOMA ALA-41.
RX   MEDLINE=22024348; PubMed=12027456; DOI=10.1006/excr.2002.5520;
RA   van Noort M., van de Wetering M., Clevers H.;
RT   "Identification of two novel regulated serines in the N-terminus of
RT   beta-catenin.";
RL   Exp. Cell Res. 276:264-272(2002).
RN   [26]
RP   WNT SIGNALING MODULATES PHOSPHORYLATION.
RX   MEDLINE=22001286; PubMed=11834740; DOI=10.1074/jbc.M111635200;
RA   van Noort M., Meeldijk J., van der Zee R., Destree O., Clevers H.;
RT   "Wnt signaling controls the phosphorylation status of beta-catenin.";
RL   J. Biol. Chem. 277:17901-17905(2002).
RN   [27]
RP   PHOSPHORYLATION, AND INTERACTION OF PHOSPHORYLATED CTNNB1 WITH BTRC.
RX   MEDLINE=22072105; PubMed=12077367;
RA   Sadot E., Conacci-Sorrell M., Zhurinsky J., Shnizer D., Lando Z.,
RA   Zharhary D., Kam Z., Ben-Ze'ev A., Geiger B.;
RT   "Regulation of S33/S37 phosphorylated beta-catenin in normal and
RT   transformed cells.";
RL   J. Cell Sci. 115:2771-2780(2002).
RN   [28]
RP   INTERACTION WITH PTPRJ.
RX   PubMed=12370829; DOI=10.1038/sj.onc.1205858;
RA   Holsinger L.J., Ward K., Duffield B., Zachwieja J., Jallal B.;
RT   "The transmembrane receptor protein tyrosine phosphatase DEP1
RT   interacts with p120(ctn).";
RL   Oncogene 21:7067-7076(2002).
RN   [29]
RP   INTERACTION WITH PCDH11Y.
RX   PubMed=12420223; DOI=10.1038/sj.onc.1205991;
RA   Chen M.-W., Vacherot F., De La Taille A., Gil-Diez-De-Medina S.,
RA   Shen R., Friedman R.A., Burchardt M., Chopin D.K., Buttyan R.;
RT   "The emergence of protocadherin-PC expression during the acquisition
RT   of apoptosis-resistance by prostate cancer cells.";
RL   Oncogene 21:7861-7871(2002).
RN   [30]
RP   INTERACTION WITH SLC9A3R1.
RX   MEDLINE=22713327; PubMed=12830000; DOI=10.1053/jhep.2003.50270;
RA   Shibata T., Chuma M., Kokubu A., Sakamoto M., Hirohashi S.;
RT   "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and
RT   is over-expressed in hepatocellular carcinoma.";
RL   Hepatology 38:178-186(2003).
RN   [31]
RP   REVIEW.
RX   MEDLINE=20145417; PubMed=10679188; DOI=10.1006/bbrc.1999.1860;
RA   Kikuchi A.;
RT   "Regulation of beta-catenin signaling in the Wnt pathway.";
RL   Biochem. Biophys. Res. Commun. 268:243-248(2000).
RN   [32]
RP   PHOSPHORYLATION AT TYR-142 BY FYN.
RX   PubMed=12640114; DOI=10.1128/MCB.23.7.2287-2297.2003;
RA   Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N.,
RA   Garcia de Herreros A., Dunach M.;
RT   "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-
RT   catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin
RT   Interaction.";
RL   Mol. Cell. Biol. 23:2287-2297(2003).
RN   [33]
RP   INTERACTION WITH AJAP1.
RC   TISSUE=Brain;
RX   PubMed=14595118; DOI=10.1091/mbc.E03-05-0281;
RA   Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A.,
RA   Baumann R., Starzinski-Powitz A.;
RT   "Novel membrane protein shrew-1 targets to cadherin-mediated junctions
RT   in polarized epithelial cells.";
RL   Mol. Biol. Cell 15:397-406(2004).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NANOS1.
RX   PubMed=17047063; DOI=10.1158/0008-5472.CAN-05-3096;
RA   Strumane K., Bonnomet A., Stove C., Vandenbroucke R.,
RA   Nawrocki-Raby B., Bruyneel E., Mareel M., Birembaut P., Berx G.,
RA   van Roy F.;
RT   "E-cadherin regulates human Nanos1, which interacts with p120ctn and
RT   induces tumor cell migration and invasion.";
RL   Cancer Res. 66:10007-10015(2006).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH EMD.
RX   PubMed=16858403; DOI=10.1038/sj.emboj.7601230;
RA   Markiewicz E., Tilgner K., Barker N., van de Wetering M., Clevers H.,
RA   Dorobek M., Hausmanowa-Petrusewicz I., Ramaekers F.C.S.,
RA   Broers J.L.V., Blankesteijn W.M., Salpingidou G., Wilson R.G.,
RA   Ellis J.A., Hutchison C.J.;
RT   "The inner nuclear membrane protein emerin regulates beta-catenin
RT   activity by restricting its accumulation in the nucleus.";
RL   EMBO J. 25:3275-3285(2006).
RN   [37]
RP   INTERACTION WITH MUC1, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009;
RA   Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.;
RT   "MUC1 inhibits cell proliferation by a beta-catenin-dependent
RT   mechanism.";
RL   Biochim. Biophys. Acta 1773:1028-1038(2007).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-552, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate
RT   cancer cells: identification of phosphoproteins in the LNCaP cell
RT   line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [39]
RP   INTERACTION WITH GLIS2, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=17289029; DOI=10.1016/j.febslet.2007.01.058;
RA   Kim Y.-S., Kang H.S., Jetten A.M.;
RT   "The Kruppel-like zinc finger protein Glis2 functions as a negative
RT   modulator of the Wnt/beta-catenin signaling pathway.";
RL   FEBS Lett. 581:858-864(2007).
RN   [40]
RP   PHOSPHORYLATION AT SER-191 AND SER-246, INTERACTION WITH CDK5,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17009320; DOI=10.1002/jcb.21041;
RA   Munoz J.P., Huichalaf C.H., Orellana D., Maccioni R.B.;
RT   "cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal
RT   cells.";
RL   J. Cell. Biochem. 100:738-749(2007).
RN   [41]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH
RP   NEK2.
RX   PubMed=18086858; DOI=10.1101/gad.1596308;
RA   Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H. Jr.,
RA   O'Toole E.T., Winey M., Salmon E.D., Casey P.J., Nelson W.J.,
RA   Barth A.I.;
RT   "beta-Catenin is a Nek2 substrate involved in centrosome separation.";
RL   Genes Dev. 22:91-105(2008).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-551; SER-552; THR-556
RP   AND SER-675, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [43]
RP   INTERACTION WITH SOX7.
RX   PubMed=18819930; DOI=10.1158/1541-7786.MCR-07-2175;
RA   Guo L., Zhong D., Lau S., Liu X., Dong X.Y., Sun X., Yang V.W.,
RA   Vertino P.M., Moreno C.S., Varma V., Dong J.T., Zhou W.;
RT   "Sox7 Is an independent checkpoint for beta-catenin function in
RT   prostate and colon epithelial cells.";
RL   Mol. Cancer Res. 6:1421-1430(2008).
RN   [44]
RP   INTERACTION WITH CHD8.
RX   PubMed=18378692; DOI=10.1128/MCB.00322-08;
RA   Thompson B.A., Tremblay V., Lin G., Bochar D.A.;
RT   "CHD8 is an ATP-dependent chromatin remodeling factor that regulates
RT   beta-catenin target genes.";
RL   Mol. Cell. Biol. 28:3894-3904(2008).
RN   [45]
RP   INTERACTION WITH TCF7L2 AND TNIK.
RX   PubMed=19816403; DOI=10.1038/emboj.2009.285;
RA   Mahmoudi T., Li V.S.W., Ng S.S., Taouatas N., Vries R.G.J.,
RA   Mohammed S., Heck A.J., Clevers H.;
RT   "The kinase TNIK is an essential activator of Wnt target genes.";
RL   EMBO J. 28:3329-3340(2009).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-552, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [47]
RP   FUNCTION.
RX   PubMed=18957423; DOI=10.1074/jbc.M805612200;
RA   Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V.;
RT   "Down-regulation of death-associated protein kinase-2 is required for
RT   beta-catenin-induced anoikis resistance of malignant epithelial
RT   cells.";
RL   J. Biol. Chem. 284:2012-2022(2009).
RN   [48]
RP   PHOSPHORYLATION AT SER-33 AND SER-37 BY HIPK2.
RX   PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099;
RA   Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.;
RT   "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin
RT   for phosphorylation and proteasomal degradation.";
RL   Biochem. Biophys. Res. Commun. 394:966-971(2010).
RN   [49]
RP   INTERACTION WITH SESTD1.
RX   PubMed=20164195; DOI=10.1074/jbc.M109.068304;
RA   Miehe S., Bieberstein A., Arnould I., Ihdene O., Rutten H.,
RA   Strubing C.;
RT   "The phospholipid-binding protein SESTD1 is a novel regulator of the
RT   transient receptor potential channels TRPC4 and TRPC5.";
RL   J. Biol. Chem. 285:12426-12434(2010).
RN   [50]
RP   INTERACTION WITH TRPC4.
RX   PubMed=19996314; DOI=10.1074/jbc.M109.060301;
RA   Graziani A., Poteser M., Heupel W.M., Schleifer H., Krenn M.,
RA   Drenckhahn D., Romanin C., Baumgartner W., Groschner K.;
RT   "Cell-cell contact formation governs Ca2+ signaling by TRPC4 in the
RT   vascular endothelium: evidence for a regulatory TRPC4-beta-catenin
RT   interaction.";
RL   J. Biol. Chem. 285:4213-4223(2010).
RN   [51]
RP   INTERACTION WITH CDK5.
RX   PubMed=19693690; DOI=10.1007/s11033-009-9752-7;
RA   Li Q., Liu X., Zhang M., Ye G., Qiao Q., Ling Y., Wu Y., Zhang Y.,
RA   Yu L.;
RT   "Characterization of a novel human CDK5 splicing variant that inhibits
RT   Wnt/beta-catenin signaling.";
RL   Mol. Biol. Rep. 37:2415-2421(2010).
RN   [52]
RP   PHOSPHORYLATION AT TYR-64; TYR-142; TYR-331 AND TYR-333, INTERACTION
RP   WITH PTK6, AND MUTAGENESIS OF TYR-64.
RX   PubMed=20026641; DOI=10.1242/jcs.053264;
RA   Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y.,
RA   Asara J.M., Tyner A.L.;
RT   "Identification of beta-catenin as a target of the intracellular
RT   tyrosine kinase PTK6.";
RL   J. Cell Sci. 123:236-245(2010).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [54]
RP   FUNCTION IN INSULIN INTERNALIZATION, SUBCELLULAR LOCATION, INTERACTION
RP   WITH CDK2, AND PHOSPHORYLATION BY CDK2.
RX   PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019;
RA   Fiset A., Xu E., Bergeron S., Marette A., Pelletier G.,
RA   Siminovitch K.A., Olivier M., Beauchemin N., Faure R.L.;
RT   "Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and
RT   regulates insulin internalization.";
RL   Cell. Signal. 23:911-919(2011).
RN   [55]
RP   INTERACTION WITH PKT7.
RX   PubMed=21132015; DOI=10.1038/embor.2010.185;
RA   Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F.,
RA   Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M.,
RA   Shin W.-S., Lee S.-T., Kodjabachian L., Borg J.-P.;
RT   "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin
RT   canonical signalling.";
RL   EMBO Rep. 12:43-49(2011).
RN   [56]
RP   INTERACTION WITH NDRG2.
RX   PubMed=21247902; DOI=10.1074/jbc.M110.170803;
RA   Hwang J., Kim Y., Kang H.B., Jaroszewski L., Deacon A.M., Lee H.,
RA   Choi W.C., Kim K.J., Kim C.H., Kang B.S., Lee J.O., Oh T.K., Kim J.W.,
RA   Wilson I.A., Kim M.H.;
RT   "Crystal structure of the human N-Myc downstream-regulated gene 2
RT   protein provides insight into its role as a tumor suppressor.";
RL   J. Biol. Chem. 286:12450-12460(2011).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 133-664.
RX   MEDLINE=20578806; PubMed=11136974; DOI=10.1016/S0092-8674(00)00192-6;
RA   Graham T.A., Weaver C., Mao F., Kimelman D., Xu W.;
RT   "Crystal structure of a beta-catenin/Tcf complex.";
RL   Cell 103:885-896(2000).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 134-664 IN COMPLEX WITH
RP   TCF7L2, AND MUTAGENESIS OF LYS-312 AND LYS-435.
RX   MEDLINE=21580302; PubMed=11713475; DOI=10.1038/nsb718;
RA   Graham T.A., Ferkey D.M., Mao F., Kimelman D., Xu W.;
RT   "Tcf4 can specifically recognize beta-catenin using alternative
RT   conformations.";
RL   Nat. Struct. Biol. 8:1048-1052(2001).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-668 IN COMPLEX WITH
RP   TCF7L2.
RX   MEDLINE=21580303; PubMed=11713476; DOI=10.1038/nsb720;
RA   Poy F., Lepourcelet M., Shivdasani R.A., Eck M.J.;
RT   "Structure of a human Tcf4-beta-catenin complex.";
RL   Nat. Struct. Biol. 8:1053-1057(2001).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-664 IN COMPLEX WITH
RP   CTNNBIP1, AND MUTAGENESIS OF PHE-660 AND ARG-661.
RX   MEDLINE=22297628; PubMed=12408824; DOI=10.1016/S1097-2765(02)00637-8;
RA   Graham T.A., Clements W.K., Kimelman D., Xu W.;
RT   "The crystal structure of the beta-catenin/ICAT complex reveals the
RT   inhibitory mechanism of ICAT.";
RL   Mol. Cell 10:563-571(2002).
RN   [61]
RP   VARIANTS COLORECTAL CANCER TYR-33 AND SER-45 DEL.
RX   PubMed=9065402; DOI=10.1126/science.275.5307.1787;
RA   Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H.,
RA   Vogelstein B., Kinzler K.W.;
RT   "Activation of beta-catenin-Tcf signaling in colon cancer by mutations
RT   in beta-catenin or APC.";
RL   Science 275:1787-1790(1997).
RN   [62]
RP   VARIANTS HEPATOBLASTOMA TYR-32; VAL-34; CYS-37 AND ALA-41.
RX   PubMed=9927029;
RA   Koch A., Denkhaus D., Albrecht S., Leuschner I., von Schweinitz D.,
RA   Pietsch T.;
RT   "Childhood hepatoblastomas frequently carry a mutated degradation
RT   targeting box of the beta-catenin gene.";
RL   Cancer Res. 59:269-273(1999).
RN   [63]
RP   VARIANT HEPATOBLASTOMA ALA-41.
RX   PubMed=10398436;
RX   DOI=10.1002/(SICI)1098-2264(199908)25:4<399::AID-GCC14>3.3.CO;2-O;
RA   Blaeker H., Hofmann W.J., Rieker R.J., Penzel R., Graf M., Otto H.F.;
RT   "Beta-catenin accumulation and mutation of the CTNNB1 gene in
RT   hepatoblastoma.";
RL   Genes Chromosomes Cancer 25:399-402(1999).
RN   [64]
RP   VARIANTS OVARIAN CANCER CYS-37; ILE-41 AND ALA-41.
RX   PubMed=10391090;
RA   Sagae S., Kobayashi K., Nishioka Y., Sugimura M., Ishioka S.,
RA   Nagata M., Terasawa K., Tokino T., Kudo R.;
RT   "Mutational analysis of beta-catenin gene in Japanese ovarian
RT   carcinomas: frequent mutations in endometrioid carcinomas.";
RL   Jpn. J. Cancer Res. 90:510-515(1999).
RN   [65]
RP   VARIANT DESMOID TUMOR ALA-41.
RX   PubMed=10655994;
RA   Shitoh K., Konishi F., Iijima T., Ohdaira T., Sakai K., Kanazawa K.,
RA   Miyaki M.;
RT   "A novel case of a sporadic desmoid tumour with mutation of the beta
RT   catenin gene.";
RL   J. Clin. Pathol. 52:695-696(1999).
RN   [66]
RP   VARIANTS PTR GLY-32; TYR-32; PHE-33; TYR-33; GLU-34; CYS-37; PHE-37
RP   AND ILE-41.
RX   PubMed=10192393; DOI=10.1038/7747;
RA   Chan E.F., Gat U., McNiff J.M., Fuchs E.;
RT   "A common human skin tumour is caused by activating mutations in beta-
RT   catenin.";
RL   Nat. Genet. 21:410-413(1999).
RN   [67]
RP   VARIANTS HEPATOCELLULAR CARCINOMA ARG-23; 25-TRP--SER-33 DEL; ALA-32;
RP   GLY-32; TYR-32; LEU-33; PHE-33; ARG-34; SER-35; ALA-37; 37-SER-GLY-38
RP   DELINS TRP; TYR-37; ALA-41; ILE-41; PHE-45 AND PRO-45.
RX   PubMed=10435629; DOI=10.1038/sj.onc.1202800;
RA   Legoix P., Bluteau O., Bayer J., Perret C., Balabaud C., Belghiti J.,
RA   Franco D., Thomas G., Laurent-Puig P., Zucman-Rossi J.;
RT   "Beta-catenin mutations in hepatocellular carcinoma correlate with a
RT   low rate of loss of heterozygosity.";
RL   Oncogene 18:4044-4046(1999).
RN   [68]
RP   VARIANTS MDB PHE-33 AND ALA-37.
RX   PubMed=10666372;
RA   Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y.,
RA   Kleihues P., Ohgaki H.;
RT   "APC mutations in sporadic medulloblastomas.";
RL   Am. J. Pathol. 156:433-437(2000).
CC   -!- FUNCTION: Key downstream component of the canonical Wnt signaling
CC       pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2,
CC       APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal
CC       Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its
CC       subsequent degradation by the proteasome. In the presence of Wnt
CC       ligand, CTNNB1 is not ubiquitinated and accumulates in the
CC       nucleus, where it acts as a coactivator for transcription factors
CC       of the TCF/LEF family, leading to activate Wnt responsive genes.
CC       Involved in the regulation of cell adhesion. Acts as a negative
CC       regulator of centrosome cohesion. Involved in the
CC       CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization.
CC       Blocks anoikis of malignant kidney and intestinal epithelial cells
CC       and promotes their anchorage-independent growth by down-regulating
CC       DAPK2.
CC   -!- SUBUNIT: Two separate complex-associated pools are found in the
CC       cytoplasm. The majority is present as component of an E-cadherin/
CC       catenin adhesion complex composed of at least E-cadherin/CDH1 and
CC       beta-catenin/CTNNB1, and possibly alpha-catenin/CTNNA1; the
CC       complex is located to adherens junctions. The stable association
CC       of CTNNA1 is controversial as CTNNA1 was shown not to bind to F-
CC       actin when assembled in the complex. Alternatively, the CTNNA1-
CC       containing complex may be linked to F-actin by other proteins such
CC       as LIMA1. Another cytoplasmic pool is part of a large complex
CC       containing AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes
CC       phosphorylation on N-terminal Ser and Thr residues and
CC       ubiquitination of CTNNB1 via BTRC and its subsequent degradation
CC       by the proteasome. Wnt-dependent activation of DVL antagonizes the
CC       action of GSK3B. When GSK3B activity is inhibited the complex
CC       dissociates, CTNNB1 is dephosphorylated and is no longer targeted
CC       for destruction. The stabilized protein translocates to the
CC       nucleus, where it binds TCF/LEF-1 family members, TBP, BCL9 and
CC       possibly also RUVBL1 and CHD8. Binds CTNNBIP and EP300. CTNNB1
CC       forms a ternary complex with LEF1 and EP300 that is disrupted by
CC       CTNNBIP1 binding (By similarity). Interacts with TAX1BP3 (via the
CC       PDZ domain); this interaction inhibits the transcriptional
CC       activity of CTNNB1 (By similarity). Interacts with AJAP1, BAIAP1,
CC       CARM1, CTNNA3, CXADR and PCDH11Y. Binds SLC9A3R1. Interacts with
CC       GLIS2 and MUC1. Interacts with SLC30A9. Interacts with XIRP1 (By
CC       similarity). Interacts directly with AXIN1; the interaction is
CC       regulated by CDK2 phosphorylation of AXIN1 (By similarity).
CC       Interacts with SCRIB (By similarity). Interacts with PTPRU (via
CC       the cytoplasmic juxtamembrane domain). Interacts with EMD.
CC       Interacts with TNIK and TCF7L2. Interacts with SESTD1 and TRPC4.
CC       Interacts with CAV1. Interacts with TRPV4. The TRPV4 and CTNNB1
CC       complex can interact with CDH1. Interacts with VCL (By
CC       similarity). Interacts with PTPRJ. Interacts with PKT7 and CDK2.
CC       Interacts with FAT1 (via the cytoplasmic domain) (By similarity).
CC       Interacts with NANOS1 and NDRG2. Interacts with isoform 1 of NEK2.
CC       Interacts with both isoform 1 and isoform 2 of CDK5. Interacts
CC       with PTK6. Interacts with SOX7; this interaction may lead to
CC       proteasomal degradation of active CTNNB1 and thus inhibition of
CC       Wnt/beta-catenin-stimulated transcription.
CC   -!- INTERACTION:
CC       O43707:ACTN4; NbExp=6; IntAct=EBI-491549, EBI-351526;
CC       P25054:APC; NbExp=7; IntAct=EBI-491549, EBI-727707;
CC       P10275:AR; NbExp=8; IntAct=EBI-491549, EBI-608057;
CC       O15169:AXIN1; NbExp=20; IntAct=EBI-491549, EBI-710484;
CC       O00512:BCL9; NbExp=2; IntAct=EBI-491549, EBI-533127;
CC       P33724:CAV1 (xeno); NbExp=5; IntAct=EBI-491549, EBI-79998;
CC       Q6P1J9:CDC73; NbExp=9; IntAct=EBI-491549, EBI-930143;
CC       P12830:CDH1; NbExp=6; IntAct=EBI-491549, EBI-727477;
CC       P26231:Ctnna1 (xeno); NbExp=2; IntAct=EBI-491549, EBI-647895;
CC       Q9NSA3:CTNNBIP1; NbExp=6; IntAct=EBI-491549, EBI-747082;
CC       Q9NYF0:DACT1; NbExp=3; IntAct=EBI-491549, EBI-3951744;
CC       Q9UKB1:FBXW11; NbExp=2; IntAct=EBI-491549, EBI-355189;
CC       Q08050:FOXM1; NbExp=16; IntAct=EBI-491549, EBI-866480;
CC       P49841:GSK3B; NbExp=3; IntAct=EBI-491549, EBI-373586;
CC       P18012:ipaC (xeno); NbExp=4; IntAct=EBI-491563, EBI-491541;
CC       Q14678:KANK1; NbExp=2; IntAct=EBI-491549, EBI-2556221;
CC       Q2LD37:KIAA1109; NbExp=2; IntAct=EBI-491549, EBI-2683809;
CC       Q8WVC0:LEO1; NbExp=2; IntAct=EBI-491549, EBI-932432;
CC       P49768:PSEN1; NbExp=2; IntAct=EBI-491549, EBI-297277;
CC       Q13761:RUNX3; NbExp=12; IntAct=EBI-491549, EBI-925990;
CC       Q9NQB0:TCF7L2; NbExp=27; IntAct=EBI-491549, EBI-924724;
CC       P11388:TOP2A; NbExp=5; IntAct=EBI-491549, EBI-539628;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton.
CC       Cell junction, adherens junction. Cell junction. Cell membrane.
CC       Cytoplasm, cytoskeleton, centrosome. Cytoplasm, cytoskeleton,
CC       spindle pole. Note=Cytoplasmic when it is unstabilized (high level
CC       of phosphorylation) or bound to CDH1. Translocates to the nucleus
CC       when it is stabilized (low level of phosphorylation). Interaction
CC       with GLIS2 and MUC1 promotes nuclear translocation. Interaction
CC       with EMD inhibits nuclear localization. The majority of beta-
CC       catenin is localized to the cell membrane. In interphase,
CC       colocalizes with CROCC between CEP250 puncta at the proximal end
CC       of centrioles, and this localization is dependent on CROCC and
CC       CEP250. In mitosis, when NEK2 activity increases, it localizes to
CC       centrosomes at spindle poles independent of CROCC. Co-localizes
CC       with CDK5 in the cell-cell contacts and plasma membrane of
CC       undifferentiated and differentiated neuroblastoma cells.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35222-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35222-2; Sequence=VSP_006984, VSP_006985, VSP_006986;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in several hair follicle cell types:
CC       basal and peripheral matrix cells, and cells of the outer and
CC       inner root sheaths. Expressed in colon. Present in cortical
CC       neurons (at protein level).
CC   -!- PTM: Phosphorylation at Ser-552 by AMPK promotes stabilizion of
CC       the protein, enhancing TCF/LEF-mediated transcription (By
CC       similarity). Phosphorylation by GSK3B requires prior
CC       phosphorylation of Ser-45 by another kinase. Phosphorylation
CC       proceeds then from Thr-41 to Ser-37 and Ser-33. Phosphorylated by
CC       NEK2. EGF stimulates tyrosine phosphorylation. Phosphorylation on
CC       Tyr-654 decreases CDH1 binding and enhances TBP binding.
CC       Phosphorylated on Ser-33 and Ser-37 by HIPK2. This phosphorylation
CC       triggers proteasomal degradation. Phosphorylation on Ser-191 and
CC       Ser-246 by CDK5. Phosphorylation by CDK2 regulates insulin
CC       internalization. Phosphorylation by PTK6 at Tyr-64, Tyr-142, Tyr-
CC       331 and/or Tyr-333 with the predominant site at Tyr-64 is not
CC       essential for inhibition of transcriptional activity.
CC   -!- PTM: Ubiquitinated by the SCF(BTRC) E3 ligase complex when
CC       phosphorylated by GSK3B, leading to its degradation. Ubiquitinated
CC       by a E3 ubiquitin ligase complex containing UBE2D1, SIAH1,
CC       CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent
CC       proteasomal degradation (By similarity).
CC   -!- DISEASE: Defects in CTNNB1 are associated with colorectal cancer
CC       (CRC) [MIM:114500].
CC   -!- DISEASE: Note=Activating mutations in CTNNB1 have oncogenic
CC       activity resulting in tumor development. Somatic mutations are
CC       found in various tumor types, including colon cancers, ovarian and
CC       prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma
CC       (HCC). HBs are malignant embryonal tumors mainly affecting young
CC       children in the first three years of life.
CC   -!- DISEASE: Defects in CTNNB1 are a cause of pilomatrixoma (PTR)
CC       [MIM:132600]; a common benign skin tumor.
CC   -!- DISEASE: Defects in CTNNB1 are a cause of medulloblastoma (MDB)
CC       [MIM:155255]. MDB is a malignant, invasive embryonal tumor of the
CC       cerebellum with a preferential manifestation in children.
CC   -!- DISEASE: Defects in CTNNB1 are a cause of susceptibility to
CC       ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy
CC       originating from ovarian tissue. Although many histologic types of
CC       ovarian neoplasms have been described, epithelial ovarian
CC       carcinoma is the most common form. Ovarian cancers are often
CC       asymptomatic and the recognized signs and symptoms, even of late-
CC       stage disease, are vague. Consequently, most patients are
CC       diagnosed with advanced disease.
CC   -!- DISEASE: Note=A chromosomal aberration involving CTNNB1 is found
CC       in salivary gland pleiomorphic adenomas, the most common benign
CC       epithelial tumors of the salivary gland. Translocation
CC       t(3;8)(p21;q12) with PLAG1.
CC   -!- DISEASE: Defects in CTNNB1 may be a cause of mesothelioma
CC       malignant (MESOM) [MIM:156240]. An aggressive neoplasm of the
CC       serosal lining of the chest. It appears as broad sheets of cells,
CC       with some regions containing spindle-shaped, sarcoma-like cells
CC       and other regions showing adenomatous patterns. Pleural
CC       mesotheliomas have been linked to exposure to asbestos.
CC   -!- SIMILARITY: Belongs to the beta-catenin family.
CC   -!- SIMILARITY: Contains 12 ARM repeats.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB93475.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CTNNB1ID71.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ctnnb1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-catenin entry;
CC       URL="http://en.wikipedia.org/wiki/Beta-catenin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X87838; CAA61107.1; -; mRNA.
DR   EMBL; Z19054; CAA79497.1; -; mRNA.
DR   EMBL; AF130085; AAG35511.1; -; mRNA.
DR   EMBL; AY463360; AAR18817.1; -; Genomic_DNA.
DR   EMBL; AK289932; BAF82621.1; -; mRNA.
DR   EMBL; AC104307; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471055; EAW64625.1; -; Genomic_DNA.
DR   EMBL; BC058926; AAH58926.1; -; mRNA.
DR   EMBL; AY081165; AAL89457.1; -; Genomic_DNA.
DR   EMBL; AB062292; BAB93475.1; ALT_INIT; mRNA.
DR   IPI; IPI00017292; -.
DR   IPI; IPI00927799; -.
DR   PIR; A38973; A38973.
DR   RefSeq; NP_001091679.1; NM_001098209.1.
DR   RefSeq; NP_001091680.1; NM_001098210.1.
DR   RefSeq; NP_001895.1; NM_001904.3.
DR   UniGene; Hs.476018; -.
DR   PDB; 1G3J; X-ray; 2.10 A; A/C=133-664.
DR   PDB; 1JDH; X-ray; 1.90 A; A=135-663.
DR   PDB; 1JPW; X-ray; 2.50 A; A/B/C=134-670.
DR   PDB; 1LUJ; X-ray; 2.50 A; A=150-663.
DR   PDB; 1P22; X-ray; 2.95 A; C=19-44.
DR   PDB; 1QZ7; X-ray; 2.20 A; A=133-665.
DR   PDB; 1T08; X-ray; 2.10 A; A=146-664.
DR   PDB; 1TH1; X-ray; 2.50 A; A/B=133-664.
DR   PDB; 2G57; NMR; -; A=19-44.
DR   PDB; 2GL7; X-ray; 2.60 A; A/D=138-686.
DR   PDB; 2Z6H; X-ray; 2.20 A; A=138-781.
DR   PDB; 3DIW; X-ray; 2.10 A; C/D=772-781.
DR   PDB; 3FQN; X-ray; 1.65 A; C=30-39.
DR   PDB; 3FQR; X-ray; 1.70 A; C=30-39.
DR   PDB; 3SL9; X-ray; 2.20 A; A/B/E/G=141-305.
DR   PDB; 3SLA; X-ray; 2.50 A; A/B/C/D/E=141-306.
DR   PDB; 3TX7; X-ray; 2.76 A; A=138-663.
DR   PDB; 4DJS; X-ray; 3.03 A; A=148-665.
DR   PDBsum; 1G3J; -.
DR   PDBsum; 1JDH; -.
DR   PDBsum; 1JPW; -.
DR   PDBsum; 1LUJ; -.
DR   PDBsum; 1P22; -.
DR   PDBsum; 1QZ7; -.
DR   PDBsum; 1T08; -.
DR   PDBsum; 1TH1; -.
DR   PDBsum; 2G57; -.
DR   PDBsum; 2GL7; -.
DR   PDBsum; 2Z6H; -.
DR   PDBsum; 3DIW; -.
DR   PDBsum; 3FQN; -.
DR   PDBsum; 3FQR; -.
DR   PDBsum; 3SL9; -.
DR   PDBsum; 3SLA; -.
DR   PDBsum; 3TX7; -.
DR   PDBsum; 4DJS; -.
DR   ProteinModelPortal; P35222; -.
DR   SMR; P35222; 19-44, 142-665.
DR   DIP; DIP-122N; -.
DR   IntAct; P35222; 85.
DR   MINT; MINT-105089; -.
DR   STRING; P35222; -.
DR   PhosphoSite; P35222; -.
DR   DMDM; 461854; -.
DR   PaxDb; P35222; -.
DR   PRIDE; P35222; -.
DR   DNASU; 1499; -.
DR   Ensembl; ENST00000349496; ENSP00000344456; ENSG00000168036.
DR   Ensembl; ENST00000396183; ENSP00000379486; ENSG00000168036.
DR   Ensembl; ENST00000396185; ENSP00000379488; ENSG00000168036.
DR   Ensembl; ENST00000405570; ENSP00000385604; ENSG00000168036.
DR   GeneID; 1499; -.
DR   KEGG; hsa:1499; -.
DR   UCSC; uc003ckp.2; human.
DR   UCSC; uc003ckt.1; human.
DR   CTD; 1499; -.
DR   GeneCards; GC03P041236; -.
DR   H-InvDB; HIX0163439; -.
DR   H-InvDB; HIX0163473; -.
DR   HGNC; HGNC:2514; CTNNB1.
DR   HPA; CAB000108; -.
DR   HPA; CAB001950; -.
DR   HPA; HPA029159; -.
DR   HPA; HPA029160; -.
DR   MIM; 114500; phenotype.
DR   MIM; 116806; gene.
DR   MIM; 132600; phenotype.
DR   MIM; 155255; phenotype.
DR   MIM; 156240; phenotype.
DR   MIM; 167000; phenotype.
DR   MIM; 181030; phenotype.
DR   neXtProt; NX_P35222; -.
DR   Orphanet; 873; Desmoid disease.
DR   Orphanet; 33402; Hepatocellular carcinoma, childhood-onset.
DR   Orphanet; 91414; Pilomatrixoma.
DR   PharmGKB; PA27013; -.
DR   eggNOG; NOG297695; -.
DR   HOGENOM; HOG000230958; -.
DR   HOVERGEN; HBG000919; -.
DR   InParanoid; P35222; -.
DR   KO; K02105; -.
DR   OMA; TVCQVGG; -.
DR   OrthoDB; EOG4FN4H2; -.
DR   PhylomeDB; P35222; -.
DR   Pathway_Interaction_DB; arf6_traffickingpathway; Arf6 trafficking events.
DR   Pathway_Interaction_DB; wnt_canonical_pathway; Canonical Wnt signaling pathway.
DR   Pathway_Interaction_DB; ar_pathway; Coregulation of Androgen receptor activity.
DR   Pathway_Interaction_DB; foxopathway; FoxO family signaling.
DR   Pathway_Interaction_DB; ps1pathway; Presenilin action in Notch and Wnt signaling.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; tgfbrpathway; TGF-beta receptor signaling.
DR   Reactome; REACT_111045; Developmental Biology.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111155; Cell-Cell communication.
DR   Reactome; REACT_578; Apoptosis.
DR   ChEMBL; CHEMBL5866; -.
DR   DrugBank; DB01356; Lithium.
DR   EvolutionaryTrace; P35222; -.
DR   GenomeRNAi; 1499; -.
DR   NextBio; 6161; -.
DR   PMAP-CutDB; P35222; -.
DR   ArrayExpress; P35222; -.
DR   Bgee; P35222; -.
DR   CleanEx; HS_CTNNB1; -.
DR   Genevestigator; P35222; -.
DR   GermOnline; ENSG00000168036; Homo sapiens.
DR   GO; GO:0045177; C:apical part of cell; IEA:Compara.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Compara.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:BHF-UCL.
DR   GO; GO:0070369; C:beta-catenin-TCF7L2 complex; IDA:BHF-UCL.
DR   GO; GO:0016342; C:catenin complex; IDA:BHF-UCL.
DR   GO; GO:0005938; C:cell cortex; IDA:BHF-UCL.
DR   GO; GO:0005924; C:cell-substrate adherens junction; IDA:BHF-UCL.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043198; C:dendritic shaft; IBA:RefGenome.
DR   GO; GO:0030057; C:desmosome; IBA:RefGenome.
DR   GO; GO:0005916; C:fascia adherens; IBA:RefGenome.
DR   GO; GO:0009898; C:internal side of plasma membrane; IBA:RefGenome.
DR   GO; GO:0030027; C:lamellipodium; IBA:RefGenome.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:MGI.
DR   GO; GO:0031528; C:microvillus membrane; IBA:RefGenome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL.
DR   GO; GO:0034750; C:Scrib-APC-beta-catenin complex; IEA:Compara.
DR   GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell.
DR   GO; GO:0045202; C:synapse; IBA:RefGenome.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0030018; C:Z disc; IBA:RefGenome.
DR   GO; GO:0005915; C:zonula adherens; IBA:RefGenome.
DR   GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Compara.
DR   GO; GO:0003690; F:double-stranded DNA binding; IEA:Compara.
DR   GO; GO:0019901; F:protein kinase binding; IBA:RefGenome.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IEA:Compara.
DR   GO; GO:0004871; F:signal transducer activity; NAS:ProtInc.
DR   GO; GO:0005198; F:structural molecule activity; IBA:RefGenome.
DR   GO; GO:0003713; F:transcription coactivator activity; IMP:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; TAS:AgBase.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0034333; P:adherens junction assembly; IMP:BHF-UCL.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IEA:Compara.
DR   GO; GO:0045453; P:bone resorption; IEA:Compara.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IBA:RefGenome.
DR   GO; GO:0044336; P:canonical Wnt receptor signaling pathway involved in negative regulation of apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0061324; P:canonical Wnt receptor signaling pathway involved in positive regulation of cardiac outflow tract cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0044334; P:canonical Wnt receptor signaling pathway involved in positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0001708; P:cell fate specification; IEA:Compara.
DR   GO; GO:0048469; P:cell maturation; IEA:Compara.
DR   GO; GO:0016337; P:cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:0007160; P:cell-matrix adhesion; IBA:RefGenome.
DR   GO; GO:0006921; P:cellular component disassembly involved in execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Compara.
DR   GO; GO:0022009; P:central nervous system vasculogenesis; IBA:RefGenome.
DR   GO; GO:0007016; P:cytoskeletal anchoring at plasma membrane; IBA:RefGenome.
DR   GO; GO:0048262; P:determination of dorsal/ventral asymmetry; IBA:RefGenome.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IBA:RefGenome.
DR   GO; GO:0007398; P:ectoderm development; IBA:RefGenome.
DR   GO; GO:0000578; P:embryonic axis specification; IBA:RefGenome.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Compara.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IBA:RefGenome.
DR   GO; GO:0035050; P:embryonic heart tube development; IEA:Compara.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Compara.
DR   GO; GO:0036023; P:embryonic skeletal limb joint morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001711; P:endodermal cell fate commitment; IBA:RefGenome.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IEA:Compara.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; TAS:HGNC.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Compara.
DR   GO; GO:0030900; P:forebrain development; IEA:Compara.
DR   GO; GO:0061198; P:fungiform papilla formation; IEA:Compara.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IBA:RefGenome.
DR   GO; GO:0035112; P:genitalia morphogenesis; IEA:Compara.
DR   GO; GO:0007403; P:glial cell fate determination; IBA:RefGenome.
DR   GO; GO:0035315; P:hair cell differentiation; TAS:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IBA:RefGenome.
DR   GO; GO:0060789; P:hair follicle placode formation; IBA:RefGenome.
DR   GO; GO:0030902; P:hindbrain development; IBA:RefGenome.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Compara.
DR   GO; GO:0002089; P:lens morphogenesis in camera-type eye; IEA:Compara.
DR   GO; GO:0001889; P:liver development; IBA:RefGenome.
DR   GO; GO:0060479; P:lung cell differentiation; IBA:RefGenome.
DR   GO; GO:0060492; P:lung induction; IBA:RefGenome.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IBA:RefGenome.
DR   GO; GO:0030539; P:male genitalia development; IBA:RefGenome.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IBA:RefGenome.
DR   GO; GO:0003337; P:mesenchymal to epithelial transition involved in metanephros morphogenesis; IBA:RefGenome.
DR   GO; GO:0007494; P:midgut development; IEA:Compara.
DR   GO; GO:0045445; P:myoblast differentiation; IEA:Compara.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IBA:RefGenome.
DR   GO; GO:0003136; P:negative regulation of heart induction by canonical Wnt receptor signaling pathway; IBA:RefGenome.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IEA:Compara.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IBA:RefGenome.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:RefGenome.
DR   GO; GO:0072079; P:nephron tubule formation; IBA:RefGenome.
DR   GO; GO:0001764; P:neuron migration; IEA:Compara.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IBA:RefGenome.
DR   GO; GO:0048599; P:oocyte development; IBA:RefGenome.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Compara.
DR   GO; GO:0060066; P:oviduct development; IEA:Compara.
DR   GO; GO:0031016; P:pancreas development; IBA:RefGenome.
DR   GO; GO:0001569; P:patterning of blood vessels; IC:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; IBA:RefGenome.
DR   GO; GO:2000017; P:positive regulation of determination of dorsal identity; IEA:Compara.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Compara.
DR   GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IBA:RefGenome.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IBA:RefGenome.
DR   GO; GO:0010909; P:positive regulation of heparan sulfate proteoglycan biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB cascade; IBA:RefGenome.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:RefGenome.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Compara.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Compara.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IBA:RefGenome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0034394; P:protein localization to cell surface; IMP:BHF-UCL.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IBA:RefGenome.
DR   GO; GO:0045765; P:regulation of angiogenesis; TAS:BHF-UCL.
DR   GO; GO:0090279; P:regulation of calcium ion import; IDA:BHF-UCL.
DR   GO; GO:0030997; P:regulation of centriole-centriole cohesion; IDA:UniProtKB.
DR   GO; GO:0070602; P:regulation of centromeric sister chromatid cohesion; IMP:BHF-UCL.
DR   GO; GO:0048145; P:regulation of fibroblast proliferation; TAS:BHF-UCL.
DR   GO; GO:0031641; P:regulation of myelination; IEA:Compara.
DR   GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; IDA:BHF-UCL.
DR   GO; GO:0003266; P:regulation of secondary heart field cardioblast proliferation; IEA:Compara.
DR   GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0042129; P:regulation of T cell proliferation; IBA:RefGenome.
DR   GO; GO:0072053; P:renal inner medulla development; IBA:RefGenome.
DR   GO; GO:0072054; P:renal outer medulla development; IBA:RefGenome.
DR   GO; GO:0072033; P:renal vesicle formation; IBA:RefGenome.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Compara.
DR   GO; GO:0034097; P:response to cytokine stimulus; IEA:Compara.
DR   GO; GO:0042493; P:response to drug; IEP:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol stimulus; IDA:BHF-UCL.
DR   GO; GO:0014010; P:Schwann cell proliferation; IBA:RefGenome.
DR   GO; GO:0043588; P:skin development; IEA:Compara.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IBA:RefGenome.
DR   GO; GO:0050808; P:synapse organization; IBA:RefGenome.
DR   GO; GO:0048489; P:synaptic vesicle transport; IBA:RefGenome.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IBA:RefGenome.
DR   GO; GO:0048538; P:thymus development; IBA:RefGenome.
DR   GO; GO:0043587; P:tongue morphogenesis; IBA:RefGenome.
DR   GO; GO:0060440; P:trachea formation; IBA:RefGenome.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   Gene3D; 1.25.10.10; ARM-like; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000225; Armadillo.
DR   InterPro; IPR013284; Beta-catenin.
DR   Pfam; PF00514; Arm; 4.
DR   PRINTS; PR01869; BCATNINFAMLY.
DR   SMART; SM00185; ARM; 12.
DR   SUPFAM; SSF48371; ARM-type_fold; 1.
DR   PROSITE; PS50176; ARM_REPEAT; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cell adhesion;
KW   Cell junction; Cell membrane; Chromosomal rearrangement;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Disease mutation;
KW   Membrane; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transcription; Transcription regulation; Ubl conjugation;
KW   Wnt signaling pathway.
FT   CHAIN         1    781       Catenin beta-1.
FT                                /FTId=PRO_0000064271.
FT   REPEAT      151    191       ARM 1.
FT   REPEAT      193    234       ARM 2.
FT   REPEAT      235    276       ARM 3.
FT   REPEAT      277    318       ARM 4.
FT   REPEAT      319    360       ARM 5.
FT   REPEAT      361    389       ARM 6.
FT   REPEAT      400    441       ARM 7.
FT   REPEAT      442    484       ARM 8.
FT   REPEAT      489    530       ARM 9.
FT   REPEAT      531    571       ARM 10.
FT   REPEAT      594    636       ARM 11.
FT   REPEAT      637    666       ARM 12.
FT   REGION        1     23       Interaction with VCL (By similarity).
FT   REGION      772    781       Interaction with SCRIB (By similarity).
FT   MOD_RES      23     23       Phosphoserine; by GSK3-beta.
FT   MOD_RES      29     29       Phosphoserine; by GSK3-beta.
FT   MOD_RES      33     33       Phosphoserine; by GSK3-beta and HIPK2.
FT   MOD_RES      37     37       Phosphoserine; by GSK3-beta and HIPK2.
FT   MOD_RES      41     41       Phosphothreonine; by GSK3-beta.
FT   MOD_RES      45     45       Phosphoserine.
FT   MOD_RES      64     64       Phosphotyrosine; by PTK6.
FT   MOD_RES      86     86       Phosphotyrosine; by CSK.
FT   MOD_RES     142    142       Phosphotyrosine; by FYN and PTK6.
FT   MOD_RES     191    191       Phosphoserine; by CDK5.
FT   MOD_RES     246    246       Phosphoserine; by CDK5.
FT   MOD_RES     331    331       Phosphotyrosine; by PTK6.
FT   MOD_RES     333    333       Phosphotyrosine; by PTK6 (Probable).
FT   MOD_RES     551    551       Phosphothreonine.
FT   MOD_RES     552    552       Phosphoserine; by AMPK (Probable).
FT   MOD_RES     556    556       Phosphothreonine.
FT   MOD_RES     654    654       Phosphotyrosine; by CSK.
FT   MOD_RES     675    675       Phosphoserine.
FT   VAR_SEQ       1    565       Missing (in isoform 2).
FT                                /FTId=VSP_006984.
FT   VAR_SEQ     652    653       AT -> GK (in isoform 2).
FT                                /FTId=VSP_006985.
FT   VAR_SEQ     654    781       Missing (in isoform 2).
FT                                /FTId=VSP_006986.
FT   VARIANT      23     23       S -> R (in hepatocellular carcinoma; no
FT                                effect).
FT                                /FTId=VAR_017612.
FT   VARIANT      25     33       Missing (in hepatocellular carcinoma).
FT                                /FTId=VAR_017613.
FT   VARIANT      32     32       D -> A (in hepatocellular carcinoma).
FT                                /FTId=VAR_017614.
FT   VARIANT      32     32       D -> G (in PTR and hepatocellular
FT                                carcinoma).
FT                                /FTId=VAR_017615.
FT   VARIANT      32     32       D -> Y (in PTR, hepatoblastoma and
FT                                hepatocellular carcinoma;
FT                                dbSNP:rs28931588).
FT                                /FTId=VAR_017616.
FT   VARIANT      33     33       S -> F (in PTR, MDB and hepatocellular
FT                                carcinoma).
FT                                /FTId=VAR_017617.
FT   VARIANT      33     33       S -> L (in hepatocellular carcinoma).
FT                                /FTId=VAR_017618.
FT   VARIANT      33     33       S -> Y (in colorectal cancer and PTR;
FT                                enhances transactivation of target
FT                                genes).
FT                                /FTId=VAR_017619.
FT   VARIANT      34     34       G -> E (in PTR).
FT                                /FTId=VAR_017620.
FT   VARIANT      34     34       G -> R (in hepatocellular carcinoma).
FT                                /FTId=VAR_017621.
FT   VARIANT      34     34       G -> V (in hepatoblastoma;
FT                                dbSNP:rs28931589).
FT                                /FTId=VAR_017622.
FT   VARIANT      35     35       I -> S (in hepatocellular carcinoma).
FT                                /FTId=VAR_017623.
FT   VARIANT      37     38       SG -> W (in hepatocellular carcinoma).
FT                                /FTId=VAR_017628.
FT   VARIANT      37     37       S -> A (in MDB and hepatocellular
FT                                carcinoma; enhances transactivation of
FT                                target genes).
FT                                /FTId=VAR_017624.
FT   VARIANT      37     37       S -> C (in PTR, hepatoblastoma and
FT                                ovarian cancer).
FT                                /FTId=VAR_017625.
FT   VARIANT      37     37       S -> F (in PTR).
FT                                /FTId=VAR_017626.
FT   VARIANT      37     37       S -> Y (in hepatocellular carcinoma).
FT                                /FTId=VAR_017627.
FT   VARIANT      41     41       T -> A (in hepatoblastoma and
FT                                hepatocellular carcinoma; also in a
FT                                desmoid tumor; strongly reduces
FT                                phosphorylation and degradation;
FT                                abolishes phosphorylation on Ser-33 and
FT                                Ser-37 and enhances transactivation of
FT                                target genes).
FT                                /FTId=VAR_017629.
FT   VARIANT      41     41       T -> I (in PTR, hepatocellular carcinoma
FT                                and ovarian cancer).
FT                                /FTId=VAR_017630.
FT   VARIANT      45     45       S -> F (in hepatocellular carcinoma).
FT                                /FTId=VAR_017631.
FT   VARIANT      45     45       S -> P (in hepatocellular carcinoma).
FT                                /FTId=VAR_017632.
FT   VARIANT      45     45       Missing (in colorectal cancer).
FT                                /FTId=VAR_055430.
FT   VARIANT     688    688       M -> V (in dbSNP:rs4135384).
FT                                /FTId=VAR_018954.
FT   MUTAGEN      29     29       S->F: No effect.
FT   MUTAGEN      64     64       Y->F: Abolishes phosphorylation by PTK6.
FT   MUTAGEN     253    253       F->A: Abolishes or strongly reduces AXIN2
FT                                binding.
FT   MUTAGEN     260    260       H->A: Abolishes or strongly reduces AXIN1
FT                                and AXIN2 binding. Strongly reduces
FT                                phosphorylation and degradation; when
FT                                associated with A-386 and A-383.
FT   MUTAGEN     292    292       K->A: Abolishes or strongly reduces AXIN1
FT                                and AXIN2 binding.
FT   MUTAGEN     312    312       K->E: Abolishes TCF7L2 binding.
FT   MUTAGEN     345    345       K->A: Abolishes APC binding.
FT   MUTAGEN     383    383       W->A: Abolishes APC binding. Strongly
FT                                reduces phosphorylation and degradation;
FT                                when associated with A-260 and A-386.
FT   MUTAGEN     386    386       R->A: Strongly reduces APC binding.
FT                                Strongly reduces phosphorylation and
FT                                degradation; when associated with A-260
FT                                and A-383.
FT   MUTAGEN     426    426       N->A: Abolishes TCF7L2 and LEF1 binding.
FT   MUTAGEN     435    435       K->A: Strongly reduces or abolishes LEF1
FT                                binding.
FT   MUTAGEN     435    435       K->E: Abolishes TCF7L2 binding.
FT   MUTAGEN     469    469       R->A: Abolishes TCF7L2 binding, and
FT                                strongly reduces or abolishes LEF1
FT                                binding.
FT   MUTAGEN     470    470       H->A: Abolishes TCF7L2 binding, and
FT                                strongly reduces or abolishes LEF1
FT                                binding.
FT   MUTAGEN     508    508       K->A: Abolishes TCF7L2 and LEF1 binding.
FT   MUTAGEN     654    654       Y->E: Enhances TBP binding and
FT                                transactivation of target genes.
FT   MUTAGEN     654    654       Y->F: Abolishes increase of TBP binding
FT                                after phosphorylation by CSK.
FT   MUTAGEN     660    660       F->A: Abolishes CTNNBIP1 binding; when
FT                                associated with A-661.
FT   MUTAGEN     661    661       R->A: Abolishes CTNNBIP1 binding; when
FT                                associated with A-660.
FT   TURN         20     22
FT   STRAND       23     26
FT   TURN         27     29
FT   TURN         39     41
FT   HELIX       135    150
FT   HELIX       152    160
FT   HELIX       165    179
FT   HELIX       182    189
FT   HELIX       192    204
FT   HELIX       208    221
FT   HELIX       225    233
FT   HELIX       236    243
FT   HELIX       249    265
FT   HELIX       269    276
FT   HELIX       278    284
FT   HELIX       285    287
FT   HELIX       291    305
FT   HELIX       309    317
FT   HELIX       320    330
FT   HELIX       334    347
FT   HELIX       353    359
FT   HELIX       362    367
FT   TURN        368    371
FT   HELIX       375    389
FT   HELIX       399    408
FT   HELIX       414    427
FT   TURN        428    430
FT   HELIX       432    440
FT   HELIX       443    454
FT   HELIX       458    471
FT   STRAND      473    475
FT   HELIX       478    487
FT   HELIX       491    496
FT   HELIX       504    517
FT   HELIX       521    523
FT   HELIX       524    529
FT   HELIX       532    547
FT   STRAND      550    552
FT   STRAND      554    557
FT   STRAND      561    563
FT   HELIX       566    580
FT   HELIX       584    592
FT   HELIX       596    601
FT   HELIX       602    604
FT   HELIX       608    621
FT   HELIX       625    633
FT   HELIX       637    642
FT   HELIX       643    645
FT   HELIX       649    662
FT   TURN        663    665
FT   HELIX       668    682
FT   HELIX       688    690
FT   STRAND      778    780
SQ   SEQUENCE   781 AA;  85497 MW;  CB78F165A3EEF86E CRC64;
     MATQADLMEL DMAMEPDRKA AVSHWQQQSY LDSGIHSGAT TTAPSLSGKG NPEEEDVDTS
     QVLYEWEQGF SQSFTQEQVA DIDGQYAMTR AQRVRAAMFP ETLDEGMQIP STQFDAAHPT
     NVQRLAEPSQ MLKHAVVNLI NYQDDAELAT RAIPELTKLL NDEDQVVVNK AAVMVHQLSK
     KEASRHAIMR SPQMVSAIVR TMQNTNDVET ARCTAGTLHN LSHHREGLLA IFKSGGIPAL
     VKMLGSPVDS VLFYAITTLH NLLLHQEGAK MAVRLAGGLQ KMVALLNKTN VKFLAITTDC
     LQILAYGNQE SKLIILASGG PQALVNIMRT YTYEKLLWTT SRVLKVLSVC SSNKPAIVEA
     GGMQALGLHL TDPSQRLVQN CLWTLRNLSD AATKQEGMEG LLGTLVQLLG SDDINVVTCA
     AGILSNLTCN NYKNKMMVCQ VGGIEALVRT VLRAGDREDI TEPAICALRH LTSRHQEAEM
     AQNAVRLHYG LPVVVKLLHP PSHWPLIKAT VGLIRNLALC PANHAPLREQ GAIPRLVQLL
     VRAHQDTQRR TSMGGTQQQF VEGVRMEEIV EGCTGALHIL ARDVHNRIVI RGLNTIPLFV
     QLLYSPIENI QRVAAGVLCE LAQDKEAAEA IEAEGATAPL TELLHSRNEG VATYAAAVLF
     RMSEDKPQDY KKRLSVELTS SLFRTEPMAW NETADLGLDI GAQGEPLGYR QDDPSYRSFH
     SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD
     L
//
ID   BRD2_HUMAN              Reviewed;         801 AA.
AC   P25440; A2AAU0; B0S7P0; B1AZT1; O00699; O00700; Q15310; Q5STC9;
AC   Q6P3U2; Q969U4;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   09-JAN-2013, entry version 126.
DE   RecName: Full=Bromodomain-containing protein 2;
DE   AltName: Full=O27.1.1;
DE   AltName: Full=Really interesting new gene 3 protein;
GN   Name=BRD2; Synonyms=KIAA9001, RING3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   MEDLINE=92329974; PubMed=1352711;
RA   Beck S., Hanson I., Kelly A., Pappin D.J.C., Trowsdale J.;
RT   "A homologue of the Drosophila female sterile homeotic (fsh) gene in
RT   the class II region of the human MHC.";
RL   DNA Seq. 2:203-210(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SEQUENCE REVISION TO
RP   N-TERMINUS.
RX   MEDLINE=96376536; PubMed=8781126; DOI=10.1007/s002510050142;
RA   Thorpe K.L., Abdulla S., Kaufman J., Trowsdale J., Beck S.;
RT   "Phylogeny and structure of the RING3 gene.";
RL   Immunogenetics 44:391-396(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RA   Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y.,
RA   Sato S., Nagase T., Seki T., Ishikawa K., Tabata S.;
RL   Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PHE-238.
RX   MEDLINE=22935763; PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298 AND SER-301, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-724, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17287340; DOI=10.1073/pnas.0611217104;
RA   Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.;
RT   "Global proteomic profiling of phosphopeptides using electron transfer
RT   dissociation tandem mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH ACETYLATED CHROMATIN.
RX   PubMed=18406326; DOI=10.1016/j.molcel.2008.01.018;
RA   LeRoy G., Rickards B., Flint S.J.;
RT   "The double bromodomain proteins Brd2 and Brd3 couple histone
RT   acetylation to transcription.";
RL   Mol. Cell 30:51-60(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298; SER-301; SER-305
RP   AND SER-633, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-298 AND SER-301, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-298 AND SER-301,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 73-194, HOMODIMERIZATION,
RP   INTERACTION WITH E2F1 AND HISTONE H4, AND MUTAGENESIS OF GLN-78;
RP   142-MET-GLN-143; TYR-153; ILE-154; GLU-170; LEU-174; VAL-177 AND
RP   GLN-182.
RX   PubMed=17148447; DOI=10.1074/jbc.M605971200;
RA   Nakamura Y., Umehara T., Nakano K., Jang M.K., Shirouzu M., Morita S.,
RA   Uda-Tochio H., Hamana H., Terada T., Adachi N., Matsumoto T.,
RA   Tanaka A., Horikoshi M., Ozato K., Padmanabhan B., Yokoyama S.;
RT   "Crystal structure of the human BRD2 bromodomain: insights into
RT   dimerization and recognition of acetylated histone h4.";
RL   J. Biol. Chem. 282:4193-4201(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 344-452.
RX   PubMed=20871596; DOI=10.1038/nature09504;
RA   Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O.,
RA   Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M.,
RA   Munro S., McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J.,
RA   Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O.,
RA   Kung A.L., Knapp S., Bradner J.E.;
RT   "Selective inhibition of BET bromodomains.";
RL   Nature 468:1067-1073(2010).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-30; GLY-49; SER-49; PRO-212;
RP   PHE-238; GLN-260; VAL-474; GLY-558; THR-569; PRO-599 AND LEU-714.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: May play a role in spermatogenesis or folliculogenesis
CC       (By similarity). Binds hyperacetylated chromatin and plays a role
CC       in the regulation of transcription, probably by chromatin
CC       remodeling. Regulates transcription of the CCND1 gene. Plays a
CC       role in nucleosome assembly.
CC   -!- SUBUNIT: Homodimer. Interacts with E2F1 and with histone H4
CC       acetylated at 'Lys-13'.
CC   -!- SUBCELLULAR LOCATION: Nucleus (Probable). Note=Detected on
CC       chromatin and nucleosomes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P25440-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P25440-2; Sequence=VSP_022600;
CC         Note=No experimental confirmation available;
CC   -!- DOMAIN: One bromodomain is sufficient for a partial interaction
CC       with histone H4 acetylated at 'Lys-13'.
CC   -!- SIMILARITY: Contains 2 bromo domains.
CC   -!- SIMILARITY: Contains 1 NET domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA68890.1; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X62083; CAA43996.1; -; mRNA.
DR   EMBL; M80613; AAA68890.1; ALT_INIT; mRNA.
DR   EMBL; X96670; CAA65450.1; -; Genomic_DNA.
DR   EMBL; D42040; BAA07641.1; -; mRNA.
DR   EMBL; BX648109; CAH56171.1; -; mRNA.
DR   EMBL; AL645941; CAI18110.1; -; Genomic_DNA.
DR   EMBL; AL662845; CAI17492.1; -; Genomic_DNA.
DR   EMBL; AL805913; CAI18548.1; -; Genomic_DNA.
DR   EMBL; AL935042; CAI18548.1; JOINED; Genomic_DNA.
DR   EMBL; AL935042; CAI18689.1; -; Genomic_DNA.
DR   EMBL; AL805913; CAI18689.1; JOINED; Genomic_DNA.
DR   EMBL; AL805913; CAM25759.1; -; Genomic_DNA.
DR   EMBL; AL935042; CAM25759.1; JOINED; Genomic_DNA.
DR   EMBL; BX005422; CAM26115.1; -; Genomic_DNA.
DR   EMBL; BX005422; CAM26116.1; -; Genomic_DNA.
DR   EMBL; BX908719; CAQ09037.1; -; Genomic_DNA.
DR   EMBL; CR936909; CAQ09037.1; JOINED; Genomic_DNA.
DR   EMBL; CR936909; CAQ07147.1; -; Genomic_DNA.
DR   EMBL; BX908719; CAQ07147.1; JOINED; Genomic_DNA.
DR   EMBL; AL935042; CAX13939.1; -; Genomic_DNA.
DR   EMBL; AL805913; CAX13939.1; JOINED; Genomic_DNA.
DR   EMBL; Z96104; CAC69989.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03663.1; -; Genomic_DNA.
DR   EMBL; BC063840; AAH63840.1; -; mRNA.
DR   IPI; IPI00014414; -.
DR   IPI; IPI00440502; -.
DR   PIR; A56619; A56619.
DR   RefSeq; NP_001106653.1; NM_001113182.2.
DR   RefSeq; NP_001186384.1; NM_001199455.1.
DR   RefSeq; NP_001186385.1; NM_001199456.1.
DR   RefSeq; NP_005095.1; NM_005104.3.
DR   UniGene; Hs.75243; -.
DR   PDB; 1X0J; X-ray; 1.80 A; A/B/C=73-194.
DR   PDB; 2DVQ; X-ray; 2.04 A; A/B/C=73-194.
DR   PDB; 2DVR; X-ray; 2.30 A; A/B/C=73-194.
DR   PDB; 2DVS; X-ray; 2.04 A; A/B/C=73-194.
DR   PDB; 2DVV; X-ray; 1.80 A; A=348-455.
DR   PDB; 2E3K; X-ray; 2.30 A; A/B/C/D=348-455.
DR   PDB; 2G4A; NMR; -; A=348-455.
DR   PDB; 2YDW; X-ray; 1.90 A; A/B/C=67-192.
DR   PDB; 2YEK; X-ray; 1.98 A; A/B/C=67-192.
DR   PDB; 3AQA; X-ray; 2.30 A; A/B/C=73-194.
DR   PDB; 3ONI; X-ray; 1.61 A; A=344-455.
DR   PDB; 4A9E; X-ray; 1.91 A; A/B/C=67-200.
DR   PDB; 4A9F; X-ray; 1.73 A; A/B/C=67-200.
DR   PDB; 4A9H; X-ray; 2.05 A; A/B/C=67-200.
DR   PDB; 4A9I; X-ray; 2.25 A; A/B/C=67-200.
DR   PDB; 4A9J; X-ray; 1.90 A; A/B/C=67-200.
DR   PDB; 4A9M; X-ray; 2.06 A; A/B/C=67-200.
DR   PDB; 4A9N; X-ray; 1.85 A; A/B/C=67-200.
DR   PDB; 4A9O; X-ray; 1.78 A; A/B/C=67-200.
DR   PDB; 4AKN; X-ray; 1.82 A; A/B/C=67-192.
DR   PDB; 4ALG; X-ray; 1.60 A; A=67-200.
DR   PDB; 4ALH; X-ray; 1.78 A; A/B/C=67-200.
DR   PDBsum; 1X0J; -.
DR   PDBsum; 2DVQ; -.
DR   PDBsum; 2DVR; -.
DR   PDBsum; 2DVS; -.
DR   PDBsum; 2DVV; -.
DR   PDBsum; 2E3K; -.
DR   PDBsum; 2G4A; -.
DR   PDBsum; 2YDW; -.
DR   PDBsum; 2YEK; -.
DR   PDBsum; 3AQA; -.
DR   PDBsum; 3ONI; -.
DR   PDBsum; 4A9E; -.
DR   PDBsum; 4A9F; -.
DR   PDBsum; 4A9H; -.
DR   PDBsum; 4A9I; -.
DR   PDBsum; 4A9J; -.
DR   PDBsum; 4A9M; -.
DR   PDBsum; 4A9N; -.
DR   PDBsum; 4A9O; -.
DR   PDBsum; 4AKN; -.
DR   PDBsum; 4ALG; -.
DR   PDBsum; 4ALH; -.
DR   ProteinModelPortal; P25440; -.
DR   SMR; P25440; 72-189, 346-455, 637-714.
DR   IntAct; P25440; 1.
DR   STRING; P25440; -.
DR   PhosphoSite; P25440; -.
DR   DMDM; 12230989; -.
DR   PaxDb; P25440; -.
DR   PRIDE; P25440; -.
DR   DNASU; 6046; -.
DR   Ensembl; ENST00000374825; ENSP00000363958; ENSG00000204256.
DR   Ensembl; ENST00000374831; ENSP00000363964; ENSG00000204256.
DR   Ensembl; ENST00000383108; ENSP00000372588; ENSG00000234507.
DR   Ensembl; ENST00000395287; ENSP00000378702; ENSG00000204256.
DR   Ensembl; ENST00000395289; ENSP00000378704; ENSG00000204256.
DR   Ensembl; ENST00000399527; ENSP00000382443; ENSG00000215077.
DR   Ensembl; ENST00000399528; ENSP00000382444; ENSG00000215077.
DR   Ensembl; ENST00000399529; ENSP00000382445; ENSG00000215077.
DR   Ensembl; ENST00000414731; ENSP00000391246; ENSG00000234704.
DR   Ensembl; ENST00000436979; ENSP00000405634; ENSG00000235307.
DR   Ensembl; ENST00000438194; ENSP00000401791; ENSG00000234507.
DR   Ensembl; ENST00000442863; ENSP00000410994; ENSG00000234507.
DR   Ensembl; ENST00000448067; ENSP00000412885; ENSG00000235307.
DR   Ensembl; ENST00000449085; ENSP00000409145; ENSG00000204256.
DR   Ensembl; ENST00000449118; ENSP00000399009; ENSG00000234704.
DR   Ensembl; ENST00000547286; ENSP00000448429; ENSG00000234704.
DR   Ensembl; ENST00000547895; ENSP00000447736; ENSG00000234507.
DR   Ensembl; ENST00000549126; ENSP00000449380; ENSG00000235307.
DR   Ensembl; ENST00000549236; ENSP00000447519; ENSG00000215077.
DR   Ensembl; ENST00000550142; ENSP00000449815; ENSG00000215077.
DR   Ensembl; ENST00000552513; ENSP00000446894; ENSG00000234507.
DR   Ensembl; ENST00000552587; ENSP00000449609; ENSG00000235307.
DR   GeneID; 6046; -.
DR   KEGG; hsa:6046; -.
DR   UCSC; uc003ocn.4; human.
DR   CTD; 6046; -.
DR   GeneCards; GC06P032983; -.
DR   HGNC; HGNC:1103; BRD2.
DR   HPA; HPA042816; -.
DR   MIM; 601540; gene.
DR   neXtProt; NX_P25440; -.
DR   PharmGKB; PA25414; -.
DR   eggNOG; COG5076; -.
DR   HOVERGEN; HBG004896; -.
DR   KO; K08871; -.
DR   OMA; RPSQPKK; -.
DR   OrthoDB; EOG4NZTT4; -.
DR   PhylomeDB; P25440; -.
DR   ChEMBL; CHEMBL1293289; -.
DR   EvolutionaryTrace; P25440; -.
DR   GenomeRNAi; 6046; -.
DR   NextBio; 23557; -.
DR   Bgee; P25440; -.
DR   CleanEx; HS_BRD2; -.
DR   Genevestigator; P25440; -.
DR   GermOnline; ENSG00000204256; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IEA:Compara.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0070577; F:histone acetyl-lysine binding; IDA:UniProtKB.
DR   GO; GO:0016568; P:chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0006334; P:nucleosome assembly; IMP:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.920.10; Bromodomain; 2.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   Pfam; PF00439; Bromodomain; 2.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 2.
DR   SUPFAM; SSF47370; Bromodomain; 2.
DR   PROSITE; PS00633; BROMODOMAIN_1; 2.
DR   PROSITE; PS50014; BROMODOMAIN_2; 2.
DR   PROSITE; PS51525; NET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Bromodomain;
KW   Chromatin regulator; Complete proteome; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    801       Bromodomain-containing protein 2.
FT                                /FTId=PRO_0000211180.
FT   DOMAIN       91    163       Bromo 1.
FT   DOMAIN      364    436       Bromo 2.
FT   DOMAIN      632    714       NET.
FT   MOTIF       555    559       Nuclear localization signal (Potential).
FT   COMPBIAS     61     64       Poly-Pro.
FT   COMPBIAS    476    515       Glu/Ser-rich.
FT   COMPBIAS    492    506       Poly-Glu.
FT   COMPBIAS    544    566       Arg/Lys-rich (highly basic).
FT   COMPBIAS    551    559       Poly-Lys.
FT   COMPBIAS    634    638       Poly-Glu.
FT   COMPBIAS    775    801       Ser-rich.
FT   COMPBIAS    775    793       Poly-Ser.
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES      37     37       Phosphoserine.
FT   MOD_RES     298    298       Phosphoserine.
FT   MOD_RES     301    301       Phosphoserine.
FT   MOD_RES     305    305       Phosphoserine.
FT   MOD_RES     320    320       Phosphoserine.
FT   MOD_RES     633    633       Phosphoserine.
FT   MOD_RES     724    724       Phosphothreonine.
FT   VAR_SEQ     615    615       L -> LQAGVQWRDLGLLQPPLLGFKRFSCLSLPSSQDYRL
FT                                (in isoform 2).
FT                                /FTId=VSP_022600.
FT   VARIANT      30     30       G -> E (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041904.
FT   VARIANT      49     49       A -> G.
FT                                /FTId=VAR_041905.
FT   VARIANT      49     49       A -> S (in dbSNP:rs55669504).
FT                                /FTId=VAR_041906.
FT   VARIANT     212    212       A -> P (in dbSNP:rs35952031).
FT                                /FTId=VAR_041907.
FT   VARIANT     238    238       L -> F (in dbSNP:rs176250).
FT                                /FTId=VAR_022132.
FT   VARIANT     260    260       P -> Q (in dbSNP:rs35294809).
FT                                /FTId=VAR_041908.
FT   VARIANT     474    474       A -> V (in dbSNP:rs3918143).
FT                                /FTId=VAR_029300.
FT   VARIANT     547    547       R -> K (in dbSNP:rs1049369).
FT                                /FTId=VAR_029301.
FT   VARIANT     558    558       R -> G (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041909.
FT   VARIANT     569    569       A -> T (in dbSNP:rs34530779).
FT                                /FTId=VAR_041910.
FT   VARIANT     599    599       A -> P (in dbSNP:rs55952113).
FT                                /FTId=VAR_041911.
FT   VARIANT     714    714       P -> L (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041912.
FT   MUTAGEN      78     78       Q->A: Loss of homodimerization.
FT   MUTAGEN     142    143       MQ->AA: Loss of homodimerization.
FT   MUTAGEN     153    153       Y->K: Loss of homodimerization.
FT   MUTAGEN     154    154       I->A: Partial loss of homodimerization;
FT                                when associated with A-182.
FT   MUTAGEN     170    170       E->A: Loss of homodimerization.
FT   MUTAGEN     174    174       L->E: Loss of homodimerization.
FT   MUTAGEN     177    177       V->E: Loss of homodimerization.
FT   MUTAGEN     182    182       Q->A: Partial loss of homodimerization;
FT                                when associated with A-154.
FT   HELIX        77     84
FT   HELIX        86     91
FT   HELIX        97     99
FT   TURN        105    109
FT   HELIX       113    116
FT   HELIX       123    131
FT   HELIX       138    155
FT   HELIX       161    177
FT   HELIX       347    360
FT   HELIX       363    365
FT   HELIX       366    369
FT   HELIX       370    372
FT   HELIX       378    381
FT   HELIX       386    389
FT   HELIX       396    404
FT   TURN        406    408
FT   HELIX       411    428
FT   HELIX       434    450
SQ   SEQUENCE   801 AA;  88061 MW;  9A075EEB13507D8E CRC64;
     MLQNVTPHNK LPGEGNAGLL GLGPEAAAPG KRIRKPSLLY EGFESPTMAS VPALQLTPAN
     PPPPEVSNPK KPGRVTNQLQ YLHKVVMKAL WKHQFAWPFR QPVDAVKLGL PDYHKIIKQP
     MDMGTIKRRL ENNYYWAASE CMQDFNTMFT NCYIYNKPTD DIVLMAQTLE KIFLQKVASM
     PQEEQELVVT IPKNSHKKGA KLAALQGSVT SAHQVPAVSS VSHTALYTPP PEIPTTVLNI
     PHPSVISSPL LKSLHSAGPP LLAVTAAPPA QPLAKKKGVK RKADTTTPTP TAILAPGSPA
     SPPGSLEPKA ARLPPMRRES GRPIKPPRKD LPDSQQQHQS SKKGKLSEQL KHCNGILKEL
     LSKKHAAYAW PFYKPVDASA LGLHDYHDII KHPMDLSTVK RKMENRDYRD AQEFAADVRL
     MFSNCYKYNP PDHDVVAMAR KLQDVFEFRY AKMPDEPLEP GPLPVSTAMP PGLAKSSSES
     SSEESSSESS SEEEEEEDEE DEEEEESESS DSEEERAHRL AELQEQLRAV HEQLAALSQG
     PISKPKRKRE KKEKKKKRKA EKHRGRAGAD EDDKGPRAPR PPQPKKSKKA SGSGGGSAAL
     GPSGFGPSGG SGTKLPKKAT KTAPPALPTG YDSEEEEESR PMSYDEKRQL SLDINKLPGE
     KLGRVVHIIQ AREPSLRDSN PEEIEIDFET LKPSTLRELE RYVLSCLRKK PRKPYTIKKP
     VGKTKEELAL EKKRELEKRL QDVSGQLNST KKPPKKANEK TESSSAQQVA VSRLSASSSS
     SDSSSSSSSS SSSDTSDSDS G
//
ID   EVI1_HUMAN              Reviewed;        1051 AA.
AC   Q03112; A1L4F3; A8KA00; B7Z8W7; B7ZLQ3; B7ZLQ4; C9JAK0; D3DNP7;
AC   Q16122; Q5HYI1; Q6MZS6; Q8NEI5; Q99917;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-APR-2007, sequence version 2.
DT   09-JAN-2013, entry version 126.
DE   RecName: Full=MDS1 and EVI1 complex locus protein EVI1;
DE   AltName: Full=Ecotropic virus integration site 1 protein homolog;
DE            Short=EVI-1;
GN   Name=MECOM; Synonyms=EVI1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING.
RX   MEDLINE=90326419; PubMed=2115646;
RA   Morishita K., Parganas E., Douglass E.C., Ihle J.N.;
RT   "Unique expression of the human Evi-1 gene in an endometrial carcinoma
RT   cell line: sequence of cDNAs and structure of alternatively spliced
RT   transcripts.";
RL   Oncogene 5:963-971(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND CHROMOSOMAL TRANSLOCATION
RP   WITH RUNX1 IN CHRONIC MYELOCYTIC LEUKEMIA.
RX   MEDLINE=94147997; PubMed=8313895;
RA   Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa M., Mano H.,
RA   Yazaki Y., Ohki M., Hirai H.;
RT   "Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22)
RT   causes blastic crisis in chronic myelocytic leukemia.";
RL   EMBO J. 13:504-510(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [LARGE
RP   SCALE MRNA] OF 1-759 (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Adipose tissue, and Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 6), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 516-1051 (ISOFORM 5).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 970-1007 (ISOFORM 1).
RX   MEDLINE=96292241; PubMed=8700545;
RA   Ogawa S., Kurokawa M., Tanaka T., Mitani K., Inazawa J., Hangaishi A.,
RA   Tanaka K., Matsuo Y., Minowada J., Tsubota T., Yazaki Y., Hirai H.;
RT   "Structurally altered Evi-1 protein generated in the 3q21q26
RT   syndrome.";
RL   Oncogene 13:183-191(1996).
RN   [9]
RP   FUNCTION IN TGF-BETA SIGNALING, INTERACTION WITH SMAD3 AND SMAD4, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9665135; DOI=10.1038/27945;
RA   Kurokawa M., Mitani K., Irie K., Matsuyama T., Takahashi T., Chiba S.,
RA   Yazaki Y., Matsumoto K., Hirai H.;
RT   "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting
RT   Smad3.";
RL   Nature 394:92-96(1998).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH MAPK8 AND MAPK9.
RX   PubMed=10856240; DOI=10.1093/emboj/19.12.2958;
RA   Kurokawa M., Mitani K., Yamagata T., Takahashi T., Izutsu K.,
RA   Ogawa S., Moriguchi T., Nishida E., Yazaki Y., Hirai H.;
RT   "The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents
RT   stress-induced cell death.";
RL   EMBO J. 19:2958-2968(2000).
RN   [11]
RP   FUNCTION, ACETYLATION, INTERACTION WITH CREBBP; CTBP1; KAT2B AND
RP   HISTONE DEACETYLASES, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   555-ASP-LEU-556 AND 586-ASP-LEU-587.
RX   PubMed=11568182; DOI=10.1074/jbc.M106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-
RT   binding protein (CBP) and p300/CBP-associated factor (P/CAF) results
RT   in reversible acetylation of EVI1 and in co-localization in nuclear
RT   speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [12]
RP   FUNCTION, ALTERNATIVE SPLICING (ISOFORMS 1 AND 2),
RP   HOMOOLIGOMERIZATION, INTERACTION WITH CTBP1 AND SMAD3, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15897867; DOI=10.1038/sj.onc.1208754;
RA   Nitta E., Izutsu K., Yamaguchi Y., Imai Y., Ogawa S., Chiba S.,
RA   Kurokawa M., Hirai H.;
RT   "Oligomerization of Evi-1 regulated by the PR domain contributes to
RT   recruitment of corepressor CtBP.";
RL   Oncogene 24:6165-6173(2005).
RN   [13]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=16462766; DOI=10.1038/sj.onc.1209403;
RA   Liu Y., Chen L., Ko T.C., Fields A.P., Thompson E.A.;
RT   "Evi1 is a survival factor which conveys resistance to both TGFbeta-
RT   and taxol-mediated cell death via PI3K/AKT.";
RL   Oncogene 25:3565-3575(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-858 AND SER-860, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-860, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=19767769; DOI=10.1038/onc.2009.288;
RA   Shimabe M., Goyama S., Watanabe-Okochi N., Yoshimi A., Ichikawa M.,
RA   Imai Y., Kurokawa M.;
RT   "Pbx1 is a downstream target of Evi-1 in hematopoietic
RT   stem/progenitors and leukemic cells.";
RL   Oncogene 28:4364-4374(2009).
CC   -!- FUNCTION: Functions as a transcriptional regulator binding to DNA
CC       sequences in the promoter region of target genes and regulating
CC       positively or negatively their expression. Oncogene which plays a
CC       role in development, cell proliferation and differentiation. May
CC       also play a role in apoptosis through regulation of the JNK and
CC       TGF-beta signaling. Involved in hematopoiesis.
CC   -!- SUBUNIT: Homooligomer. Interacts with SUV39H1 (via SET domain);
CC       enhances MECOM transcriptional repression activity (By
CC       similarity). Interacts with CTBP1. Interacts with SMAD3 (via MH2
CC       domain); the interaction is direct. Interacts with SMAD4; through
CC       interaction with SMAD3. Interacts with CREBBP, KAT2B and histone
CC       deacetylases. Interacts with MAPK8 and MAPK9; inhibits JNK
CC       signaling.
CC   -!- INTERACTION:
CC       P56546:Ctbp2 (xeno); NbExp=3; IntAct=EBI-1384862, EBI-1384883;
CC       Q96EB6:SIRT1; NbExp=2; IntAct=EBI-1384862, EBI-1802965;
CC       Q9UBK9:UXT; NbExp=5; IntAct=EBI-1384862, EBI-357355;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus speckle.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=Long, Evi-1a;
CC         IsoId=Q03112-1; Sequence=Displayed;
CC       Name=2; Synonyms=Evi-1c, Mds1/Evi1;
CC         IsoId=Q03112-3; Sequence=VSP_038733;
CC         Note=Produced by alternative promoter usage. Contains an
CC         additional SET domain at positions 79-194. Unable to form
CC         homooligomers, to interact with CTBP1 and SMAD3 and to repress
CC         TGF-beta signaling;
CC       Name=3; Synonyms=Mds1;
CC         IsoId=Q13465-1; Sequence=External;
CC         Note=Produced by alternative promoter usage;
CC       Name=4;
CC         IsoId=Q03112-4; Sequence=VSP_038734, VSP_038735;
CC       Name=5;
CC         IsoId=Q03112-5; Sequence=VSP_038736;
CC       Name=6;
CC         IsoId=Q03112-6; Sequence=VSP_038735, VSP_038736;
CC   -!- DOMAIN: Both zinc finger regions are required for the
CC       transcriptional activation of PBX1.
CC   -!- PTM: Phosphorylated (By similarity). Phosphorylated upon DNA
CC       damage, probably by ATM or ATR.
CC   -!- PTM: May be acetylated by CREBBP and KAT2B.
CC   -!- DISEASE: Note=A chromosomal aberration involving EVI1 is a cause
CC       of chronic myelogenous leukemia (CML). Translocation
CC       t(3;21)(q26;q22) with RUNX1/AML1.
CC   -!- SIMILARITY: Contains 10 C2H2-type zinc fingers.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB29907.1; Type=Erroneous initiation;
CC       Sequence=AAB37456.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact;
CC       Sequence=AAI30521.1; Type=Erroneous initiation;
CC       Sequence=BAH14103.1; Type=Miscellaneous discrepancy; Note=Aberrant splicing;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EVI103q26ID19.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X54989; CAA38735.1; -; mRNA.
DR   EMBL; S69002; AAB29907.1; ALT_INIT; mRNA.
DR   EMBL; AK292865; BAF85554.1; -; mRNA.
DR   EMBL; AK304098; BAH14103.1; ALT_SEQ; mRNA.
DR   EMBL; BX640908; CAE45952.1; -; mRNA.
DR   EMBL; BX647613; CAI46086.1; -; mRNA.
DR   EMBL; AC007849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC024099; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC074033; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC078985; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78553.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78556.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78557.1; -; Genomic_DNA.
DR   EMBL; BC031019; AAH31019.1; -; mRNA.
DR   EMBL; BC130520; AAI30521.1; ALT_INIT; mRNA.
DR   EMBL; BC143951; AAI43952.1; -; mRNA.
DR   EMBL; BC143952; AAI43953.1; -; mRNA.
DR   EMBL; S82592; AAB37456.1; ALT_SEQ; mRNA.
DR   IPI; IPI00446866; -.
DR   IPI; IPI00790776; -.
DR   IPI; IPI00921346; -.
DR   IPI; IPI00943898; -.
DR   IPI; IPI00943944; -.
DR   PIR; A60191; A60191.
DR   PIR; S41705; S41705.
DR   RefSeq; NP_001098547.3; NM_001105077.3.
DR   RefSeq; NP_001098548.2; NM_001105078.3.
DR   RefSeq; NP_001157471.1; NM_001163999.1.
DR   RefSeq; NP_001157472.1; NM_001164000.1.
DR   RefSeq; NP_001192123.1; NM_001205194.1.
DR   RefSeq; NP_004982.2; NM_004991.3.
DR   RefSeq; NP_005232.2; NM_005241.3.
DR   UniGene; Hs.659873; -.
DR   HSSP; P08047; 1SP2.
DR   ProteinModelPortal; Q03112; -.
DR   SMR; Q03112; 16-239, 676-815.
DR   IntAct; Q03112; 3.
DR   STRING; Q03112; -.
DR   PhosphoSite; Q03112; -.
DR   DMDM; 145559472; -.
DR   PaxDb; Q03112; -.
DR   PRIDE; Q03112; -.
DR   DNASU; 2122; -.
DR   Ensembl; ENST00000264674; ENSP00000264674; ENSG00000085276.
DR   Ensembl; ENST00000392736; ENSP00000376493; ENSG00000085276.
DR   Ensembl; ENST00000433243; ENSP00000394302; ENSG00000085276.
DR   Ensembl; ENST00000464456; ENSP00000419770; ENSG00000085276.
DR   Ensembl; ENST00000468789; ENSP00000419995; ENSG00000085276.
DR   Ensembl; ENST00000472280; ENSP00000420048; ENSG00000085276.
DR   GeneID; 2122; -.
DR   KEGG; hsa:2122; -.
DR   UCSC; uc003ffi.3; human.
DR   UCSC; uc003ffj.3; human.
DR   UCSC; uc003ffk.2; human.
DR   UCSC; uc011bpi.1; human.
DR   UCSC; uc011bpj.1; human.
DR   CTD; 2122; -.
DR   GeneCards; GC03M168802; -.
DR   H-InvDB; HIX0003836; -.
DR   HGNC; HGNC:3498; MECOM.
DR   MIM; 165215; gene.
DR   neXtProt; NX_Q03112; -.
DR   Orphanet; 52688; Myelodysplastic syndromes.
DR   PharmGKB; PA27912; -.
DR   eggNOG; COG5048; -.
DR   HOVERGEN; HBG005619; -.
DR   InParanoid; Q03112; -.
DR   KO; K04462; -.
DR   PhylomeDB; Q03112; -.
DR   GenomeRNAi; 2122; -.
DR   NextBio; 8579; -.
DR   ArrayExpress; Q03112; -.
DR   Bgee; Q03112; -.
DR   CleanEx; HS_EVI1; -.
DR   Genevestigator; Q03112; -.
DR   GermOnline; ENSG00000085276; Homo sapiens.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Compara.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Compara.
DR   GO; GO:0030900; P:forebrain development; IEA:Compara.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; ISS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Compara.
DR   GO; GO:0006954; P:inflammatory response; IEA:Compara.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-dependent; IDA:UniProtKB.
DR   GO; GO:0001780; P:neutrophil homeostasis; IEA:Compara.
DR   GO; GO:0060039; P:pericardium development; IEA:Compara.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Compara.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-dependent; IDA:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Compara.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Compara.
DR   GO; GO:0072001; P:renal system development; IEA:Compara.
DR   GO; GO:0009617; P:response to bacterium; IEA:Compara.
DR   GO; GO:0009605; P:response to external stimulus; IEA:Compara.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.160.60; Znf_C2H2/integrase_DNA-bd; 8.
DR   InterPro; IPR007087; Znf_C2H2.
DR   InterPro; IPR015880; Znf_C2H2-like.
DR   InterPro; IPR013087; Znf_C2H2/integrase_DNA-bd.
DR   Pfam; PF00096; zf-C2H2; 10.
DR   SMART; SM00355; ZnF_C2H2; 10.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 8.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 10.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative promoter usage; Alternative splicing;
KW   Apoptosis; Chromosomal rearrangement; Complete proteome;
KW   Developmental protein; Differentiation; DNA-binding; Metal-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Zinc; Zinc-finger.
FT   CHAIN         1   1051       MDS1 and EVI1 complex locus protein EVI1.
FT                                /FTId=PRO_0000047273.
FT   ZN_FING      21     44       C2H2-type 1.
FT   ZN_FING      75     97       C2H2-type 2.
FT   ZN_FING     103    125       C2H2-type 3.
FT   ZN_FING     131    154       C2H2-type 4.
FT   ZN_FING     160    182       C2H2-type 5.
FT   ZN_FING     188    210       C2H2-type 6.
FT   ZN_FING     217    239       C2H2-type 7.
FT   ZN_FING     733    755       C2H2-type 8.
FT   ZN_FING     761    784       C2H2-type 9.
FT   ZN_FING     790    812       C2H2-type 10.
FT   REGION        1    252       Interaction with MAPK9, SMAD3 and
FT                                probably SUV39H1.
FT   MOTIF       421    434       Nuclear localization signal (Potential).
FT   MOTIF       553    557       CTBP-binding motif 1 (By similarity).
FT   MOTIF       584    588       CTBP-binding motif 2 (By similarity).
FT   COMPBIAS    886    937       Asp/Glu-rich (acidic).
FT   MOD_RES     854    854       Phosphoserine (By similarity).
FT   MOD_RES     858    858       Phosphoserine.
FT   MOD_RES     860    860       Phosphoserine.
FT   VAR_SEQ       1      1       M -> MRSKGRARKLATNNECVYGNYPEIPLEEMPDADGVA
FT                                STPSLNIQEPCSPATSSEAFTPKEGSPYKAPIYIPDDIPIP
FT                                AEFELRESNMPGAGLGIWTKRKIEVGEKFGPYVGEQRSNLK
FT                                DPSYGWEILDEFYNVKFCIDASQPDVGSWLKYIRFAGCYDQ
FT                                HNLVACQINDQIFYRVVADIAPGEELLLFM (in
FT                                isoform 2).
FT                                /FTId=VSP_038733.
FT   VAR_SEQ       1      1       M -> MILDEFYNVKFCIDASQPDVGSWLKYIRFAGCYDQH
FT                                NLVACQINDQIFYRVVADIAPGEELLLFM (in isoform
FT                                4).
FT                                /FTId=VSP_038734.
FT   VAR_SEQ     138    138       K -> KQ (in isoform 4 and isoform 6).
FT                                /FTId=VSP_038735.
FT   VAR_SEQ     672    680       Missing (in isoform 5 and isoform 6).
FT                                /FTId=VSP_038736.
FT   VARIANT     107    107       Q -> R (in dbSNP:rs34896995).
FT                                /FTId=VAR_061928.
FT   MUTAGEN     555    556       DL->AS: Partial loss of interaction with
FT                                CTBP1. Loss of interaction with CTBP1;
FT                                when associated with 586-A-S-587.
FT   MUTAGEN     586    587       DL->AS: Partial loss of interaction with
FT                                CTBP1. Loss of interaction with CTBP1;
FT                                when associated with 555-A-S-556.
FT   CONFLICT     20     20       Q -> R (in Ref. 4; CAE45952).
FT   CONFLICT    175    175       L -> P (in Ref. 4; CAE45952).
FT   CONFLICT    301    301       F -> S (in Ref. 3; BAF85554).
FT   CONFLICT    303    303       F -> V (in Ref. 1; CAA38735).
FT   CONFLICT    443    443       S -> P (in Ref. 4; CAI46086).
FT   CONFLICT    543    543       K -> R (in Ref. 4; CAE45952).
FT   CONFLICT    730    730       K -> R (in Ref. 3; BAF85554).
FT   CONFLICT    741    741       I -> V (in Ref. 4; CAI46086).
FT   CONFLICT    796    796       D -> Y (in Ref. 1; CAA38735).
FT   CONFLICT    875    875       D -> E (in Ref. 1; CAA38735).
FT   CONFLICT    881    881       T -> P (in Ref. 1; CAA38735).
FT   CONFLICT    906    906       N -> Y (in Ref. 1; CAA38735).
FT   CONFLICT    992    992       V -> A (in Ref. 3; BAF85554).
FT   CONFLICT   1013   1013       L -> P (in Ref. 4; CAE45952).
SQ   SEQUENCE   1051 AA;  118276 MW;  BD132C53EA08D263 CRC64;
     MKSEDYPHET MAPDIHEERQ YRCEDCDQLF ESKAELADHQ KFPCSTPHSA FSMVEEDFQQ
     KLESENDLQE IHTIQECKEC DQVFPDLQSL EKHMLSHTEE REYKCDQCPK AFNWKSNLIR
     HQMSHDSGKH YECENCAKVF TDPSNLQRHI RSQHVGARAH ACPECGKTFA TSSGLKQHKH
     IHSSVKPFIC EVCHKSYTQF SNLCRHKRMH ADCRTQIKCK DCGQMFSTTS SLNKHRRFCE
     GKNHFAAGGF FGQGISLPGT PAMDKTSMVN MSHANPGLAD YFGANRHPAG LTFPTAPGFS
     FSFPGLFPSG LYHRPPLIPA SSPVKGLSST EQTNKSQSPL MTHPQILPAT QDILKALSKH
     PSVGDNKPVE LQPERSSEER PFEKISDQSE SSDLDDVSTP SGSDLETTSG SDLESDIESD
     KEKFKENGKM FKDKVSPLQN LASINNKKEY SNHSIFSPSL EEQTAVSGAV NDSIKAIASI
     AEKYFGSTGL VGLQDKKVGA LPYPSMFPLP FFPAFSQSMY PFPDRDLRSL PLKMEPQSPG
     EVKKLQKGSS ESPFDLTTKR KDEKPLTPVP SKPPVTPATS QDQPLDLSMG SRSRASGTKL
     TEPRKNHVFG GKKGSNVESR PASDGSLQHA RPTPFFMDPI YRVEKRKLTD PLEALKEKYL
     RPSPGFLFHP QFQLPDQRTW MSAIENMAEK LESFSALKPE ASELLQSVPS MFNFRAPPNA
     LPENLLRKGK ERYTCRYCGK IFPRSANLTR HLRTHTGEQP YRCKYCDRSF SISSNLQRHV
     RNIHNKEKPF KCHLCDRCFG QQTNLDRHLK KHENGNMSGT ATSSPHSELE STGAILDDKE
     DAYFTEIRNF IGNSNHGSQS PRNVEERMNG SHFKDEKALV TSQNSDLLDD EEVEDEVLLD
     EEDEDNDITG KTGKEPVTSN LHEGNPEDDY EETSALEMSC KTSPVRYKEE EYKSGLSALD
     HIRHFTDSLK MRKMEDNQYS EAELSSFSTS HVPEELKQPL HRKSKSQAYA MMLSLSDKES
     LHSTSHSSSN VWHSMARAAA ESSAIQSISH V
//
ID   AXIN1_HUMAN             Reviewed;         862 AA.
AC   O15169; Q4TT26; Q4TT27; Q86YA7; Q8WVW6; Q96S28;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2002, sequence version 2.
DT   09-JAN-2013, entry version 145.
DE   RecName: Full=Axin-1;
DE   AltName: Full=Axis inhibition protein 1;
DE            Short=hAxin;
GN   Name=AXIN1; Synonyms=AXIN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=97373830; PubMed=9230313; DOI=10.1016/S0092-8674(00)80324-4;
RA   Zeng L., Fagotto F., Zhang T., Hsu W., Vasicek T.J., Perry W.L. III,
RA   Lee J.J., Tilghman S.M., Gumbiner B.M., Costantini F.;
RT   "The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling
RT   pathway that regulates embryonic axis formation.";
RL   Cell 90:181-192(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=21096910; PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K.,
RA   Tufarelli C., Kearney L., Buckle V.J., Doggett N.A., Flint J.,
RA   Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2
RT   Mb of the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 471-862 (ISOFORM 1).
RC   TISSUE=Lymphoma, and Renal cell carcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH GSK3B AND PPP2CA, PHOSPHORYLATION, AND
RP   DEPHOSPHORYLATION.
RX   MEDLINE=99121080; PubMed=9920888; DOI=10.1074/jbc.274.6.3439;
RA   Hsu W., Zeng L., Costantini F.;
RT   "Identification of a domain of Axin that binds to the serine/threonine
RT   protein phosphatase 2A and a self-binding domain.";
RL   J. Biol. Chem. 274:3439-3445(1999).
RN   [6]
RP   DISEASE.
RX   MEDLINE=20164320; PubMed=10700176; DOI=10.1038/73448;
RA   Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T.,
RA   Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S.,
RA   Murata M., Shimano T., Yamaoka Y., Nakamura Y.;
RT   "AXIN1 mutations in hepatocellular carcinomas, and growth suppression
RT   in cancer cells by virus-mediated transfer of AXIN1.";
RL   Nat. Genet. 24:245-250(2000).
RN   [7]
RP   INTERACTION WITH LRP5.
RX   PubMed=11336703; DOI=10.1016/S1097-2765(01)00224-6;
RA   Mao J., Wang J., Liu B., Pan W., Farr G.H. III, Flynn C., Yuan H.,
RA   Takada S., Kimelman D., Li L., Wu D.;
RT   "Low-density lipoprotein receptor-related protein-5 binds to Axin and
RT   regulates the canonical Wnt signaling pathway.";
RL   Mol. Cell 7:801-809(2001).
RN   [8]
RP   INTERACTION WITH MDFI AND MDFIC, AND FUNCTION.
RX   PubMed=12192039; DOI=10.1128/MCB.22.18.6393-6405.2002;
RA   Kusano S., Raab-Traub N.;
RT   "I-mfa domain proteins interact with Axin and affect its regulation of
RT   the Wnt and c-Jun N-terminal kinase signaling pathways.";
RL   Mol. Cell. Biol. 22:6393-6405(2002).
RN   [9]
RP   INTERACTION WITH DAB2.
RX   PubMed=12805222; DOI=10.1093/emboj/cdg286;
RA   Howe P.H.;
RT   "Regulation of the Wnt signaling pathway by disabled-2 (Dab2).";
RL   EMBO J. 22:3084-3094(2003).
RN   [10]
RP   INTERACTION WITH DIXDC1; MAP3K1 AND MAP3K4.
RX   PubMed=15262978; DOI=10.1074/jbc.M404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal
RT   kinase activation by Axin and dishevelled through distinct
RT   mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [11]
RP   INVOLVEMENT IN CAUDAL DUPLICATION ANOMALY.
RX   PubMed=16773576; DOI=10.1086/505031;
RA   Oates N.A., van Vliet J., Duffy D.L., Kroes H.Y., Martin N.G.,
RA   Boomsma D.I., Campbell M., Coulthard M.G., Whitelaw E., Chong S.;
RT   "Increased DNA methylation at the AXIN1 gene in a monozygotic twin
RT   from a pair discordant for a caudal duplication anomaly.";
RL   Am. J. Hum. Genet. 79:155-162(2006).
RN   [12]
RP   INTERACTION WITH SMAD6; SMAD7 AND RNF111, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16601693; DOI=10.1038/sj.emboj.7601057;
RA   Liu W., Rui H., Wang J., Lin S., He Y., Chen M., Li Q., Ye Z.,
RA   Zhang S., Chan S.C., Chen Y.-G., Han J., Lin S.-C.;
RT   "Axin is a scaffold protein in TGF-beta signaling that promotes
RT   degradation of Smad7 by Arkadia.";
RL   EMBO J. 25:1646-1658(2006).
RN   [13]
RP   INTERACTION WITH DAXX, IDENTIFICATION AS A COMPONENT OF THE
RP   AXIN1-HIPK2-TP53 COMPLEX, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17210684; DOI=10.1158/0008-5472.CAN-06-1671;
RA   Li Q., Wang X., Wu X., Rui Y., Liu W., Wang J., Wang X., Liou Y.C.,
RA   Ye Z., Lin S.C.;
RT   "Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell
RT   death.";
RL   Cancer Res. 67:66-74(2007).
RN   [14]
RP   PHOSPHORYLATION AT SER-75; SER-77; SER-217 AND SER-469, MASS
RP   SPECTROMETRY, AND INTERACTION WITH GSK3B AND PPP1CA.
RX   PubMed=17318175; DOI=10.1038/sj.emboj.7601607;
RA   Luo W., Peterson A., Garcia B.A., Coombs G., Kofahl B., Heinrich R.,
RA   Shabanowitz J., Hunt D.F., Yost H.J., Virshup D.M.;
RT   "Protein phosphatase 1 regulates assembly and function of the beta-
RT   catenin degradation complex.";
RL   EMBO J. 26:1511-1521(2007).
RN   [15]
RP   SUMOYLATION.
RX   PubMed=18632848; DOI=10.1096/fj.08-113910;
RA   Kim M.J., Chia I.V., Costantini F.;
RT   "SUMOylation target sites at the C terminus protect Axin from
RT   ubiquitination and confer protein stability.";
RL   FASEB J. 22:3785-3794(2008).
RN   [16]
RP   ADP-RIBOSYLATION, UBIQUITINATION, DOMAIN TANKYRASE-BINDING MOTIF, AND
RP   INTERACTION WITH TNKS AND TNKS2.
RX   PubMed=19759537; DOI=10.1038/nature08356;
RA   Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F.,
RA   Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S.,
RA   Hild M., Shi X., Wilson C.J., Mickanin C., Myer V., Fazal A.,
RA   Tomlinson R., Serluca F., Shao W., Cheng H., Shultz M., Rau C.,
RA   Schirle M., Schlegl J., Ghidelli S., Fawell S., Lu C., Curtis D.,
RA   Kirschner M.W., Lengauer C., Finan P.M., Tallarico J.A.,
RA   Bouwmeester T., Porter J.A., Bauer A., Cong F.;
RT   "Tankyrase inhibition stabilizes axin and antagonizes Wnt
RT   signalling.";
RL   Nature 461:614-620(2009).
RN   [17]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP34, AND SUBCELLULAR LOCATION.
RX   PubMed=21383061; DOI=10.1128/MCB.01094-10;
RA   Lui T.T., Lacroix C., Ahmed S.M., Goldenberg S.J., Leach C.A.,
RA   Daulat A.M., Angers S.;
RT   "The Ubiquitin specific protease USP34 regulates Axin stability and
RT   Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 31:2053-2065(2011).
RN   [18]
RP   ADP-RIBOSYLATION, UBIQUITINATION, AND INTERACTION WITH RNF146; TNKS
RP   AND TNKS2.
RX   PubMed=21478859; DOI=10.1038/ncb2222;
RA   Zhang Y., Liu S., Mickanin C., Feng Y., Charlat O., Michaud G.A.,
RA   Schirle M., Shi X., Hild M., Bauer A., Myer V.E., Finan P.M.,
RA   Porter J.A., Huang S.M., Cong F.;
RT   "RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin
RT   degradation and Wnt signalling.";
RL   Nat. Cell Biol. 13:623-629(2011).
RN   [19]
RP   INTERACTION WITH TNKS, AND UBIQUITINATION.
RX   PubMed=21799911; DOI=10.1371/journal.pone.0022595;
RA   Callow M.G., Tran H., Phu L., Lau T., Lee J., Sandoval W.N., Liu P.S.,
RA   Bheddah S., Tao J., Lill J.R., Hongo J.A., Davis D., Kirkpatrick D.S.,
RA   Polakis P., Costa M.;
RT   "Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt
RT   signaling.";
RL   PLoS ONE 6:E22595-E22595(2011).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 74-220 IN COMPLEX WITH APC.
RX   MEDLINE=20271867; PubMed=10811618; DOI=10.1093/emboj/19.10.2270;
RA   Spink K.E., Polakis P., Weis W.I.;
RT   "Structural basis of the axin-adenomatous polyposis coli
RT   interaction.";
RL   EMBO J. 19:2270-2279(2000).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 383-400 IN COMPLEX WITH
RP   GSK3B.
RX   PubMed=12554650; DOI=10.1093/emboj/cdg068;
RA   Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V.,
RA   Dale T.C., Pearl L.H.;
RT   "Structural basis for recruitment of glycogen synthase kinase 3beta to
RT   the axin-APC scaffold complex.";
RL   EMBO J. 22:494-501(2003).
RN   [22]
RP   VARIANTS HCC ARG-106; LEU-345; SER-425 AND SER-650, AND VARIANT
RP   HEPATOBLASTOMA GLN-841.
RX   MEDLINE=22096103; PubMed=12101426; DOI=10.1038/sj.onc.1205591;
RA   Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C.,
RA   Murphy L.M., Nagorney D.M., Burgart L.J., Roche P.C., Smith D.I.,
RA   Ross J.A., Liu W.;
RT   "Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in
RT   hepatocellular carcinomas and hepatoblastomas.";
RL   Oncogene 21:4863-4871(2002).
CC   -!- FUNCTION: Component of the beta-catenin destruction complex
CC       required for regulating CTNNB1 levels through phosphorylation and
CC       ubiquitination, and modulating Wnt-signaling. Controls
CC       dorsoventral patterning via two opposing effects; down-regulates
CC       CTNNB1 to inhibit the Wnt signaling pathway and ventralize
CC       embryos, but also dorsalizes embryos by activating a Wnt-
CC       independent JNK signaling pathway. In Wnt signaling, probably
CC       facilitates the phosphorylation of CTNNB1 and APC by GSK3B. Likely
CC       to function as a tumor suppressor. Facilitates the phosphorylation
CC       of TP53 by HIPK2 upon ultraviolet irradiation. Enhances TGF-beta
CC       signaling by recruiting the RNF111 E3 ubiquitin ligase and
CC       promoting the degradation of inhibitory SMAD7. Also component of
CC       the AXIN1-HIPK2-TP53 complex which controls cell growth, apoptosis
CC       and development.
CC   -!- SUBUNIT: Homodimer (By similarity). Component of the beta-catenin
CC       destruction complex, containing at least, CTNNB1, an axin and
CC       GSK3B, that regulates CTNNB1 protein levels through
CC       phosphorylation and ubiquitination. Interacts with CTNNB1 (via the
CC       armadillo repeats 2-7). Interacts with GSK3B; the interaction
CC       hyperphosphorylates CTNNB1 leading to its ubiquitination and
CC       destruction. Component of the AXIN1-HIPK2-TP53 complex. Interacts
CC       directly in the complex with TP53 and HIPK2. Interacts with DAXX;
CC       the interaction stimulates the interaction of DAXX with TP53,
CC       stimulates 'Ser-46' phosphorylation of TP53 and induces cell death
CC       on UV irradiation. Also binds APC, SMAD6, SMAD7 and RNF111.
CC       Interacts with DIXDC1; prevents interaction with MAP3K1. Interacts
CC       with MAP3K4. Interacts with ANKRD6 and AIDA (By similarity).
CC       Interacts with MDFI; the interaction decreases AXIN1-mediated JUN
CC       N-terminal kinase (JNK) activation. Interacts with MDFIC; the
CC       interaction inhibits beta-cateninin-mediated signaling and AXIN1-
CC       mediated JUN N-terminal kinase (JNK) activation. Interacts with
CC       LRP5 (via its phosphorylated PPPSP motifs); the interaction is
CC       stimulated by WNT1 and GSK3B and activates beta-catenin signaling.
CC       Interacts (via the C-terminal) with PPP1CA; the interaction
CC       dephosphorylates AXIN1 and regulates interaction with GSK3B.
CC       Interacts with PPP2CA; the interaction dephosphorylates AXIN1.
CC       Interacts with MACF1 (By similarity). Found in a complex composed
CC       of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). Interacts
CC       with TNKS. Interacts with DAB2; the interaction is mutually
CC       exclusive with the AXIN1:PPP1CA interaction.
CC   -!- INTERACTION:
CC       P39687:ANP32A; NbExp=2; IntAct=EBI-710484, EBI-359234;
CC       Q14194:CRMP1; NbExp=2; IntAct=EBI-710484, EBI-473101;
CC       P49674:CSNK1E; NbExp=4; IntAct=EBI-710484, EBI-749343;
CC       P35222:CTNNB1; NbExp=20; IntAct=EBI-710484, EBI-491549;
CC       Q02248:Ctnnb1 (xeno); NbExp=5; IntAct=EBI-710484, EBI-397872;
CC       Q9UKB1:FBXW11; NbExp=4; IntAct=EBI-710484, EBI-355189;
CC       P49841:GSK3B; NbExp=26; IntAct=EBI-710484, EBI-373586;
CC       Q9H2K2:TNKS2; NbExp=2; IntAct=EBI-710484, EBI-4398527;
CC       P04637:TP53; NbExp=4; IntAct=EBI-710484, EBI-366083;
CC       Q14134:TRIM29; NbExp=2; IntAct=EBI-710484, EBI-702370;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane (By
CC       similarity). Note=MACF1 is required for its translocation to cell
CC       membrane (By similarity). On UV irradiation, translocates to the
CC       nucleus and colocalizes with DAAX.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15169-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15169-2; Sequence=VSP_019398;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC   -!- DOMAIN: The tankyrase-binding motif (also named TBD) is required
CC       for interaction with tankyrase TNKS and TNKS2.
CC   -!- PTM: Phosphorylation and dephosphorylation of AXIN1 regulates
CC       assembly and function of the beta-catenin complex. Phosphorylated
CC       by CK1 and GSK3B. Dephosphorylated by PPP1CA and PPP2CA.
CC       Phosphorylation by CK1 enhances binding of GSK3B to AXIN1.
CC   -!- PTM: ADP-ribosylated by tankyrase TNKS and TNKS2. Poly-ADP-
CC       ribosylated protein is recognized by RNF146, followed by
CC       ubiquitination at 'Lys-48' and subsequent activation of the Wnt
CC       signaling pathway.
CC   -!- PTM: Ubiquitinated by RNF146 when poly-ADP-ribosylated, leading to
CC       its degradation and subsequent activation of the Wnt signaling
CC       pathway. Sumoylation at Lys-857 and Lys-860 prevents
CC       ubiquitination and degradation. Sumoylation is required for AXIN1-
CC       mediated JNK activation. Deubiquitinated by USP34, deubiquitinated
CC       downstream of beta-catenin stabilization step: deubiquitination is
CC       important for nuclear accumulation during Wnt signaling to
CC       positively regulate beta-catenin (CTNBB1)-mediated transcription.
CC   -!- DISEASE: Defects in AXIN1 are involved in hepatocellular carcinoma
CC       (HCC) [MIM:114550].
CC   -!- DISEASE: Defects in AXIN1 are a cause of caudal duplication
CC       anomaly (CADUA) [MIM:607864]. Caudal duplication anomaly is
CC       characterized by the occurrence of duplications of different
CC       organs in the caudal region. Note=Caudal duplication anomaly is
CC       associated with hypermethylation of the AXIN1 promoter.
CC   -!- SIMILARITY: Contains 1 DIX domain.
CC   -!- SIMILARITY: Contains 1 RGS domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51624.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF009674; AAC51624.1; ALT_INIT; mRNA.
DR   EMBL; AE006463; AAK61224.1; -; Genomic_DNA.
DR   EMBL; Z69667; CAI95589.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95589.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95589.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95590.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95590.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95590.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95600.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95600.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95600.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95601.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95601.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95601.2; JOINED; Genomic_DNA.
DR   EMBL; BC017447; AAH17447.1; -; mRNA.
DR   EMBL; BC044648; AAH44648.1; -; mRNA.
DR   IPI; IPI00747002; -.
DR   IPI; IPI00748214; -.
DR   RefSeq; NP_003493.1; NM_003502.3.
DR   RefSeq; NP_851393.1; NM_181050.2.
DR   UniGene; Hs.592082; -.
DR   PDB; 1DK8; X-ray; 1.57 A; A=74-220.
DR   PDB; 1EMU; X-ray; 1.90 A; A=80-211.
DR   PDB; 1O9U; X-ray; 2.40 A; B=383-400.
DR   PDBsum; 1DK8; -.
DR   PDBsum; 1EMU; -.
DR   PDBsum; 1O9U; -.
DR   ProteinModelPortal; O15169; -.
DR   SMR; O15169; 18-220, 779-862.
DR   DIP; DIP-34630N; -.
DR   IntAct; O15169; 43.
DR   MINT; MINT-100969; -.
DR   STRING; O15169; -.
DR   PhosphoSite; O15169; -.
DR   PaxDb; O15169; -.
DR   PRIDE; O15169; -.
DR   Ensembl; ENST00000262320; ENSP00000262320; ENSG00000103126.
DR   Ensembl; ENST00000354866; ENSP00000346935; ENSG00000103126.
DR   GeneID; 8312; -.
DR   KEGG; hsa:8312; -.
DR   UCSC; uc002cgp.2; human.
DR   UCSC; uc002cgq.2; human.
DR   CTD; 8312; -.
DR   GeneCards; GC16M000338; -.
DR   HGNC; HGNC:903; AXIN1.
DR   HPA; CAB012987; -.
DR   MIM; 114550; phenotype.
DR   MIM; 603816; gene.
DR   MIM; 607864; phenotype.
DR   neXtProt; NX_O15169; -.
DR   PharmGKB; PA25195; -.
DR   eggNOG; NOG238205; -.
DR   HOVERGEN; HBG004324; -.
DR   InParanoid; O15169; -.
DR   KO; K02157; -.
DR   OMA; IMQWIIE; -.
DR   OrthoDB; EOG47SSDB; -.
DR   PhylomeDB; O15169; -.
DR   Pathway_Interaction_DB; wnt_canonical_pathway; Canonical Wnt signaling pathway.
DR   Pathway_Interaction_DB; ps1pathway; Presenilin action in Notch and Wnt signaling.
DR   Pathway_Interaction_DB; tgfbrpathway; TGF-beta receptor signaling.
DR   Reactome; REACT_111102; Signal Transduction.
DR   ChEMBL; CHEMBL1255127; -.
DR   EvolutionaryTrace; O15169; -.
DR   GenomeRNAi; 8312; -.
DR   NextBio; 31127; -.
DR   ArrayExpress; O15169; -.
DR   Bgee; O15169; -.
DR   CleanEx; HS_AXIN1; -.
DR   Genevestigator; O15169; -.
DR   GermOnline; ENSG00000103126; Homo sapiens.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IBA:RefGenome.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IBA:RefGenome.
DR   GO; GO:0005881; C:cytoplasmic microtubule; IBA:RefGenome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0014069; C:postsynaptic density; IBA:RefGenome.
DR   GO; GO:0070016; F:armadillo repeat domain binding; ISS:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0005096; F:GTPase activator activity; IBA:RefGenome.
DR   GO; GO:0002039; F:p53 binding; IDA:MGI.
DR   GO; GO:0032947; F:protein complex scaffold; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; IDA:BHF-UCL.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IBA:RefGenome.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048320; P:axial mesoderm formation; IBA:RefGenome.
DR   GO; GO:0060823; P:canonical Wnt receptor signaling pathway involved in neural plate anterior/posterior pattern formation; IBA:RefGenome.
DR   GO; GO:0008219; P:cell death; IBA:RefGenome.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IBA:RefGenome.
DR   GO; GO:0031122; P:cytoplasmic microtubule organization; IBA:RefGenome.
DR   GO; GO:0007368; P:determination of left/right symmetry; IBA:RefGenome.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IBA:RefGenome.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IBA:RefGenome.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IBA:RefGenome.
DR   GO; GO:0021797; P:forebrain anterior/posterior pattern specification; IBA:RefGenome.
DR   GO; GO:0071514; P:genetic imprinting; IEA:Compara.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Compara.
DR   GO; GO:0055001; P:muscle cell development; IBA:RefGenome.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt receptor signaling pathway; IBA:RefGenome.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IBA:RefGenome.
DR   GO; GO:0051248; P:negative regulation of protein metabolic process; IEA:Compara.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Compara.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IEA:Compara.
DR   GO; GO:0030910; P:olfactory placode formation; IBA:RefGenome.
DR   GO; GO:0001743; P:optic placode formation; IBA:RefGenome.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Compara.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-dependent; IMP:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IEA:Compara.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein ligase activity; IMP:BHF-UCL.
DR   GO; GO:0030163; P:protein catabolic process; IEA:Compara.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:Compara.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Compara.
DR   GO; GO:0035412; P:regulation of catenin import into nucleus; IBA:RefGenome.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Compara.
DR   GO; GO:0038032; P:termination of G-protein coupled receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0021881; P:Wnt receptor signaling pathway involved in forebrain neuron fate commitment; IBA:RefGenome.
DR   GO; GO:0090244; P:Wnt receptor signaling pathway involved in somitogenesis; IBA:RefGenome.
DR   Gene3D; 1.10.196.10; G3DSA:1.10.196.10; 2.
DR   InterPro; IPR014936; Axin_b-cat-bd.
DR   InterPro; IPR001158; DIX.
DR   InterPro; IPR000342; Regulat_G_prot_signal.
DR   InterPro; IPR024066; Regulat_G_prot_signal_dom1.
DR   InterPro; IPR016137; Regulat_G_prot_signal_superfam.
DR   Pfam; PF08833; Axin_b-cat_bind; 1.
DR   Pfam; PF00778; DIX; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR01301; RGSPROTEIN.
DR   SMART; SM00021; DAX; 1.
DR   SMART; SM00315; RGS; 1.
DR   SUPFAM; SSF48097; Regulat_G_prot_signal_superfam; 1.
DR   PROSITE; PS50841; DIX; 1.
DR   PROSITE; PS50132; RGS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis;
KW   Cell membrane; Complete proteome; Cytoplasm; Developmental protein;
KW   Disease mutation; Isopeptide bond; Membrane; Nucleus; Phosphoprotein;
KW   Reference proteome; Tumor suppressor; Ubl conjugation;
KW   Wnt signaling pathway.
FT   CHAIN         1    862       Axin-1.
FT                                /FTId=PRO_0000220888.
FT   DOMAIN       88    211       RGS.
FT   DOMAIN      780    862       DIX.
FT   REGION      209    338       Interaction with TP53 (By similarity).
FT   REGION      348    433       Interaction with GSK3B (By similarity).
FT   REGION      434    502       Interaction with CTNNB1 (By similarity).
FT   REGION      507    757       Interaction with RNF111.
FT   REGION      575    789       Interaction with PPP2CA.
FT   REGION      677    752       Interaction with HIPK2 (By similarity).
FT   MOTIF        20     29       Tankyrase-binding motif.
FT   MOD_RES      75     75       Phosphoserine; by CK1.
FT   MOD_RES      77     77       Phosphoserine; by CK1.
FT   MOD_RES     217    217       Phosphoserine; by CK1.
FT   MOD_RES     469    469       Phosphoserine; by CK1.
FT   MOD_RES     481    481       Phosphothreonine; by GSK3-beta
FT                                (Probable).
FT   MOD_RES     486    486       Phosphoserine; by GSK3-beta (By
FT                                similarity).
FT   MOD_RES     493    493       Phosphoserine (By similarity).
FT   CROSSLNK    857    857       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO) (By
FT                                similarity).
FT   CROSSLNK    860    860       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO) (By
FT                                similarity).
FT   VAR_SEQ     730    765       Missing (in isoform 2).
FT                                /FTId=VSP_019398.
FT   VARIANT     106    106       L -> R (in HCC).
FT                                /FTId=VAR_015589.
FT   VARIANT     345    345       P -> L (in HCC).
FT                                /FTId=VAR_015590.
FT   VARIANT     425    425       G -> S (in HCC).
FT                                /FTId=VAR_015591.
FT   VARIANT     650    650       G -> S (in HCC and in hepatoblastoma).
FT                                /FTId=VAR_015592.
FT   VARIANT     841    841       R -> Q (in hepatoblastoma;
FT                                dbSNP:rs34015754).
FT                                /FTId=VAR_015593.
FT   CONFLICT    360    360       V -> A (in Ref. 1; AAC51624).
FT   CONFLICT    451    455       CVDMG -> LCWTWA (in Ref. 1; AAC51624).
FT   CONFLICT    482    482       P -> T (in Ref. 1; AAC51624).
FT   HELIX        81     87
FT   HELIX        89     92
FT   HELIX        96    107
FT   TURN        108    110
FT   HELIX       112    126
FT   HELIX       131    133
FT   HELIX       134    148
FT   HELIX       155    159
FT   HELIX       162    174
FT   TURN        179    182
FT   HELIX       183    195
FT   HELIX       197    201
FT   HELIX       205    208
FT   TURN        209    212
SQ   SEQUENCE   862 AA;  95635 MW;  10779173F5092F3F CRC64;
     MNIQEQGFPL DLGASFTEDA PRPPVPGEEG ELVSTDPRPA SYSFCSGKGV GIKGETSTAT
     PRRSDLDLGY EPEGSASPTP PYLKWAESLH SLLDDQDGIS LFRTFLKQEG CADLLDFWFA
     CTGFRKLEPC DSNEEKRLKL ARAIYRKYIL DNNGIVSRQT KPATKSFIKG CIMKQLIDPA
     MFDQAQTEIQ ATMEENTYPS FLKSDIYLEY TRTGSESPKV CSDQSSGSGT GKGISGYLPT
     LNEDEEWKCD QDMDEDDGRD AAPPGRLPQK LLLETAAPRV SSSRRYSEGR EFRYGSWREP
     VNPYYVNAGY ALAPATSAND SEQQSLSSDA DTLSLTDSSV DGIPPYRIRK QHRREMQESV
     QVNGRVPLPH IPRTYRVPKE VRVEPQKFAE ELIHRLEAVQ RTREAEEKLE ERLKRVRMEE
     EGEDGDPSSG PPGPCHKLPP APAWHHFPPR CVDMGCAGLR DAHEENPESI LDEHVQRVLR
     TPGRQSPGPG HRSPDSGHVA KMPVALGGAA SGHGKHVPKS GAKLDAAGLH HHRHVHHHVH
     HSTARPKEQV EAEATRRAQS SFAWGLEPHS HGARSRGYSE SVGAAPNASD GLAHSGKVGV
     ACKRNAKKAE SGKSASTEVP GASEDAEKNQ KIMQWIIEGE KEISRHRRTG HGSSGTRKPQ
     PHENSRPLSL EHPWAGPQLR TSVQPSHLFI QDPTMPPHPA PNPLTQLEEA RRRLEEEEKR
     ASRAPSKQRY VQEVMRRGRA CVRPACAPVL HVVPAVSDME LSETETRSQR KVGGGSAQPC
     DSIVVAYYFC GEPIPYRTLV RGRAVTLGQF KELLTKKGSY RYYFKKVSDE FDCGVVFEEV
     REDEAVLPVF EEKIIGKVEK VD
//
ID   RB_HUMAN                Reviewed;         928 AA.
AC   P06400; A8K5E3; P78499; Q5VW46; Q8IZL4;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 2.
DT   09-JAN-2013, entry version 179.
DE   RecName: Full=Retinoblastoma-associated protein;
DE   AltName: Full=p105-Rb;
DE   AltName: Full=pRb;
DE            Short=Rb;
DE   AltName: Full=pp110;
GN   Name=RB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=88014238; PubMed=3657987; DOI=10.1038/329642a0;
RA   Lee W.-H., Shew J.-Y., Hong F.D., Sery T.W., Donoso L.A.,
RA   Young L.-J.S., Bookstein R., Lee E.Y.-H.P.;
RT   "The retinoblastoma susceptibility gene encodes a nuclear
RT   phosphoprotein associated with DNA binding activity.";
RL   Nature 329:642-645(1987).
RN   [2]
RP   SEQUENCE REVISION.
RX   MEDLINE=87149066; PubMed=3823889; DOI=10.1126/science.3823889;
RA   Lee W.-H., Bookstein R., Hong F.D., Young L.-J., Shew J.-Y.,
RA   Lee E.Y.-H.P.;
RT   "Human retinoblastoma susceptibility gene: cloning, identification,
RT   and sequence.";
RL   Science 235:1394-1399(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=88097427; PubMed=3480530; DOI=10.1073/pnas.84.24.9059;
RA   Friend S.H., Horowitz J.M., Gerber M.R., Wang X.-F., Bogenmann E.,
RA   Li F.P., Weinberg R.A.;
RT   "Deletions of a DNA sequence in retinoblastomas and mesenchymal
RT   tumors: organization of the sequence and its encoded protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:9059-9063(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90006771; PubMed=2701949; DOI=10.1016/0378-1119(89)90256-4;
RA   McGee T.L., Yandell D.W., Dryja T.P.;
RT   "Structure and partial genomic sequence of the human retinoblastoma
RT   susceptibility gene.";
RL   Gene 80:119-128(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Carcinoma;
RX   MEDLINE=92319557; PubMed=1352398;
RA   Hogg A., Onadim Z., Baird P.N., Cowell J.K.;
RT   "Detection of heterozygous mutations in the RB1 gene in retinoblastoma
RT   patients using single-strand conformation polymorphism analysis and
RT   polymerase chain reaction sequencing.";
RL   Oncogene 7:1445-1451(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=94063891; PubMed=7902321; DOI=10.1006/geno.1993.1368;
RA   Toguchida J., McGee T.L., Paterson J.C., Eagle J.R., Tucker S.,
RA   Yandell D.W., Dryja T.P.;
RT   "Complete genomic sequence of the human retinoblastoma susceptibility
RT   gene.";
RL   Genomics 17:535-543(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-436 AND GLY-525.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45.
RX   MEDLINE=89239464; PubMed=2717184;
RA   T'Ang A., Wu K.J., Hashimoto T., Liu W.Y., Takahashi R., Shi X.H.,
RA   Mihara K., Zhang F.H., Chen Y.Y., Du C., Qian J., Lin Y.G.,
RA   Murphree A.L., Qiu W.R., Thompson T., Benedict W.F., Fung Y.K.T.;
RT   "Genomic organization of the human retinoblastoma gene.";
RL   Oncogene 4:401-407(1989).
RN   [13]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN AND HPV E7 PROTEIN.
RX   PubMed=1316611; DOI=10.1073/pnas.89.10.4549;
RA   Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M.,
RA   Phelps W.C., Nevins J.R.;
RT   "Adenovirus E1A, simian virus 40 tumor antigen, and human
RT   papillomavirus E7 protein share the capacity to disrupt the
RT   interaction between transcription factor E2F and the retinoblastoma
RT   gene product.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4549-4553(1992).
RN   [14]
RP   PROTEIN SEQUENCE OF 47-65, AND INVOLVEMENT IN RETINOBLASTOMA.
RX   MEDLINE=95187159; PubMed=7881418; DOI=10.1093/hmg/3.12.2187;
RA   Lohmann D.R., Brandt B., Hopping W., Passarge E., Horsthemke B.;
RT   "Spectrum of small length germline mutations in the RB1 gene.";
RL   Hum. Mol. Genet. 3:2187-2193(1994).
RN   [15]
RP   PHOSPHORYLATION BY CDK6.
RX   PubMed=8114739;
RA   Meyerson M., Harlow E.;
RT   "Identification of G1 kinase activity for cdk6, a novel cyclin D
RT   partner.";
RL   Mol. Cell. Biol. 14:2077-2086(1994).
RN   [16]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN.
RX   MEDLINE=88270506; PubMed=2839300; DOI=10.1016/0092-8674(88)90559-4;
RA   Decaprio J.A., Ludlow J.W., Figge J., Shew J.-Y., Huang C.-M.,
RA   Lee W.-H., Marsilio E., Paucha E., Livingston D.M.;
RT   "SV40 large tumor antigen forms a specific complex with the product of
RT   the retinoblastoma susceptibility gene.";
RL   Cell 54:275-283(1988).
RN   [17]
RP   INVOLVEMENT IN RETINOBLASTOMA.
RX   MEDLINE=88320373; PubMed=3413073; DOI=10.1073/pnas.85.16.6017;
RA   Lee E.Y.-H.P., Bookstein R., Young L.-J., Lin C.-J., Rosenfeld M.G.,
RA   Lee W.-H.;
RT   "Molecular mechanism of retinoblastoma gene inactivation in
RT   retinoblastoma cell line Y79.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988).
RN   [18]
RP   PHOSPHORYLATION AT SER-249; THR-252; THR-373; SER-807 AND SER-811.
RX   MEDLINE=92097548; PubMed=1756735;
RA   Lees J.A., Buchkovich K.J., Marshak D.R., Anderson C.W., Harlow E.;
RT   "The retinoblastoma protein is phosphorylated on multiple sites by
RT   human cdc2.";
RL   EMBO J. 10:4279-4290(1991).
RN   [19]
RP   INTERACTION WITH KDM5A AND ARID4A.
RX   MEDLINE=94020841; PubMed=8414517;
RA   Fattaey A.R., Helin K., Dembski M.S., Dyson N., Harlow E.,
RA   Vuocolo G.A., Hanobik M.G., Haskell K.M., Oliff A., Defeo-Jones D.,
RA   Jones R.E.;
RT   "Characterization of the retinoblastoma binding proteins RBP1 and
RT   RBP2.";
RL   Oncogene 8:3149-3156(1993).
RN   [20]
RP   INTERACTION WITH THOC1.
RX   MEDLINE=95050936; PubMed=7525595; DOI=10.1083/jcb.127.3.609;
RA   Durfee T., Mancini M.A., Jones D., Elledge S.J., Lee W.H.;
RT   "The amino-terminal region of the retinoblastoma gene product binds a
RT   novel nuclear matrix protein that co-localizes to centers for RNA
RT   processing.";
RL   J. Cell Biol. 127:609-622(1994).
RN   [21]
RP   INTERACTION WITH KDM5A.
RX   PubMed=7935440;
RA   Kim Y.W., Otterson G.A., Kratzke R.A., Coxon A.B., Kaye F.J.;
RT   "Differential specificity for binding of retinoblastoma binding
RT   protein 2 to RB, p107, and TATA-binding protein.";
RL   Mol. Cell. Biol. 14:7256-7264(1994).
RN   [22]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=8892909;
RA   Poma E.E., Kowalik T.F., Zhu L., Sinclair J.H., Huang E.S.;
RT   "The human cytomegalovirus IE1-72 protein interacts with the cellular
RT   p107 protein and relieves p107-mediated transcriptional repression of
RT   an E2F-responsive promoter.";
RL   J. Virol. 70:7867-7877(1996).
RN   [23]
RP   INTERACTION WITH ARID3B.
RX   PubMed=10446990;
RA   Numata S., Claudio P.P., Dean C., Giordano A., Croce C.M.;
RT   "Bdp, a new member of a family of DNA-binding proteins, associates
RT   with the retinoblastoma gene product.";
RL   Cancer Res. 59:3741-3747(1999).
RN   [24]
RP   PHOSPHORYLATION AT SER-567 BY CDK2, AND PHOSPHORYLATION BY CDK4 AND
RP   CDK6.
RX   PubMed=10499802; DOI=10.1016/S0092-8674(00)81519-6;
RA   Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C.;
RT   "Cdk phosphorylation triggers sequential intramolecular interactions
RT   that progressively block Rb functions as cells move through G1.";
RL   Cell 98:859-869(1999).
RN   [25]
RP   INTERACTION WITH NDC80.
RX   PubMed=10409732;
RA   Zheng L., Chen Y., Lee W.-H.;
RT   "Hec1p, an evolutionarily conserved coiled-coil protein, modulates
RT   chromosome segregation through interaction with SMC proteins.";
RL   Mol. Cell. Biol. 19:5417-5428(1999).
RN   [26]
RP   INTERACTION WITH NDC80.
RX   PubMed=10779342; DOI=10.1128/MCB.20.10.3529-3537.2000;
RA   Zheng L., Chen Y., Riley D.J., Chen P.-L., Lee W.-H.;
RT   "Retinoblastoma protein enhances the fidelity of chromosome
RT   segregation mediated by hsHec1p.";
RL   Mol. Cell. Biol. 20:3529-3537(2000).
RN   [27]
RP   INTERACTION WITH TAF1.
RX   MEDLINE=99078021; PubMed=9858607;
RA   Siegert J.L., Robbins P.D.;
RT   "Rb inhibits the intrinsic kinase activity of TATA-binding protein-
RT   associated factor TAFII250.";
RL   Mol. Cell. Biol. 19:846-854(1999).
RN   [28]
RP   INTERACTION WITH E4F1.
RX   PubMed=10869426; DOI=10.1073/pnas.130198397;
RA   Fajas L., Paul C., Zugasti O., Le Cam L., Polanowska J., Fabbrizio E.,
RA   Medema R., Vignais M.-L., Sardet C.;
RT   "pRB binds to and modulates the transrepressing activity of the E1A-
RT   regulated transcription factor p120E4F.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:7738-7743(2000).
RN   [29]
RP   INTERACTION WITH EID1.
RX   PubMed=11223246; DOI=10.1016/S0378-1119(00)00585-0;
RA   Wen H., Ao S.;
RT   "Identification and characterization of a novel human cDNA encoding a
RT   21 kDa pRb-associated protein.";
RL   Gene 263:85-92(2001).
RN   [30]
RP   INTERACTION WITH DNMT1.
RX   MEDLINE=20347723; PubMed=10888886; DOI=10.1038/77124;
RA   Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L.,
RA   Wolffe A.P.;
RT   "DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses
RT   transcription from E2F-responsive promoters.";
RL   Nat. Genet. 25:338-342(2000).
RN   [31]
RP   INTERACTION WITH SUV39H1.
RX   MEDLINE=21376604; PubMed=11484059; DOI=10.1038/35087620;
RA   Nielsen S.J., Schneider R., Bauer U.-M., Bannister A.J., Morrison A.,
RA   O'Carroll D., Firestein R., Cleary M.L., Jenuwein T., Herrera R.E.,
RA   Kouzarides T.;
RT   "Rb targets histone H3 methylation and HP1 to promoters.";
RL   Nature 412:561-565(2001).
RN   [32]
RP   INTERACTION WITH USP4.
RX   PubMed=11571652; DOI=10.1038/sj.onc.1204824;
RA   DeSalle L.M., Latres E., Lin D., Graner E., Montagnoli A., Baker R.T.,
RA   Pagano M., Loda M.;
RT   "The de-ubiquitinating enzyme Unp interacts with the retinoblastoma
RT   protein.";
RL   Oncogene 20:5538-5542(2001).
RN   [33]
RP   INTERACTION WITH AATF.
RX   MEDLINE=22338441; PubMed=12450794; DOI=10.1016/S1535-6108(02)00182-4;
RA   Bruno T., De Angelis R., De Nicola F., Barbato C., Di Padova M.,
RA   Corbi N., Libri V., Benassi B., Mattei E., Chersi A., Soddu S.,
RA   Floridi A., Passananti C., Fanciulli M.;
RT   "Che-1 affects cell growth by interfering with the recruitment of
RT   HDAC1 by Rb.";
RL   Cancer Cell 2:387-399(2002).
RN   [34]
RP   INTERACTION WITH TMPO-ALPHA AND LMNA.
RX   MEDLINE=22363929; PubMed=12475961; DOI=10.1091/mbc.E02-07-0450;
RA   Markiewicz E., Dechat T., Foisner R., Quinlan R.A., Hutchison C.J.;
RT   "Lamin A/C binding protein LAP2alpha is required for nuclear anchorage
RT   of retinoblastoma protein.";
RL   Mol. Biol. Cell 13:4401-4413(2002).
RN   [35]
RP   INTERACTION WITH PELP1.
RX   PubMed=12682072; DOI=10.1074/jbc.M212822200;
RA   Balasenthil S., Vadlamudi R.K.;
RT   "Functional interactions between the estrogen receptor coactivator
RT   PELP1/MNAR and retinoblastoma protein.";
RL   J. Biol. Chem. 278:22119-22127(2003).
RN   [36]
RP   FUNCTION IN G0-G1 TRANSITION, AND PHOSPHORYLATION AT SER-807 AND
RP   SER-811 BY CDK3.
RX   PubMed=15084261; DOI=10.1016/S0092-8674(04)00300-9;
RA   Ren S., Rollins B.J.;
RT   "Cyclin C/cdk3 promotes Rb-dependent G0 exit.";
RL   Cell 117:239-251(2004).
RN   [37]
RP   INTERACTION WITH LIN9.
RX   PubMed=15538385; DOI=10.1038/sj.emboj.7600470;
RA   Gagrica S., Hauser S., Kolfschoten I., Osterloh L., Agami R.,
RA   Gaubatz S.;
RT   "Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-
RT   associated protein.";
RL   EMBO J. 23:4627-4638(2004).
RN   [38]
RP   INTERACTION WITH LIMD1.
RX   PubMed=15542589; DOI=10.1073/pnas.0407123101;
RA   Sharp T.V., Munoz F., Bourboulia D., Presneau N., Darai E.,
RA   Wang H.-W., Cannon M., Butcher D.N., Nicholson A.G., Klein G.,
RA   Imreh S., Boshoff C.;
RT   "LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded
RT   at chromosome 3p21.3, binds pRB and represses E2F-driven
RT   transcription.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:16531-16536(2004).
RN   [39]
RP   PHOSPHORYLATION AT THR-821 AND THR-826.
RX   PubMed=15809340; DOI=10.1093/jb/mvi050;
RA   Takaki T., Fukasawa K., Suzuki-Takahashi I., Semba K., Kitagawa M.,
RA   Taya Y., Hirai H.;
RT   "Preferences for phosphorylation sites in the retinoblastoma protein
RT   of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro.";
RL   J. Biochem. 137:381-386(2005).
RN   [40]
RP   INTERACTION WITH KDM4A.
RX   PubMed=15927959; DOI=10.1074/jbc.M413687200;
RA   Gray S.G., Iglesias A.H., Lizcano F., Villanueva R., Camelo S.,
RA   Jingu H., Teh B.T., Koibuchi N., Chin W.W., Kokkotou E., Dangond F.;
RT   "Functional characterization of JMJD2A, a histone deacetylase- and
RT   retinoblastoma-binding protein.";
RL   J. Biol. Chem. 280:28507-28518(2005).
RN   [41]
RP   INTERACTION WITH KDM5B.
RX   PubMed=15803180; DOI=10.1038/modpathol.3800413;
RA   Roesch A., Becker B., Meyer S., Wild P., Hafner C., Landthaler M.,
RA   Vogt T.;
RT   "Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding
RT   protein downregulated in malignant melanomas.";
RL   Mod. Pathol. 18:1249-1257(2005).
RN   [42]
RP   INTERACTION WITH KDM5A.
RX   PubMed=15949438; DOI=10.1016/j.molcel.2005.05.012;
RA   Benevolenskaya E.V., Murray H.L., Branton P., Young R.A.,
RA   Kaelin W.G. Jr.;
RT   "Binding of pRB to the PHD protein RBP2 promotes cellular
RT   differentiation.";
RL   Mol. Cell 18:623-635(2005).
RN   [43]
RP   INTERACTION WITH PSMA3.
RX   PubMed=16337594; DOI=10.1016/j.molcel.2005.10.017;
RA   Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R.,
RA   Allday M.J., Xiao Z.X.;
RT   "MDM2 promotes proteasome-dependent ubiquitin-independent degradation
RT   of retinoblastoma protein.";
RL   Mol. Cell 20:699-708(2005).
RN   [44]
RP   INTERACTION WITH ZUBR1.
RX   PubMed=16214886; DOI=10.1073/pnas.0507458102;
RA   Nakatani Y., Konishi H., Vassilev A., Kurooka H., Ishiguro K.,
RA   Sawada J., Ikura T., Korsmeyer S.J., Qin J., Herlitz A.M.;
RT   "p600, a unique protein required for membrane morphogenesis and cell
RT   survival.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15093-15098(2005).
RN   [45]
RP   INTERACTION WITH KDM5B.
RX   PubMed=16645588; DOI=10.1038/sj.jid.5700324;
RA   Roesch A., Becker B., Schneider-Brachert W., Hagen I., Landthaler M.,
RA   Vogt T.;
RT   "Re-expression of the retinoblastoma-binding protein 2-homolog 1
RT   reveals tumor-suppressive functions in highly metastatic melanoma
RT   cells.";
RL   J. Invest. Dermatol. 126:1850-1859(2006).
RN   [46]
RP   PHOSPHORYLATION AT SER-612 BY CHEK2, AND INTERACTION WITH CHEK2.
RX   PubMed=17380128; DOI=10.1038/sj.emboj.7601652;
RA   Inoue Y., Kitagawa M., Taya Y.;
RT   "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between
RT   pRB and E2F-1 after DNA damage.";
RL   EMBO J. 26:2083-2093(2007).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-252; THR-356
RP   AND THR-373, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-252;
RP   SER-807; SER-811; THR-823; THR-826 AND SER-855, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-821 AND
RP   THR-823, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-252;
RP   THR-373; SER-807; SER-811; THR-821; THR-823; THR-826; THR-841 AND
RP   SER-882, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [51]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-548 AND LYS-896, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [52]
RP   METHYLATION AT LYS-860, INTERACTION WITH L3MBTL1, AND MUTAGENESIS OF
RP   LYS-860; LYS-870 AND 873-LYS-LYS-874.
RX   PubMed=20870719; DOI=10.1074/jbc.M110.137612;
RA   Saddic L.A., West L.E., Aslanian A., Yates J.R. III, Rubin S.M.,
RA   Gozani O., Sage J.;
RT   "Methylation of the retinoblastoma tumor suppressor by SMYD2.";
RL   J. Biol. Chem. 285:37733-37740(2010).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [54]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 378-562.
RX   MEDLINE=97290453; PubMed=9145110; DOI=10.1038/nsb0597-390;
RA   Kim H.Y., Cho Y.;
RT   "Structural similarity between the pocket region of retinoblastoma
RT   tumour suppressor and the cyclin-box.";
RL   Nat. Struct. Biol. 4:390-395(1997).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 380-785.
RX   MEDLINE=98154728; PubMed=9495340; DOI=10.1038/36038;
RA   Lee J.O., Russo A.A., Pavletich N.P.;
RT   "Structure of the retinoblastoma tumour-suppressor pocket domain bound
RT   to a peptide from HPV E7.";
RL   Nature 391:859-865(1998).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 860-876 IN COMPLEX WITH
RP   KPNA2.
RX   PubMed=12695505; DOI=10.1074/jbc.M303275200;
RA   Fontes M.R.M., Teh T., Jans D., Brinkworth R.I., Kobe B.;
RT   "Structural basis for the specificity of bipartite nuclear
RT   localization sequence binding by importin-alpha.";
RL   J. Biol. Chem. 278:27981-27987(2003).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 829-874 IN COMPLEX WITH E2F1
RP   AND TFDP1, INTERACTION WITH HETERODIMERIC COMPLEXES CONTAINING TFDP1
RP   AND EITHER E2F1; E2F3; E2F4 OR E2F5, MUTAGENESIS OF THR-821 AND
RP   THR-826, AND PHOSPHORYLATION AT THR-821 AND THR-826.
RX   PubMed=16360038; DOI=10.1016/j.cell.2005.09.044;
RA   Rubin S.M., Gall A.-L., Zheng N., Pavletich N.P.;
RT   "Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism
RT   for phosphorylation-induced E2F release.";
RL   Cell 123:1093-1106(2005).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 380-787 IN COMPLEX WITH
RP   HUMAN ADENOVIRUS E1A PROTEIN.
RX   PubMed=17974914; DOI=10.1101/gad.1590607;
RA   Liu X., Marmorstein R.;
RT   "Structure of the retinoblastoma protein bound to adenovirus E1A
RT   reveals the molecular basis for viral oncoprotein inactivation of a
RT   tumor suppressor.";
RL   Genes Dev. 21:2711-2716(2007).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 52-355, PARTIAL PROTEIN
RP   SEQUENCE, MASS SPECTROMETRY, INTERACTION WITH THOC1 AND GRIP1, AND
RP   INTERACTION OF THE UNPHOSPHORYLATED PROTEIN WITH EID1.
RX   PubMed=17996702; DOI=10.1016/j.molcel.2007.08.023;
RA   Hassler M., Singh S., Yue W.W., Luczynski M., Lakbir R.,
RA   Sanchez-Sanchez F., Bader T., Pearl L.H., Mittnacht S.;
RT   "Crystal structure of the retinoblastoma protein N domain provides
RT   insight into tumor suppression, ligand interaction, and holoprotein
RT   architecture.";
RL   Mol. Cell 28:371-385(2007).
RN   [61]
RP   VARIANT RB LEU-567.
RX   MEDLINE=90081757; PubMed=2594029;
RA   Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D.,
RA   Little J.B., McConkie-Rosell A., Buckley E., Dryja T.P.;
RT   "Oncogenic point mutations in the human retinoblastoma gene: their
RT   application to genetic counseling.";
RL   N. Engl. J. Med. 321:1689-1695(1989).
RN   [62]
RP   VARIANT RB TRP-661.
RX   MEDLINE=92335261; PubMed=1352883; DOI=10.1073/pnas.89.13.6177;
RA   Onadim Z., Hogg A., Baird P.N., Cowell J.K.;
RT   "Oncogenic point mutations in exon 20 of the RB1 gene in families
RT   showing incomplete penetrance and mild expression of the
RT   retinoblastoma phenotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6177-6181(1992).
RN   [63]
RP   VARIANT RB ARG-457.
RX   MEDLINE=93348271; PubMed=8346255; DOI=10.1073/pnas.90.15.7351;
RA   Hogg A., Bia B., Onadim Z., Cowell J.K.;
RT   "Molecular mechanisms of oncogenic mutations in tumors from patients
RT   with bilateral and unilateral retinoblastoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7351-7355(1993).
RN   [64]
RP   VARIANT RB ARG-530.
RX   MEDLINE=95219415; PubMed=7704558;
RA   Cowell J.K., Smith T., Bia B.;
RT   "Frequent constitutional C to T mutations in CGA-arginine codons in
RT   the RB1 gene produce premature stop codons in patients with bilateral
RT   (hereditary) retinoblastoma.";
RL   Eur. J. Hum. Genet. 2:281-290(1994).
RN   [65]
RP   VARIANTS RB ASN-480 DEL AND TRP-661.
RX   MEDLINE=95012220; PubMed=7927327; DOI=10.1007/BF00201591;
RA   Lohmann D.R., Brandt B., Hoepping W., Passarge E., Horsthemke B.;
RT   "Distinct RB1 gene mutations with low penetrance in hereditary
RT   retinoblastoma.";
RL   Hum. Genet. 94:349-354(1994).
RN   [66]
RP   VARIANTS RB GLN-72; TYR-549 AND LYS-803.
RX   MEDLINE=96187126; PubMed=8605116; DOI=10.1002/gcc.2870140406;
RA   Liu Z., Song Y., Bia B., Cowell J.K.;
RT   "Germline mutations in the RB1 gene in patients with hereditary
RT   retinoblastoma.";
RL   Genes Chromosomes Cancer 14:277-284(1995).
RN   [67]
RP   VARIANTS RB THR-185; PRO-635; GLU-654 AND PRO-685.
RX   MEDLINE=95315934; PubMed=7795591; DOI=10.1093/hmg/4.3.383;
RA   Blanquet V., Turleau C., Gross-Morand M.S., Senamaud-Beaufort C.,
RA   Doz F., Besmond C.;
RT   "Spectrum of germline mutations in the RB1 gene: a study of 232
RT   patients with hereditary and non hereditary retinoblastoma.";
RL   Hum. Mol. Genet. 4:383-388(1995).
RN   [68]
RP   VARIANTS RB GLY-358; PRO-657 AND TRP-661.
RX   MEDLINE=96372810; PubMed=8776589; DOI=10.1093/hmg/5.6.755;
RA   Van Orsouw N.J., Li D., van der Vlies P., Scheffer H., Eng C.,
RA   Buys C.H.C.M., Li F.P., Vijg J.;
RT   "Mutational scanning of large genes by extensive PCR multiplexing and
RT   two-dimensional electrophoresis: application to the RB1 gene.";
RL   Hum. Mol. Genet. 5:755-761(1996).
RN   [69]
RP   VARIANTS RB ASP-137 AND TRP-661.
RX   MEDLINE=97456418; PubMed=9311732;
RA   Lohmann D.R., Gerick M., Brandt B., Oelschlaeger U., Lorenz B.,
RA   Passarge E., Horsthemke B.;
RT   "Constitutional RB1-gene mutations in patients with isolated
RT   unilateral retinoblastoma.";
RL   Am. J. Hum. Genet. 61:282-294(1997).
RN   [70]
RP   VARIANT RB GLN-447.
RX   MEDLINE=97285179; PubMed=9140452; DOI=10.1016/S0165-4608(96)00387-1;
RA   Mateu E., Sanchez F., Najera C., Beneyto M., Castell V., Hernandez M.,
RA   Serra I., Prieto F.;
RT   "Genetics of retinoblastoma: a study.";
RL   Cancer Genet. Cytogenet. 95:40-50(1997).
RN   [71]
RP   VARIANTS RB LEU-567; PRO-662 AND ARG-712.
RX   PubMed=10671068;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU16>3.3.CO;2-Z;
RA   Yilmaz S., Horsthemke B., Lohmann D.R.;
RT   "Twelve novel RB1 gene mutations in patients with hereditary
RT   retinoblastoma.";
RL   Hum. Mutat. 12:434-434(1998).
RN   [72]
RP   VARIANT RB GLU-310.
RX   MEDLINE=99138683; PubMed=9973307; DOI=10.1086/302254;
RA   Klutz M., Horsthemke B., Lohmann D.R.;
RT   "RB1 gene mutations in peripheral blood DNA of patients with isolated
RT   unilateral retinoblastoma.";
RL   Am. J. Hum. Genet. 64:667-668(1999).
RN   [73]
RP   VARIANTS RB GLY-500 AND GLU-616.
RX   MEDLINE=21415586; PubMed=11524739; DOI=10.1002/humu.1184;
RA   Yu Y.S., Kim I.-J., Ku J.-L., Park J.-G.;
RT   "Identification of four novel RB1 germline mutations in Korean
RT   retinoblastoma patients.";
RL   Hum. Mutat. 18:252-252(2001).
CC   -!- FUNCTION: Key regulator of entry into cell division that acts as a
CC       tumor suppressor. Promotes G0-G1 transition when phosphorylated by
CC       CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target
CC       genes. The underphosphorylated, active form of RB1 interacts with
CC       E2F1 and represses its transcription activity, leading to cell
CC       cycle arrest. Directly involved in heterochromatin formation by
CC       maintaining overall chromatin structure and, in particular, that
CC       of constitutive heterochromatin by stabilizing histone
CC       methylation. Recruits and targets histone methyltransferases
CC       SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic
CC       transcriptional repression. Controls histone H4 'Lys-20'
CC       trimethylation. Inhibits the intrinsic kinase activity of TAF1.
CC       Mediates transcriptional repression by SMARCA4/BRG1 by recruiting
CC       a histone deacetylase (HDAC) complex to the c-FOS promoter. In
CC       resting neurons, transcription of the c-FOS promoter is inhibited
CC       by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor
CC       complex. Upon calcium influx, RB1 is dephosphorylated by
CC       calcineurin, which leads to release of the repressor complex (By
CC       similarity). In case of viral infections, interactions with SV40
CC       large T antigen, HPV E7 protein or adenovirus E1A protein induce
CC       the disassembly of RB1-E2F1 complex thereby disrupting RB1's
CC       activity.
CC   -!- SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2
CC       (By similarity). The hypophosphorylated form interacts with and
CC       sequesters the E2F1 transcription factor. Interacts with
CC       heterodimeric E2F/DP transcription factor complexes containing
CC       TFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. The
CC       unphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,
CC       MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain of
CC       TAF1. Interacts with AATF, DNMT1, LIN9, LMNA, SUV420H1, SUV420H2,
CC       PELP1, UHRF2 and TMPO-alpha. May interact with NDC80. Interacts
CC       with GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interacts
CC       with E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1 (By
CC       similarity). Interacts with adenovirus E1A protein, HPV E7 protein
CC       and SV40 large T antigen. Interacts with PSMA3 and USP4. Interacts
CC       (when methylated at Lys-860) with L3MBTL1. Interacts with CHEK2;
CC       phosphorylates RB1. Interacts with human cytomegalovirus/HHV-5
CC       protein UL123.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=2; IntAct=EBI-491274, EBI-617698;
CC       P24941:CDK2; NbExp=3; IntAct=EBI-491274, EBI-375096;
CC       P30285:Cdk4 (xeno); NbExp=2; IntAct=EBI-491274, EBI-847225;
CC       Q155P7:Cenpf (xeno); NbExp=4; IntAct=EBI-491274, EBI-2211248;
CC       Q13574-2:DGKZ; NbExp=6; IntAct=EBI-491274, EBI-715527;
CC       Q01094:E2F1; NbExp=10; IntAct=EBI-491274, EBI-448924;
CC       P06465:E7 (xeno); NbExp=2; IntAct=EBI-491274, EBI-963841;
CC       P42685:FRK; NbExp=3; IntAct=EBI-491274, EBI-1383583;
CC       Q13547:HDAC1; NbExp=2; IntAct=EBI-491274, EBI-301834;
CC       P52927:Hmga2 (xeno); NbExp=5; IntAct=EBI-491274, EBI-912574;
CC       Q9R002:Ifi202 (xeno); NbExp=5; IntAct=EBI-491274, EBI-3043899;
CC       Q14653:IRF3; NbExp=2; IntAct=EBI-491274, EBI-2650369;
CC       Q16539:MAPK14; NbExp=3; IntAct=EBI-491274, EBI-73946;
CC       Q00987:MDM2; NbExp=3; IntAct=EBI-491274, EBI-389668;
CC       Q14686:NCOA6; NbExp=3; IntAct=EBI-491274, EBI-78670;
CC       P07197:NEFM; NbExp=2; IntAct=EBI-491274, EBI-1105035;
CC       Q9UQ80:PA2G4; NbExp=4; IntAct=EBI-491274, EBI-924893;
CC       P62136:PPP1CA; NbExp=2; IntAct=EBI-491274, EBI-357253;
CC       P55345:PRMT2; NbExp=3; IntAct=EBI-491274, EBI-78458;
CC       Q00577:PURA; NbExp=6; IntAct=EBI-491274, EBI-1045860;
CC       P04049:RAF1; NbExp=3; IntAct=EBI-491274, EBI-365996;
CC       O75150:RNF40; NbExp=3; IntAct=EBI-491274, EBI-744408;
CC       Q923E4:Sirt1 (xeno); NbExp=4; IntAct=EBI-491274, EBI-1802585;
CC       Q3TKT4:Smarca4 (xeno); NbExp=4; IntAct=EBI-491274, EBI-1210244;
CC       Q96PU4:UHRF2; NbExp=4; IntAct=EBI-491274, EBI-625304;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- TISSUE SPECIFICITY: Expressed in the retina.
CC   -!- DOMAIN: The Pocket domain binds to the threonine-phosphorylated
CC       domain C, thereby preventing interaction with heterodimeric E2F/DP
CC       transcription factor complexes.
CC   -!- PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 at
CC       Ser-567 in G1, thereby releasing E2F1 which is then able to
CC       activate cell growth. Dephosphorylated at the late M phase. SV40
CC       large T antigen, HPV E7 and adenovirus E1A bind to the
CC       underphosphorylated, active form of pRb. Phosphorylation at Thr-
CC       821 and Thr-826 promotes interaction between the C-terminal domain
CC       C and the Pocket domain, and thereby inhibits interactions with
CC       heterodimeric E2F/DP transcription factor complexes.
CC       Dephosphorylated at Ser-795 by calcineruin upon calcium
CC       stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and
CC       Ser-811 is required for G0-G1 transition. Phosphorylated by CDK1
CC       and CDK2 upon TGFB1-mediated apoptosis (By similarity).
CC   -!- PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).
CC       Monomethylated at Lys-860 by SMYD2, promoting interaction with
CC       L3MBTL1.
CC   -!- DISEASE: Defects in RB1 are the cause of childhood cancer
CC       retinoblastoma (RB) [MIM:180200]. RB is a congenital malignant
CC       tumor that arises from the nuclear layers of the retina. It occurs
CC       in about 1:20'000 live births and represents about 2% of childhood
CC       malignancies. It is bilateral in about 30% of cases. Although most
CC       RB appear sporadically, about 20% are transmitted as an autosomal
CC       dominant trait with incomplete penetrance. The diagnosis is
CC       usually made before the age of 2 years when strabismus or a gray
CC       to yellow reflex from pupil ('cat eye') is investigated.
CC   -!- DISEASE: Defects in RB1 are a cause of susceptibility to bladder
CC       cancer (BLC) [MIM:109800]. A malignancy originating in tissues of
CC       the urinary bladder. It often presents with multiple tumors
CC       appearing at different times and at different sites in the
CC       bladder. Most bladder cancers are transitional cell carcinomas.
CC       They begin in cells that normally make up the inner lining of the
CC       bladder. Other types of bladder cancer include squamous cell
CC       carcinoma (cancer that begins in thin, flat cells) and
CC       adenocarcinoma (cancer that begins in cells that make and release
CC       mucus and other fluids). Bladder cancer is a complex disorder with
CC       both genetic and environmental influences.
CC   -!- DISEASE: Defects in RB1 are a cause of osteogenic sarcoma (OSRC)
CC       [MIM:259500].
CC   -!- SIMILARITY: Belongs to the retinoblastoma protein (RB) family.
CC   -!- WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;
CC       URL="http://rb1-lsdb.d-lohmann.de/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RB1ID90.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/RB1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rb1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;
CC       URL="http://en.wikipedia.org/wiki/Retinoblastoma_protein";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15400; AAA69807.1; ALT_SEQ; mRNA.
DR   EMBL; M28419; AAA69808.1; -; mRNA.
DR   EMBL; M33647; AAA69806.1; -; mRNA.
DR   EMBL; L41870; AAB59465.1; -; mRNA.
DR   EMBL; M27866; AAA53484.1; -; Genomic_DNA.
DR   EMBL; M27845; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27846; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27847; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27849; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27850; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27851; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; L35146; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27852; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27853; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27854; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27855; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27856; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27857; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27858; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27859; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27860; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; L35147; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27862; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27863; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27864; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27865; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; L41889; AAB59467.1; -; Genomic_DNA.
DR   EMBL; L41890; AAA65735.1; -; Genomic_DNA.
DR   EMBL; L41891; AAA65736.1; -; Genomic_DNA.
DR   EMBL; L41893; AAA65737.1; -; Genomic_DNA.
DR   EMBL; L41894; AAA65738.1; -; Genomic_DNA.
DR   EMBL; L41895; AAA65739.1; -; Genomic_DNA.
DR   EMBL; L41896; AAA65740.1; -; Genomic_DNA.
DR   EMBL; L41897; AAA65741.1; -; Genomic_DNA.
DR   EMBL; L41898; AAB59471.1; -; Genomic_DNA.
DR   EMBL; L41899; AAB59473.1; -; Genomic_DNA.
DR   EMBL; L41997; AAB59482.1; -; Genomic_DNA.
DR   EMBL; X16439; CAA34462.1; -; Genomic_DNA.
DR   EMBL; AF551763; AAN64133.1; -; Genomic_DNA.
DR   EMBL; AK291258; BAF83947.1; -; mRNA.
DR   EMBL; AL136960; CAH70901.1; -; Genomic_DNA.
DR   EMBL; AL392048; CAH70901.1; JOINED; Genomic_DNA.
DR   EMBL; AL392048; CAH72243.1; -; Genomic_DNA.
DR   EMBL; AL136960; CAH72243.1; JOINED; Genomic_DNA.
DR   EMBL; CH471075; EAX08793.1; -; Genomic_DNA.
DR   EMBL; BC039060; AAH39060.1; -; mRNA.
DR   EMBL; BC040540; AAH40540.1; -; mRNA.
DR   EMBL; L11910; AAA53483.1; -; Genomic_DNA.
DR   IPI; IPI00302829; -.
DR   PIR; JS0276; RBHU.
DR   RefSeq; NP_000312.2; NM_000321.2.
DR   UniGene; Hs.408528; -.
DR   PDB; 1AD6; X-ray; 2.30 A; A=378-562.
DR   PDB; 1GH6; X-ray; 3.20 A; B=379-772.
DR   PDB; 1GUX; X-ray; 1.85 A; A=372-589, B=636-787.
DR   PDB; 1H25; X-ray; 2.50 A; E=868-878.
DR   PDB; 1N4M; X-ray; 2.20 A; A/B=380-785.
DR   PDB; 1O9K; X-ray; 2.60 A; A/C/E/G=372-589, B/D/F/H=636-787.
DR   PDB; 1PJM; X-ray; 2.50 A; A=860-876.
DR   PDB; 2AZE; X-ray; 2.55 A; C=829-874.
DR   PDB; 2QDJ; X-ray; 2.00 A; A=52-355.
DR   PDB; 2R7G; X-ray; 1.67 A; A/C=380-787.
DR   PDB; 3N5U; X-ray; 3.20 A; C=870-882.
DR   PDB; 3POM; X-ray; 2.50 A; A/B=380-787.
DR   PDB; 4ELJ; X-ray; 2.70 A; A=53-787.
DR   PDB; 4ELL; X-ray; 1.98 A; A/B=380-787.
DR   PDBsum; 1AD6; -.
DR   PDBsum; 1GH6; -.
DR   PDBsum; 1GUX; -.
DR   PDBsum; 1H25; -.
DR   PDBsum; 1N4M; -.
DR   PDBsum; 1O9K; -.
DR   PDBsum; 1PJM; -.
DR   PDBsum; 2AZE; -.
DR   PDBsum; 2QDJ; -.
DR   PDBsum; 2R7G; -.
DR   PDBsum; 3N5U; -.
DR   PDBsum; 3POM; -.
DR   PDBsum; 4ELJ; -.
DR   PDBsum; 4ELL; -.
DR   ProteinModelPortal; P06400; -.
DR   SMR; P06400; 53-786, 829-872.
DR   DIP; DIP-582N; -.
DR   IntAct; P06400; 55.
DR   MINT; MINT-98847; -.
DR   STRING; P06400; -.
DR   PhosphoSite; P06400; -.
DR   DMDM; 132164; -.
DR   PaxDb; P06400; -.
DR   PeptideAtlas; P06400; -.
DR   PRIDE; P06400; -.
DR   DNASU; 5925; -.
DR   Ensembl; ENST00000267163; ENSP00000267163; ENSG00000139687.
DR   GeneID; 5925; -.
DR   KEGG; hsa:5925; -.
DR   UCSC; uc001vcb.3; human.
DR   CTD; 5925; -.
DR   GeneCards; GC13P048877; -.
DR   HGNC; HGNC:9884; RB1.
DR   HPA; CAB000095; -.
DR   HPA; CAB016687; -.
DR   MIM; 109800; phenotype.
DR   MIM; 180200; phenotype.
DR   MIM; 259500; phenotype.
DR   MIM; 614041; gene.
DR   neXtProt; NX_P06400; -.
DR   Orphanet; 790; Retinoblastoma.
DR   PharmGKB; PA295; -.
DR   eggNOG; NOG296920; -.
DR   HOVERGEN; HBG008967; -.
DR   InParanoid; P06400; -.
DR   KO; K06618; -.
DR   OMA; SNGLPEV; -.
DR   OrthoDB; EOG4TXBRB; -.
DR   PhylomeDB; P06400; -.
DR   Pathway_Interaction_DB; foxm1pathway; FOXM1 transcription factor network.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_383; DNA Replication.
DR   ChEMBL; CHEMBL5288; -.
DR   DrugBank; DB00047; Insulin Glargine recombinant.
DR   DrugBank; DB00046; Insulin Lyspro recombinant.
DR   DrugBank; DB00030; Insulin recombinant.
DR   DrugBank; DB00071; Insulin, porcine.
DR   EvolutionaryTrace; P06400; -.
DR   GenomeRNAi; 5925; -.
DR   NextBio; 23076; -.
DR   PMAP-CutDB; P06400; -.
DR   ArrayExpress; P06400; -.
DR   Bgee; P06400; -.
DR   CleanEx; HS_RB1; -.
DR   Genevestigator; P06400; -.
DR   GermOnline; ENSG00000139687; Homo sapiens.
DR   GO; GO:0000785; C:chromatin; TAS:ProtInc.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0035189; C:Rb-E2F complex; TAS:BHF-UCL.
DR   GO; GO:0005819; C:spindle; IEA:Compara.
DR   GO; GO:0016514; C:SWI/SNF complex; TAS:BHF-UCL.
DR   GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:BHF-UCL.
DR   GO; GO:0051301; P:cell division; IEA:Compara.
DR   GO; GO:0048667; P:cell morphogenesis involved in neuron differentiation; IEA:Compara.
DR   GO; GO:0006338; P:chromatin remodeling; TAS:BHF-UCL.
DR   GO; GO:0048565; P:digestive tract development; IEA:Compara.
DR   GO; GO:0043353; P:enucleate erythrocyte differentiation; IEA:Compara.
DR   GO; GO:0000080; P:G1 phase of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0034088; P:maintenance of mitotic sister chromatid cohesion; IMP:BHF-UCL.
DR   GO; GO:0031575; P:mitotic cell cycle G1/S transition checkpoint; TAS:BHF-UCL.
DR   GO; GO:0045445; P:myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Compara.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IPI:UniProtKB.
DR   GO; GO:0045749; P:negative regulation of S phase of mitotic cell cycle; TAS:BHF-UCL.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; TAS:BHF-UCL.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IEA:Compara.
DR   GO; GO:0071930; P:negative regulation of transcription involved in G1/S phase of mitotic cell cycle; IEA:Compara.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-dependent; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Compara.
DR   GO; GO:0042551; P:neuron maturation; IEA:Compara.
DR   GO; GO:0031175; P:neuron projection development; IEA:Compara.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; IEA:Compara.
DR   GO; GO:0045842; P:positive regulation of mitotic metaphase/anaphase transition; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Compara.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-dependent; NAS:UniProtKB.
DR   GO; GO:0071459; P:protein localization to chromosome, centromeric region; IMP:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0090230; P:regulation of centromere complex assembly; TAS:BHF-UCL.
DR   GO; GO:0071922; P:regulation of cohesin localization to chromatin; IMP:BHF-UCL.
DR   GO; GO:0043550; P:regulation of lipid kinase activity; IDA:UniProtKB.
DR   GO; GO:0000083; P:regulation of transcription involved in G1/S phase of mitotic cell cycle; TAS:BHF-UCL.
DR   GO; GO:0000084; P:S phase of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0031134; P:sister chromatid biorientation; IMP:BHF-UCL.
DR   GO; GO:0051146; P:striated muscle cell differentiation; IEA:Compara.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019048; P:virus-host interaction; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.472.10; Cyclin_related; 2.
DR   InterPro; IPR013763; Cyclin-like.
DR   InterPro; IPR024599; DUF3452_retinoblatoma-assoc.
DR   InterPro; IPR002720; RB_A.
DR   InterPro; IPR015652; Rb_associated.
DR   InterPro; IPR002719; RB_B.
DR   InterPro; IPR015030; Rb_C.
DR   PANTHER; PTHR13742:SF10; PTHR13742:SF10; 1.
DR   Pfam; PF11934; DUF3452; 1.
DR   Pfam; PF01858; RB_A; 1.
DR   Pfam; PF01857; RB_B; 1.
DR   Pfam; PF08934; Rb_C; 1.
DR   SMART; SM00385; CYCLIN; 1.
DR   SUPFAM; SSF47954; Cyclin_like; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell cycle; Chromatin regulator;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   DNA-binding; Host-virus interaction; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Repressor; Transcription; Transcription regulation.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    928       Retinoblastoma-associated protein.
FT                                /FTId=PRO_0000167836.
FT   REGION      373    771       Pocket; binds T and E1A.
FT   REGION      373    579       Domain A.
FT   REGION      580    639       Spacer.
FT   REGION      640    771       Domain B.
FT   REGION      763    928       Interaction with LIMD1.
FT   REGION      771    928       Domain C; mediates interaction with E4F1.
FT   MOTIF       870    876       Nuclear localization signal (Probable).
FT   COMPBIAS     10     18       Poly-Ala.
FT   COMPBIAS     20     29       Poly-Pro.
FT   MOD_RES       2      2       N,N-dimethylproline (By similarity).
FT   MOD_RES      37     37       Phosphoserine.
FT   MOD_RES     249    249       Phosphoserine; by CDK1.
FT   MOD_RES     252    252       Phosphothreonine; by CDK1.
FT   MOD_RES     356    356       Phosphothreonine.
FT   MOD_RES     373    373       Phosphothreonine; by CDK1.
FT   MOD_RES     548    548       N6-acetyllysine.
FT   MOD_RES     567    567       Phosphoserine; by CDK2.
FT   MOD_RES     612    612       Phosphoserine; by CHEK2 and CHEK1.
FT   MOD_RES     795    795       Phosphoserine (By similarity).
FT   MOD_RES     807    807       Phosphoserine; by CDK1 and CDK3.
FT   MOD_RES     811    811       Phosphoserine; by CDK1 and CDK3.
FT   MOD_RES     821    821       Phosphothreonine; by CDK6.
FT   MOD_RES     823    823       Phosphothreonine.
FT   MOD_RES     826    826       Phosphothreonine; by CDK4.
FT   MOD_RES     841    841       Phosphothreonine.
FT   MOD_RES     855    855       Phosphoserine.
FT   MOD_RES     860    860       N6-methyllysine; by SMYD2; alternate.
FT   MOD_RES     882    882       Phosphoserine.
FT   MOD_RES     896    896       N6-acetyllysine.
FT   VARIANT      72     72       E -> Q (in RB).
FT                                /FTId=VAR_005572.
FT   VARIANT     133    133       N -> H (in dbSNP:rs3092900).
FT                                /FTId=VAR_051909.
FT   VARIANT     137    137       E -> D (in RB; unilateral form).
FT                                /FTId=VAR_005573.
FT   VARIANT     185    185       I -> T (in RB).
FT                                /FTId=VAR_005574.
FT   VARIANT     310    310       G -> E (in RB; unknown pathological
FT                                significance).
FT                                /FTId=VAR_010045.
FT   VARIANT     358    358       R -> G (in RB).
FT                                /FTId=VAR_010046.
FT   VARIANT     358    358       R -> Q (in RB).
FT                                /FTId=VAR_005575.
FT   VARIANT     436    436       Q -> K (in dbSNP:rs4151534).
FT                                /FTId=VAR_019379.
FT   VARIANT     447    447       K -> Q (in RB).
FT                                /FTId=VAR_010048.
FT   VARIANT     457    457       M -> R (in RB).
FT                                /FTId=VAR_005576.
FT   VARIANT     480    480       Missing (in RB; mild form).
FT                                /FTId=VAR_005577.
FT   VARIANT     500    500       R -> G (in RB).
FT                                /FTId=VAR_011580.
FT   VARIANT     525    525       A -> G (in dbSNP:rs4151539).
FT                                /FTId=VAR_019380.
FT   VARIANT     530    530       K -> R (in RB).
FT                                /FTId=VAR_010049.
FT   VARIANT     549    549       H -> Y (in RB).
FT                                /FTId=VAR_005578.
FT   VARIANT     567    567       S -> L (in RB).
FT                                /FTId=VAR_005579.
FT   VARIANT     569    569       L -> F (in dbSNP:rs3092895).
FT                                /FTId=VAR_051910.
FT   VARIANT     616    616       K -> E (in RB).
FT                                /FTId=VAR_011581.
FT   VARIANT     635    635       A -> P (in RB).
FT                                /FTId=VAR_005580.
FT   VARIANT     654    654       V -> E (in RB).
FT                                /FTId=VAR_005581.
FT   VARIANT     657    657       L -> P (in RB).
FT                                /FTId=VAR_010050.
FT   VARIANT     661    661       R -> W (in RB; mild form).
FT                                /FTId=VAR_005582.
FT   VARIANT     662    662       L -> P (in RB).
FT                                /FTId=VAR_005583.
FT   VARIANT     673    673       H -> P (in RB).
FT                                /FTId=VAR_005584.
FT   VARIANT     685    685       Q -> P (in RB).
FT                                /FTId=VAR_005585.
FT   VARIANT     697    697       D -> E (in dbSNP:rs3092903).
FT                                /FTId=VAR_051911.
FT   VARIANT     706    706       C -> Y (in RB).
FT                                /FTId=VAR_005586.
FT   VARIANT     712    712       C -> R (in RB).
FT                                /FTId=VAR_005587.
FT   VARIANT     746    746       E -> G (in dbSNP:rs3092905).
FT                                /FTId=VAR_034442.
FT   VARIANT     803    803       N -> K (in RB).
FT                                /FTId=VAR_005588.
FT   MUTAGEN     821    821       T->A: Abolishes interaction with Pocket
FT                                domain; when associated with A-826.
FT   MUTAGEN     826    826       T->A: Abolishes interaction with Pocket
FT                                domain; when associated with A-821.
FT   MUTAGEN     860    860       K->R: Abolishes monomethylation by SMYD2
FT                                and subsequent interaction with L3MBTL1.
FT   MUTAGEN     870    870       K->R: Does not affect the ability to be
FT                                methylated by SMYD2; when associated with
FT                                873-R-R-874.
FT   MUTAGEN     873    874       KK->R: Does not affect the ability to be
FT                                methylated by SMYD2; when associated with
FT                                873-R-R-874.
FT   CONFLICT    500    501       RS -> SN (in Ref. 7; AAN64133).
FT   HELIX        55     63
FT   HELIX        68     82
FT   HELIX        95    110
FT   HELIX       117    124
FT   HELIX       128    135
FT   HELIX       142    172
FT   STRAND      180    182
FT   HELIX       188    204
FT   STRAND      207    209
FT   HELIX       212    228
FT   HELIX       232    234
FT   TURN        237    240
FT   HELIX       241    243
FT   HELIX       272    281
FT   HELIX       285    294
FT   HELIX       296    299
FT   HELIX       302    306
FT   HELIX       314    328
FT   HELIX       333    338
FT   HELIX       341    343
FT   HELIX       347    353
FT   HELIX       382    391
FT   HELIX       398    405
FT   STRAND      407    409
FT   HELIX       412    434
FT   HELIX       436    438
FT   HELIX       439    468
FT   HELIX       474    477
FT   HELIX       480    501
FT   TURN        504    506
FT   STRAND      511    513
FT   HELIX       516    521
FT   HELIX       525    529
FT   HELIX       532    538
FT   HELIX       544    559
FT   HELIX       561    563
FT   STRAND      564    566
FT   HELIX       569    577
FT   HELIX       602    607
FT   HELIX       645    669
FT   HELIX       676    690
FT   HELIX       692    695
FT   HELIX       700    714
FT   HELIX       721    728
FT   STRAND      731    733
FT   HELIX       737    740
FT   STRAND      741    743
FT   STRAND      745    747
FT   STRAND      748    750
FT   HELIX       752    758
FT   HELIX       760    770
FT   STRAND      773    775
FT   STRAND      830    836
FT   TURN        838    840
FT   HELIX       841    853
SQ   SEQUENCE   928 AA;  106159 MW;  C8E746111E19CC32 CRC64;
     MPPKTPRKTA ATAAAAAAEP PAPPPPPPPE EDPEQDSGPE DLPLVRLEFE ETEEPDFTAL
     CQKLKIPDHV RERAWLTWEK VSSVDGVLGG YIQKKKELWG ICIFIAAVDL DEMSFTFTEL
     QKNIEISVHK FFNLLKEIDT STKVDNAMSR LLKKYDVLFA LFSKLERTCE LIYLTQPSSS
     ISTEINSALV LKVSWITFLL AKGEVLQMED DLVISFQLML CVLDYFIKLS PPMLLKEPYK
     TAVIPINGSP RTPRRGQNRS ARIAKQLEND TRIIEVLCKE HECNIDEVKN VYFKNFIPFM
     NSLGLVTSNG LPEVENLSKR YEEIYLKNKD LDARLFLDHD KTLQTDSIDS FETQRTPRKS
     NLDEEVNVIP PHTPVRTVMN TIQQLMMILN SASDQPSENL ISYFNNCTVN PKESILKRVK
     DIGYIFKEKF AKAVGQGCVE IGSQRYKLGV RLYYRVMESM LKSEEERLSI QNFSKLLNDN
     IFHMSLLACA LEVVMATYSR STSQNLDSGT DLSFPWILNV LNLKAFDFYK VIESFIKAEG
     NLTREMIKHL ERCEHRIMES LAWLSDSPLF DLIKQSKDRE GPTDHLESAC PLNLPLQNNH
     TAADMYLSPV RSPKKKGSTT RVNSTANAET QATSAFQTQK PLKSTSLSLF YKKVYRLAYL
     RLNTLCERLL SEHPELEHII WTLFQHTLQN EYELMRDRHL DQIMMCSMYG ICKVKNIDLK
     FKIIVTAYKD LPHAVQETFK RVLIKEEEYD SIIVFYNSVF MQRLKTNILQ YASTRPPTLS
     PIPHIPRSPY KFPSSPLRIP GGNIYISPLK SPYKISEGLP TPTKMTPRSR ILVSIGESFG
     TSEKFQKINQ MVCNSDRVLK RSAEGSNPPK PLKKLRFDIE GSDEADGSKH LPGESKFQQK
     LAEMTSTRTR MQKQKMNDSM DTSNKEEK
//
